Updated on 2023/10/14

写真a

 
ISHIKAWA, Tetsuya
 
Organization
Graduate School of Medicine Professor
Graduate School
Graduate School of Medicine
Undergraduate School
School of Health Sciences
Title
Professor
Contact information
メールアドレス
Profile

External link

Degree 1

  1. Doctor of Medicine ( 1996.3   Nagoya University ) 

Research Interests 4

  1. Hepatology

  2. Regenerative Medicine

  3. Immunology

  4. Virology

Research Areas 1

  1. Life Science / Gastroenterology  / Digestive Organs Internal Medicine

Current Research Project and SDGs 5

  1. B型慢性肝炎に対する新規経口TLR-7アゴニスト(SA-5)を基盤とした治療法の開発と医師主導FIH試験の体制整備

  2. ウイルス・発がんを統合的に制御する新規B型肝炎分子免疫治療の開発

  3. 細胞移植をベースとする肝再生治療モデルの確立と免疫拒絶回避のための新規治療の 開発

  4. 新規HBV感染症モデルを用いた治療的ワクチン療法の開発

  5. HBs抗原陰性化に関わるB型肝炎ウイルス変異と腸内細菌叢が及ぼす免疫応答の解明

Research History 10

  1. Nagoya University   Omics Health Sciences, Department of Integrated Health Sciences,   Professor

    2020.4

      More details

    Country:Japan

  2. Nagoya University Graduate School of Medicine   Lab. of Biomolecular Sciences, Div. of Omics Health Sciences, Dept. of Integrated Health Sciences   Professor   MD, PhD

    2020.4

      More details

    Country:Japan

    researchmap

  3. Nagoya University   Institute of Nano-Life-Systems, Institutes of Innovation for Future Society

    2018.10

      More details

    Country:Japan

  4. Nagoya University Graduate School of Medicine   Department of Radiological & Medical Laboratory Sciences   Professor

    2012.4 - 2020.3

      More details

    Country:Japan

  5. Professor, Nagoya University School of Health Sciences   Professor

    2010.4

      More details

    Country:Japan

  6. Chairman, Cancer Immunotherapy Center, Nagoya Kyoritsu Hospital

    2007.11 - 2010.3

      More details

    Country:Japan

  7. Associate Professor, Aichi Medical University   Associate professor

    2006.11 - 2007.10

      More details

    Country:Japan

  8. Lecturer, Aichi Medical University   Lecturer

    1998.4 - 2006.11

      More details

    Country:Japan

  9. Research Associate, Aichi Medical University   Assistant

    1996.7 - 1998.3

      More details

    Country:Japan

  10. The Scripps Research Institute   Research Associate

    1993.1 - 1995.5

▼display all

Education 2

  1. Nagoya University   Graduate School, Division of Medicine   Internal Medicine Ⅲ

    1989.4 - 1995.8

      More details

    Country: Japan

  2. Nagoya University   Faculty of Medicine

    1979.4 - 1985.3

      More details

    Country: Japan

Professional Memberships 13

  1. The Japan Society of Hepatology   Councillor

    2008.4

  2. The Japanese Society of Gastroenterology   Councillor

    1987.6

  3. The Japanese Society of Internal Medicine

    1988.6

  4. The Japanese Society of Inflammation and Regeneration

    2016.4

      More details

  5. 日本再生医療学会

    2014.1

  6. Japanese Society of Immunology

    1996.6

  7. The Japanese Society for Virology

    2002.1

  8. Japanese Cancer Association

    2008.10

  9. Japan Society of Clinical Oncology

    2008.10

  10. Japan Association of Cancer Immunology

    2008.2

  11. The Japanese Society for the Research of Hepatic Cells

    2016.5

  12. Asian Pacific Association for the Study of the Liver

    2015.9

  13. Japanese Society of Laboratory Medicine

    2012.7

▼display all

Committee Memberships 6

  1. 名古屋大学大学院医学系研究科総合保健学専攻   副学科長  

    2018.4   

  2. 名古屋大学大学院医学系研究科総合保健学専攻   予算委員会 委員長  

    2018.4   

  3. 名古屋大学大学院医学系研究科総合保健学専攻   整備計画委員会保健学部会 委員長  

    2018.4   

  4. 名古屋大学   キャンパスマネジメント推進本部会議 委員  

    2018.4   

  5. 名古屋大学   防災対策推進本部会議 委員  

    2018.4   

  6. 名古屋大学   極低温実験室運営委員会  

    2012.4   

▼display all

Awards 3

  1. 研究助成費

    1999.1   国際科学振興財団  

    石川哲也

     More details

    Award type:Award from publisher, newspaper, foundation, etc.  Country:Japan

  2. 日東学術振興財団海外派遣助成費

    1999.1   日東工業  

    石川哲也

     More details

    Award type:Award from publisher, newspaper, foundation, etc.  Country:Japan

  3. 愛知医科大学研究奨励賞

    1997.10   愛知医科大学  

    石川哲也

     More details

    Country:Japan

 

Papers 230

  1. Spermidine enhances the efficacy of adjuvant in HBV vaccination in mice Reviewed

    Ito D, Ito H, Ando T, Sakai Y, Ideta T, Ishii KJ, Ishikawa T, Shimizu M.

    Hepatology Communications   Vol. 24 ( 4 ) page: e0104   2023.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1097/HC9.0000000000000104.

  2. Proteomic analysis reveals changes in tight junctions in the small intestinal eepithelium of mice fed a high-fat diet Reviewed

    Muto H, Honda T, Tanaka T, Yokoyama S, Yamamoto K, Ito T, Imai N, Ishizu Y, Maeda K, Ishikawa T, Adachi S, Sato C, Tsuji NM Ishigami M, Fujishiro M, Kawashima H.

    Nutrients   Vol. 15 ( 6 ) page: 1473   2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: https://doi.org/10.3390/nu15061473

  3. In Vivo Real-Time Quantum Dots Imaging to Track Transplanted Adipose Stem Cells in Different Inflammatory States of Acute Liver Failure Mice. International journal

    Shota Yamada, Hiroshi Yukawa, Koudai Kitamura, Toshiki Mizumaki, Yasuma Yoshizumi, Tomomi Oohara, Eri Nanizawa, Fumika Hirano, Kazuhide Sato, Ayae Sugawara-Narutaki, Tetsuya Ishikawa, Yoshinobu Baba

    Cell transplantation   Vol. 32   page: 9636897231176442 - 9636897231176442   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Stem cell therapy plays an important role in regenerative therapy; however, there is little information on the in vivo dynamics of transplanted stem cells and the influence of the inflammation of affected tissues or organs on these dynamics. In this study, we revealed real-time dynamics of transplanted adipose tissue-derived stem cells (ASCs) and the influence of the inflammatory states on these dynamics in acute liver failure mice. Quantum dots (QDs) labeling did not affect the cytokine profile of ASCs, and intravenously transplanted ASCs labeled with QDs could be detected in real time with high efficiency without laparotomy. Until 30 min after ASC transplantation, no marked differences in the behavior or accumulation of transplanted ASCs in the liver were observed among the three groups with different degrees of liver damage (normal, weak, and strong). However, significant differences in the engraftment rate of transplanted ASCs in the liver were observed among the three groups from 4 h after transplantation. The engraftment rate was inversely correlated with the extent of the liver damage. These data suggested that QDs are useful for in vivo real-time imaging of transplanted cells, and the inflammatory state of tissues or organs may affect the engraftment rate of transplanted cells.

    DOI: 10.1177/09636897231176442

    Scopus

    PubMed

    researchmap

  4. Treatment with hepatocyte transplantation in a novel mouse model of persistent liver failure. Reviewed International journal

    Yuki Tamaki, Yuria Shibata, Misaki Hayakawa, Nodoka Kato, Ami Machii, Yuma Ikeda, Eri Nanizawa, Yumi Hayashi, Hiroshi Suemizu, Hiroyasu Ito, Tetsuya Ishikawa

    Biochemistry and biophysics reports   Vol. 32   page: 101382 - 101382   2022.12

     More details

    Authorship:Last author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND AND AIM: Cell-based transplantation therapy using hepatocytes, hepatic stem cells, hepatocyte-like cells induced from stem cells, etc. is thought to be an attractive alternative to liver transplantation, and have been studied to date. For its clinical application, however, it is extremely important to develop a model that reproduces the pathological conditions with indication for treatment and enables the study for the ideal treatment strategy. METHODS: The transgenic mice which express the thymidine kinase (TK) gene of human herpes simplex virus (HSV) in their hepatocytes with normal immunity has been developed (designated as HSVtk). After ganciclovir (GCV) administration which injure TK-expressing hepatocytes, the primary hepatocytes (PHs) isolated from green fluorescent protein (GFP) transgenic mouse (GFP-tg) were transplanted to HSVtk intrasplenically, and replacement index (RI) with transplanted PHs in the liver, liver histology, and mRNA expressions in the liver were analyzed up to 8 weeks after transplantation. RESULTS: HSVtk without PH transplantation after GCV administration developed persistent liver failure with degenerated hepatocytes, persistent elevation of ALT and hepatic p16 mRNA levels, suggesting the existence of cellular senescence in the base of the disease. When autologous GFP-PHs were transplanted to HSVtk, the transplanted cells were successfully engrafted in the liver. Eight weeks after transplantation, serum ALT levels and liver histology were almost normalized, while RIs varied from 19.8 to 73.8%. Since the hepatic p16 mRNA levels were decreased significantly in these mice, the senescence of hepatocytes associated with liver injury was thought to be resolved. On the other hand, allogenic GFP-PHs transplanted to HSVtk were eliminated as early as 1 week after transplantation. In these mice, hepatic p16 mRNA levels were significantly increased at 8 weeks after transplantation, suggesting the aggravation of hepatocyte senescence. FK506 administration to HSVtk protected the transplanted hepatocytes with allogenic background from rejection at 2 weeks after transplantation, but the condition of mice and the senescent status in the liver seemed worsened. CONCLUSIONS: The mouse model with HSVtk/GCV system was useful for studying the mechanism of liver regeneration and the immune rejection responses in the hepatocyte transplantation treatment. It may also be utilized to develop the effective remedies to avoid immune rejection.

    DOI: 10.1016/j.bbrep.2022.101382

    Scopus

    PubMed

    researchmap

  5. Factors associated with the progression of myosteatosis in patients with cirrhosis. Reviewed

    Ishizu Y, Ishigami M, Honda T, Imai N, Ito T, Yamamoto K, Yokoyama S, Ishikawa T, Fujishiro M

    Nutrition (Burbank, Los Angeles County, Calif.)   Vol. 103-104   page: 111777   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Nutrition  

    Objectives: The presence of myosteatosis is one factor associated with poor prognosis for patients with cirrhosis; however, the factors contributing to worsening myosteatosis are, to our knowledge, unknown. The aim of this study was to clarify the changes in myosteatosis, and the factors involved in these changes. Methods: The present study enrolled 178 patients with cirrhosis who underwent computed tomography twice to measure changes in skeletal muscle attenuation (SMA) at the L3 level. Factors associated with SMA and those associated with changes in SMA were examined. Results: Using linear multiple regression analysis, age (β = –0.22), skeletal muscle index (SMI; skeletal muscle area divided by height squared; β = 0.25), and visceral and subcutaneous fat indices (VFI and SFI; the visceral and subcutaneous fat areas at the umbilical level divided by height squared; β = –0.08, β = –0.06, respectively) were identified as associated with SMA. The 100-d change in SMA was –0.21 ± 1.29 Hounsfield units (HU). Changes in SMI and SMA were positively associated (R = 0.183, P = 0.014), whereas those in VFI and SMA were negatively associated (R = –0.172, P = 0.022). No association was noted between the 100-d changes in SFI and SMA. In patients whose SMI increased and VFI decreased, the 100-d change in SMA was 0.24 ± 1.82 HU, which was marginally different from that in patients whose SMI decreased and VFI increased (–0.44 ± 1.32 HU, P = 0.077). Conclusions: In patients with cirrhosis, myosteatosis progressed, and decreases in SMI and increases in VFI were correlated with its progression.

    DOI: 10.1016/j.nut.2022.111777

    Scopus

    PubMed

  6. Effect of illness uncertainty on alanine transaminase levels and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease Reviewed

    Naoki Ozawa, Kazuki Sato, Ayumi Sugimura, Shigeyoshi Maki, Taku Tanaka, Kenta Yamamoto, Takanori Ito, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Masatoshi Ishigami, Mitsuhiro Fujishiro, Tetsuya Ishikawa, Shoko Ando

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 84 ( 4 ) page: 857 - 864   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NAGOYA UNIV, SCH MED  

    Patients with nonalcoholic fatty liver disease (NAFLD) have illness uncertainty. The purpose of this longitudinal study was to investigate the effect of the degree of illness uncertainty in patients with NAFLD on liver function values. We conducted a questionnaire survey and collected blood samples from outpatients with NAFLD. The items in the questionnaire were measured for illness uncertainty using the Japanese version of the Mishel Uncertainty in Illness Scale-Community (MUIS-C). Blood samples were collected at baseline and after 1 year. We divided the patients into two groups: one with high illness uncertainty and the other with low illness uncertainty. We then compared changes in alanine transaminase (ALT) and aspartate aminotransferase (AST) levels over time from baseline using multiple regression analysis. This study analyzed 148 patients with NAFLD; 75 were male and 73 were female, with a mean age of 58.4 +/- 12.3 years. The group with higher illness uncertainty had significantly higher ALT and AST levels at 1 year (b = .185 and .183, respectively) than the group with lower illness uncertainty. High illness uncertainty in patients with NAFLD can lead to higher ALT and AST levels. Healthcare providers must focus on reducing illness uncertainty in patients with NAFLD.

    DOI: 10.18999/nagjms.84.4.857

    Web of Science

    Scopus

    PubMed

    researchmap

  7. Decreased appetite is associated with the presence of sarcopenia in patients with cirrhosis. Reviewed

    Ishizu Y, Ishigami M, Honda T, Imai N, Ito T, Yamamoto K, Yokoyama S, Ishikawa T, Kawashima H

    Nutrition (Burbank, Los Angeles County, Calif.)   Vol. 103-104   page: 111807   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Nutrition  

    Objectives: To our knowledge, the relationship between appetite and sarcopenia in patients with cirrhosis is unknown. The aims of this study were to examine the factors associated with decreased appetite and to clarify the relationship between appetite and sarcopenia. Methods: This study included 61 patients with cirrhosis. The patients were asked to describe their appetite using a numerical rating scale (NRS) from 0 (none at all) to 10 (most), with ≤5 defined as decreased appetite. The clinical characteristics, gastrointestinal symptoms as assessed using the Gastrointestinal Symptom Rating Scale, handgrip strength, and skeletal muscle area at the third vertebra were collected retrospectively. Sarcopenia was diagnosed according to the criteria of the Japan Society of Hepatology. The differences in these factors between patients with and without decreased appetite, and the factors associated with the presence of sarcopenia were examined. Results: Alcoholic liver disease was the most common etiology. The median Model for End-Stage Liver Disease score was 8 (interquartile range = 7 - 10) and hepatocellular carcinoma was present in 35 patients. Overall, 36% of the patients with cirrhosis had decreased appetite. Patients with decreased appetite had a higher frequency of abdominal pain and acid reflux–related symptoms and significantly lower handgrip strength than patients without, among both men (P = 0.034) and women (P = 0.017). The multivariate analysis identified a decrease in appetite as a significant factor associated with the presence of sarcopenia (NRS one increase, odds ratio, 0.701; 95% confidence interval, 0.502–0.977; P = 0.036). Conclusion: Decreased appetite was associated with the presence of sarcopenia.

    DOI: 10.1016/j.nut.2022.111807

    Scopus

    PubMed

  8. An improved method to assess skeletal muscle mass in patients with liver cirrhosis based on computed tomography images. Reviewed

    Sugiyama Y, Ishizu Y, Ando Y, Yokoyama S, Yamamoto K, Ito T, Imai N, Nakamura M, Honda T, Kawashima H, Ishikawa T, Ishigami M

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 52 ( 11 ) page: 937 - 946   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Hepatology Research  

    Aim: Conventionally, the skeletal muscle area with computed tomography (CT) attenuation ranging from −29 to +150 Hounsfield unit (HU) divided by height squared (the conventional skeletal muscle index [SMI]) was used as an index of skeletal muscle mass. However, it includes fat-infiltrated skeletal muscle, which is known to have poor function. This study aims to determine whether the low-fat SMI, which uses skeletal muscle mass with CT attenuation ranging from +30 to +150 HU, or conventional SMI appropriately reflects the function of skeletal muscle. Methods: We retrospectively analyzed 120 patients with cirrhosis whose handgrip strength was measured. Among them, 48 patients underwent a physical performance assessment such as liver frailty index (LFI) and short physical performance battery (SPPB), and 80 underwent quality of life (QOL) assessment. The relationships between each SMI and handgrip strength, LFI, SPPB, and QOL were evaluated. Results: Low-fat SMI was significantly correlated with handgrip strength (males, R = 0.393, p = 0.002; females, R = 0.423, p < 0.001) and LFI (males, R = −0.535, p = 0.035; females, R = −0.368, p = 0.039), whereas conventional SMI was not. When using low-fat SMI, patients with low skeletal muscle mass had significantly low handgrip strength, LFI, SPPB, and physical and social-related QOL score than those without. By contrast, no significant differences were found for any items when using conventional SMI. Conclusions: Low-fat SMI is a good index of skeletal muscle mass that appropriately reflects skeletal muscle function.

    DOI: 10.1111/hepr.13820

    Scopus

    PubMed

  9. Short-term high-fat and high-carbohydrate diets increase susceptibility to liver injury by inducing hepatic procoagulant and proinflammatory conditions with different balances. Reviewed International journal

    Eri Nanizawa, Shun Otsuka, Naoyuki Hatayama, Yuki Tamaki, Yumi Hayashi, Tetsuya Ishikawa, Shuichi Hirai, Munekazu Naito

    Nutrition (Burbank, Los Angeles County, Calif.)   Vol. 101   page: 111710 - 111710   2022.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: High-fat diet (HFD) and high-carbohydrate diet (HCD) are strongly linked to nonalcoholic fatty liver disease, a hepatic manifestation of metabolic syndrome. The mechanism of pathologic progression from nonalcoholic fatty liver disease to nonalcoholic steatohepatitis, which is a more severe form associated with inflammation and fibrosis, remains poorly understood. Thus, the aim of this study was to investigate and compare the inflammatory and coagulative state of the liver in short-term HFD- or HCD-fed mice with acute liver injury induced by concanavalin A (Con A). METHODS: Histopathologic evaluation, real-time polymerase chain reaction, and immunohistochemical evaluation were performed on the liver of mice fed HFDs and HCDs for 4 d before and after Con A administration. RESULTS: The liver of the HFD-fed mice had larger fibrinogen/fibrin depositions than those fed the HCD. HCD induced the expression of the proinflammatory cytokine tumor necrosis factor-α in the liver. Moreover, the expression of proinflammatory cytokines and chemokines was further enhanced after Con A stimulation in HCD (e.g., interleukin-1α, interleukin-6 at 1 h), with a strong tendency for inflammatory cell infiltration also found (24 h). CONCLUSIONS: Short-term HCD and HFD increased susceptibility to liver injury. HCD tended to induce more intense inflammation, whereas HFD tended to induce more intense hypercoagulation, suggesting that HCD and HFD may have different mechanisms of pathologic progression to nonalcoholic steatohepatitis.

    DOI: 10.1016/j.nut.2022.111710

    Scopus

    PubMed

    researchmap

  10. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study Reviewed

    Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T

    EBioMedicine   Vol. 80   page: 104069   2022.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1016/j.ebiom.2022.104069.

  11. Changes in the gut microbiota after hepatitis C virus eradication. International journal

    Takashi Honda, Masatoshi Ishigami, Kenta Yamamoto, Tomoaki Takeyama, Takanori Ito, Yoji Ishizu, Teiji Kuzuya, Masanao Nakamura, Hiroki Kawashima, Ryoji Miyahara, Tetsuya Ishikawa, Yoshiki Hirooka, Mitsuhiro Fujishiro

    Scientific reports   Vol. 11 ( 1 ) page: 23568 - 23568   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The gut microbiota interacts with infectious diseases and affects host immunity. Liver disease is also reportedly associated with changes in the gut microbiota. To elucidate the changes in the gut microbiota before and after hepatitis C virus (HCV) eradication through direct-acting antiviral (DAA) treatment in patients with chronic hepatitis C (CHC), we investigated 42 samples from 14 patients who received DAA therapy for HCV. Fecal samples were obtained before treatment (Pre), when treatment ended (EOT), and 24 weeks after treatment ended (Post24). The target V3-4 region of the 16S rRNA gene from fecal samples was amplified using the Illumina Miseq sequencing platform. The diversity of the gut microbiota did not significantly differ between Pre, EOT, and Post24. Principal coordinates analysis showed that for each patient, the values at Pre, EOT, and Post24 were concentrated within a small area. The linear discriminant analysis of effect size showed that the relative abundances of Faecalibacterium and Bacillus increased at EOT, further increased at Post24, and were significantly increased at Post24 compared to Pre. These suggest that changes in the gut microbiota should be considered as among the various effects observed on living organisms after HCV eradication.

    DOI: 10.1038/s41598-021-03009-0

    Scopus

    PubMed

    researchmap

  12. Obesity and myosteatosis: the two characteristics of dynapenia in patients with cirrhosis.

    Sugiyama Y, Ishizu Y, Ando Y, Yokoyama S, Yamamoto K, Ito T, Imai N, Nakamura M, Honda T, Kawashima H, Ishikawa T, Ishigami M

    European journal of gastroenterology & hepatology   Vol. 33 ( 1S Suppl 1 ) page: e916 - e921   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:European journal of gastroenterology &amp; hepatology  

    OBJECTIVE: In patients with liver cirrhosis, the clinical characteristics of dynapenia, a condition in which skeletal muscle mass is maintained but muscle strength is reduced, are not yet known. This study aimed to clarify the characteristics of dynapenia and its impact on quality of life (QOL) in patients with liver cirrhosis. METHODS: We retrospectively analyzed 116 patients with cirrhosis. Based on grip strength and skeletal muscle mass measured by the bioelectrical impedance analysis method, patients were divided into four groups: normal muscle status, dynapenia, pre-sarcopenia (a condition involving only low muscle mass), and sarcopenia. The characteristics of dynapenia and its influence on QOL were examined. RESULTS: Fourteen patients had dynapenia. Liver function did not differ among the four groups. In patients with dynapenia, BMI was highest and computed tomography attenuation of skeletal muscle at the third lumbar spine vertebra was lowest among the four groups. The percentage of patients with both BMI ≥25 kg/m2 and myosteatosis was significantly higher in patients with dynapenia [9/14 (64.3%)] than in those with sarcopenia [2/23 (8.7%), P = 0.004] and pre-sarcopenia [0/18 (0%), P < 0.001] and tended to be higher than those with normal muscle status [16/61 (26.2%), P = 0.065]. The physical QOL in patients with dynapenia was as low as that in those with sarcopenia and significantly lower than that in those with normal muscle status. CONCLUSION: Cirrhotic patients with dynapenia had high BMI and myosteatosis, and impaired physical QOL.

    DOI: 10.1097/MEG.0000000000002303

    Scopus

    PubMed

  13. All-atom molecular dynamics study of hepatitis B virus containing pregenome RNA in solution. Reviewed

    Fujimoto K, Yamaguchi Y, Urano R, Shinoda W, Ishikawa T, Omagari K, Tanaka Y, Nakagawa A, Okazaki S

    The Journal of chemical physics   Vol. 155 ( 14 ) page: 145101   2021.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of Chemical Physics  

    Immature hepatitis B virus (HBV) captures nucleotides in its capsid for reverse transcription. The nucleotides and nucleotide analog drugs, which are triphosphorylated and negatively charged in the cell, approach the capsid via diffusion and are absorbed into it. In this study, we performed a long-time molecular dynamics calculation of the entire HBV capsid containing pregenome RNA to investigate the interactions between the capsid and negatively charged substances. Electric field analysis demonstrated that negatively charged substances can approach the HBV capsid by thermal motion, avoiding spikes. The substances then migrate all over the floor of the HBV capsid. Finally, they find pores through which they can pass through the HBV capsid shell. Free energy profiles were calculated along these pores for small ions to understand their permeability through the pores. Anions (Cl−) showed higher free energy barriers than cations (Na+ and K+) through all pores, and the permeation rate of Cl− was eight times slower than that of K+ or Na+. Furthermore, the ions were more stable in the capsid than in the bulk water. Thus, the HBV capsid exerts ion selectivity for uptake and provides an environment for ions, such as nucleotides and nucleotide analog drugs, to be stabilized within the capsid.

    DOI: 10.1063/5.0065765

    Scopus

    PubMed

  14. Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the Gut-Liver axis. Reviewed

    Muto H, Ito T, Tanaka T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Maeda K, Honda T, Ishikawa T, Kato A, Ohshiro T, Kano F, Yamamoto A, Sakai K, Hibi H, Ishigami M, Fujishiro M

    Scientific reports   Vol. 11 ( 1 ) page: 18778   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Scientific Reports  

    Non-alcoholic steatohepatitis (NASH) occurrence has been increasing and is becoming a major cause of liver cirrhosis and liver cancer. However, effective treatments for NASH are still lacking. We examined the benefits of serum-free conditioned medium from stem cells derived from human exfoliated deciduous teeth (SHED-CM) on a murine non-alcoholic steatohepatitis (NASH) model induced by a combination of Western diet (WD) and repeated administration of low doses of carbon tetrachloride intraperitoneally, focusing on the gut-liver axis. We showed that repeated intravenous administration of SHED-CM significantly ameliorated histological liver fibrosis and inflammation in a murine NASH model. SHED-CM inhibited parenchymal cell apoptosis and reduced the activation of inflammatory macrophages. Gene expression of pro-inflammatory and pro-fibrotic mediators (such as Tnf-α, Tgf-β, and Ccl-2) in the liver was reduced in mice treated with SHED-CM. Furthermore, SHED-CM protected intestinal tight junctions and maintained intestinal barrier function, while suppressing gene expression of the receptor for endotoxin, Toll-like receptor 4, in the liver. SHED-CM promoted the recovery of Caco-2 monolayer dysfunction induced by IFN-γ and TNF-α in vitro. Our findings suggest that SHED-CM may inhibit NASH fibrosis via the gut-liver axis, in addition to its protective effect on hepatocytes and the induction of macrophages with unique anti-inflammatory phenotypes.

    DOI: 10.1038/s41598-021-98254-8

    Scopus

    PubMed

  15. Transient deterioration of albumin-bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation: A STROBE-compliant retrospective observational study. International journal

    Hisanori Muto, Teiji Kuzuya, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Masatoshi Ishigami, Mitsuhiro Fujishiro

    Medicine   Vol. 100 ( 31 ) page: e26820   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    ABSTRACT: Real-world clinical cases of molecularly targeted agent (MTA) administration to patients with advanced hepatocellular carcinoma (HCC) with ≥50% liver occupation have been reported, but treatment outcomes have rarely been described. We have encountered several cases in which albumin-bilirubin (ALBI) scores deteriorated markedly and C-reactive protein (CRP) levels elevated in the early post-dose period. The present study therefore investigated early clinical changes in ALBI score and CRP levels after initiating MTA in advanced HCC patients with ≥50% liver occupation, focusing on antitumor response at 6 weeks.This retrospective study included 46 HCC patients with liver occupation ≥50% and 191 patients with <50%, Child-Pugh score ≤7, and Eastern Cooperative Oncology Group Performance Status scores of 0 or 1, who were treated with sorafenib or lenvatinib as first-line systemic therapy at our hospital between June 2011 and January 2020. We analyzed their medical records up to March 2020 and investigated the outcomes and changes in CRP and ALBI scores classified according to antitumor response at 6 weeks.Overall survival was significantly longer in patients with partial response (PR) + stable disease (SD) (13.7 months) than in patients with progressive disease (PD) (1.7 months, P < .001) in the ≥50% group. Patients with antitumor response of PR + SD at 6 weeks in the ≥50% group showed more marked deterioration of ALBI score at 2 weeks than those in the <50% group. These significant differences between groups had again disappeared at 4 and 6 weeks. Focusing on patients with PD at 6 weeks, ALBI score deteriorated over time in both groups. Regarding CRP, on 6-week PR + SD patients, a significant increase in CRP levels at 1 and 2 weeks was evident in the >50% group compared to the <50% group. These significant differences between groups had again disappeared at 4 and 6 weeks. In PD patients, no difference between groups in CRP elevation occurred at 1 and 2 weeks.In MTA treatment for patients with ≥50% liver occupation, to obtain an antitumor response of PR + SD, adequate management might be important considering transient deteriorated ALBI scores and elevated CRP levels.

    DOI: 10.1097/MD.0000000000026820

    Scopus

    PubMed

    researchmap

  16. Amino Acid Polymorphism in Hepatitis B Virus Associated With Functional Cure. Invited Reviewed

    Honda T, Yamada N, Murayama A, Shiina M, Aly HH, Kato A, Ito T, Ishizu Y, Kuzuya T, Ishigami M, Murakami Y, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Ishikawa T, Fujishiro M, Muramatsu M, Wakita T, Kato T

    Cellular and molecular gastroenterology and hepatology   Vol. 12 ( 5 ) page: 1583 - 1598   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Cellular and Molecular Gastroenterology and Hepatology  

    Background & Aims: To provide an adequate treatment strategy for chronic hepatitis B, it is essential to know which patients are expected to have a good prognosis and which patients do not require therapeutic intervention. Previously, we identified the substitution of isoleucine to leucine at amino acid 97 (I97L) in the hepatitis B core region as a key predictor among patients with stable hepatitis. In this study, we attempted to identify the point at which I97L affects the hepatitis B virus (HBV) life cycle and to elucidate the underlying mechanisms governing the stabilization of hepatitis. Methods: To confirm the clinical features of I97L, we used a cohort of hepatitis B e antigen–negative patients with chronic hepatitis B infected with HBV-I97 wild-type (wt) or HBV-I97L. The effects of I97L on viral characteristics were evaluated by in vitro HBV production and infection systems with the HBV reporter virus and cell culture-generated HBV. Results: The ratios of reduction in hepatitis B surface antigen and HBV DNA were higher in patients with HBV-I97L than in those with HBV-I97wt. HBV-I97L exhibited lower infectivity than HBV-I97wt in both infection systems with reporter HBV and cell culture-generated HBV. HBV-I97L virions exhibiting low infectivity primarily contained a single-stranded HBV genome. The lower efficiency of cccDNA synthesis was demonstrated after infection of HBV-I97L or transfection of the molecular clone of HBV-I97L. Conclusions: The I97L substitution reduces the level of cccDNA through the generation of immature virions with single-stranded genomes. This I97L-associated low efficiency of cccDNA synthesis may be involved in the stabilization of hepatitis.

    DOI: 10.1016/j.jcmgh.2021.07.013

    Scopus

    PubMed

  17. Interferon signaling suppresses the unfolded protein response and induces cell death in hepatocytes accumulating hepatitis B surface antigen. Reviewed International coauthorship International journal

    Ian Baudi, Masanori Isogawa, Federica Moalli, Masaya Onishi, Keigo Kawashima, Yuji Ishida, Chise Tateno, Yusuke Sato, Hideyoshi Harashima, Hiroyasu Ito, Tetsuya Ishikawa, Takaji Wakita, Matteo Iannacone, Yasuhito Tanaka

    PLoS pathogens   Vol. 17 ( 5 ) page: e1009228   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Virus infection, such as hepatitis B virus (HBV), occasionally causes endoplasmic reticulum (ER) stress. The unfolded protein response (UPR) is counteractive machinery to ER stress, and the failure of UPR to cope with ER stress results in cell death. Mechanisms that regulate the balance between ER stress and UPR are poorly understood. Type 1 and type 2 interferons have been implicated in hepatic flares during chronic HBV infection. Here, we examined the interplay between ER stress, UPR, and IFNs using transgenic mice that express hepatitis B surface antigen (HBsAg) (HBs-Tg mice) and humanized-liver chimeric mice infected with HBV. IFNα causes severe and moderate liver injury in HBs-Tg mice and HBV infected chimeric mice, respectively. The degree of liver injury is directly correlated with HBsAg levels in the liver, and reduction of HBsAg in the transgenic mice alleviates IFNα mediated liver injury. Analyses of total gene expression and UPR biomarkers' protein expression in the liver revealed that UPR is induced in HBs-Tg mice and HBV infected chimeric mice, indicating that HBsAg accumulation causes ER stress. Notably, IFNα administration transiently suppressed UPR biomarkers before liver injury without affecting intrahepatic HBsAg levels. Furthermore, UPR upregulation by glucose-regulated protein 78 (GRP78) suppression or low dose tunicamycin alleviated IFNα mediated liver injury. These results suggest that IFNα induces ER stress-associated cell death by reducing UPR. IFNγ uses the same mechanism to exert cytotoxicity to HBsAg accumulating hepatocytes. Collectively, our data reveal a previously unknown mechanism of IFN-mediated cell death. This study also identifies UPR as a potential target for regulating ER stress-associated cell death.

    DOI: 10.1371/journal.ppat.1009228

    Scopus

    PubMed

    researchmap

  18. Quality of Life in patients with nonalcoholic fatty liver disease: Structure and related factors focusing on illness uncertainty. Reviewed

    Naoki Ozawa, Kazuki Sato, Ayumi Sugimura, Shigeyoshi Maki, Taku Tanaka, Kenta Yamamoto, Takanori Ito, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Masatoshi Ishigami, Mitsuhiro Fujishiro, Tetsuya Ishikawa, Shoko Ando

    Japan journal of nursing science : JJNS   Vol. 18 ( 3 ) page: e12415   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    AIM: Patients with nonalcoholic fatty liver disease (NAFLD) have a low quality of life (QOL) and illness uncertainty. This study examined the structure of QOL and associated factors, including illness uncertainty, among individuals with NAFLD. METHODS: A cross-sectional survey was conducted using a self-administered questionnaire for outpatients with NAFLD. QOL was measured using the Short Form-8. Dietary habits, physical activity level, illness uncertainty, health locus of control, and knowledge of NAFLD were assessed. Path analysis was used to study the associated factors of QOL and their structure, including uncertainty of disease. RESULTS: Path analysis of 168 NAFLD patients indicated that a high Physical Component Summary score on the Short Form-8-representing physical QOL-was predicted by a body mass index <25 kg/m2 and high educational level. A high Mental Component Summary score-representing mental QOL-was predicted by being male, good dietary habits, low illness uncertainty, and presence of consultants. The model showed satisfactory goodness-of-fit without being rejected by the chi-square test (goodness-of-fit index = .947, adjusted goodness-of-fit index = .917, comparative fit index = .967, root mean square error of approximation = 0.023). CONCLUSIONS: Nurses need to work closely with NAFLD patients as consultants, providing adequate information about the causes, treatments, and dietary habits, and focusing on the individual's perception of health. This could reduce illness uncertainty and contribute to the improvement of QOL.

    DOI: 10.1111/jjns.12415

    Scopus

    PubMed

    researchmap

  19. Novel hepatitis B virus infection mouse model using herpes simplex virus type 1 thymidine kinase transgenic mice. Reviewed International journal

    Ayumu Kanbe, Tetsuya Ishikawa, Akira Hara, Hiroshi Suemizu, Eri Nanizawa, Yuki Tamaki, Hiroyasu Ito

    Journal of gastroenterology and hepatology   Vol. 36 ( 3 ) page: 782 - 789   2021.3

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND AND AIM: The chronicity of hepatitis B virus (HBV) infection is the result of impaired HBV-specific immune responses that cannot eliminate or cure the infected hepatocytes efficiently. Previous studies have used immunodeficient mice such as herpes simplex virus type 1 thymidine kinase NOD/Scid/IL2Rrnull (HSV-TK-NOG) mice. However, it is difficult to analyze the immune response in the previous models. In the present study, we established a novel HBV infection model using herpes simplex virus type 1 thymidine kinase (HSV-TK) mice in which the host immune system was not impaired. METHODS: Herpes simplex virus type 1 thymidine kinase mice were injected intraperitoneally with ganciclovir (GCV). Seven days after GCV injection, GCV-treated mice were transplanted with 1 × 106 hepatocytes from HBV-transgenic (HBV-Tg) mice. RESULTS: Serum alanine aminotransferase levels in HSV-TK mice increased 1 and 2 weeks after GCV injection. The number and viability of hepatocytes from the whole liver of HBV-Tg mice significantly increased using digestion medium containing liberase. Hepatitis B surface antigen (HBsAg)-positive areas in the liver tissue were observed for at least 20 weeks after HBsAg-positive hepatocyte transplantation. In addition, we measured HBsAg in the serum after transplantation. HBsAg levels in HBV-Tg hepatocyte-replaced mice increased 4 weeks after transplantation. Furthermore, we examined the immune response in HSV-TK mice. The increase in hepatitis B surface antibody levels in replaced mice was maintained for 20 weeks. Also, interferon-γ-producing cells were increased in non-replaced mice. CONCLUSIONS: A novel HBV infection mouse model will help to understand the mechanisms of HBV tolerance similar to human chronic HBV-infected patients and can be used to develop a new strategy to treat chronic HBV infection.

    DOI: 10.1111/jgh.15142

    Scopus

    PubMed

    researchmap

  20. 進行肝細胞癌に対するレンバチニブPD後のラムシルマブ治療の初期経験

    葛谷 貞二, 石上 雅敏, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 石津 洋二, 本多 隆, 石川 哲也, 藤城 光弘

    Pharma Medica   Vol. 39 ( 2 ) page: 72 - 73   2021.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:(株)メディカルレビュー社  

    researchmap

  21. Free energy profile of permeation of Entecavir through Hepatitis B virus capsid studied by molecular dynamics calculation Invited Reviewed

    Fujimoto K., Fukai M., Urano R., Shinoda W., Ishikawa T., Omagari K., Tanaka Y., Nakagawa A., Okazaki S.

    Pure and Applied Chemistry   Vol. 92 ( 10 ) page: 1585 - 1594   2020.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Pure and Applied Chemistry  

    Entecavir, triphosphorylated in liver cells, is an antiviral reagent against Hepatitis B virus (HBV). The reagent inhibits reverse transcription of RNA inside the virus capsid. In the present study, free energy profile of an Entecavir triphosphate (ETVTP) molecule has been calculated when it passes through pores of the capsid along two- and three-fold rotational symmetry axes in order to investigate permeation pathway of the reagent to the inside of the capsid. The calculations have been done based on thermodynamic integration (TI) method combined with all-atomistic molecular dynamic (MD) calculations. A free energy minimum of -19 kJ/mol was found at the entrance of the pore from the outside along the three-fold symmetry axis. This stabilization is from the interaction of negatively charged ETVTP with positively charged capsid methionine residues. This excess free energy concentrates of the reagent at the entrance of the pore by a factor of about 2000. A free energy barrier of approximately 13 kJ/mol was also found near the exit of the pore to the inside of the capsid due to narrow space of the pore surrounded by hydrophobic wall made by proline residues and negatively charged wall by aspartic acid residues. There, ETVTP is partially dehydrated in order to pass through the narrow space, which causes the great free energy loss. Further, the negatively charged residues produce repulsive forces on the ETVTP molecule. In contrast, in the case of the pore along the two-fold symmetry axis, the calculated free energy profile showed shallower free energy minimum, -4 kJ/mol at the entrance in spite of the similarly high barrier, 7 kJ/mol, near the exit of the pore.

    DOI: 10.1515/pac-2020-0109

    Scopus

  22. Short-term high-fat diet intake leads to exacerbation of concanavalin A-induced liver injury through the induction of procoagulation state. Reviewed International journal

    Eri Nanizawa, Yuki Tamaki, Reika Sono, Rintaro Miyashita, Yumi Hayashi, Ayumu Kanbe, Hiroyasu Ito, Tetsuya Ishikawa

    Biochemistry and biophysics reports   Vol. 22   page: 100736 - 100736   2020.7

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    Obesity and high-fat diet (HFD) are known to cause proinflammatory and procoagulation states and suggested to become a risk of developing thromboembolic diseases. Non-alcoholic fatty liver disease (NAFLD) is usually associated with obesity and HFD, and a part of NAFLD is known to progress to nonalcoholic steatohepatitis (NASH), the pathogenesis of which has not been fully elucidated. In the current study, we examined the influence of short-term HFD on hepatic expression of the molecules related to inflammation, coagulation, metabolism, and cellular stresses from the perspective that HFD itself can be a risk for the development to NASH. In the analysis in short-term (4 days to 14 days) HFD-fed mice, we found out that HFD increased hepatic expression of IFN-γ, TNF-α, IL-10, monocyte chemotactic protein-1 (MCP-1), tissue factor (TF), plasminogen activator inhibitor-1 (PAI-1) mRNAs, and fibrin/fibrinogen deposition in the liver tissues. And it was suggested that metabolic alterations and endoplasmic reticulum (ER) stresses induced by the HFD intake were associated with this proinflammatory and procoagulation states. When we administered concanavalin A (Con A) to these HFD-fed mice, the extent of liver injury was dramatically exacerbated in HFD-fed mice. Heparin treatment to Con A-administered, HFD-fed mice (for 4 days) profoundly ameliorated the extent of liver injury. These suggest that even short-term of HFD intake induces proinflammatory and procoagulation states in the liver and thereby increases the susceptibility of the liver to circulating inflammatory stimuli. We think that it may explain a part of NASH pathogenesis.

    DOI: 10.1016/j.bbrep.2020.100736

    Scopus

    PubMed

    researchmap

  23. A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation. Invited Reviewed International journal

    Koji Nishikawa, Kiminori Kimura, Yoshinobu Kanda, Masaya Sugiyama, Kazuhiko Kakihana, Noriko Doki, Kazuteru Ohashi, Sung Kwan Bae, Kazuhiro Takahashi, Yuko Ishihara, Ishikazu Mizuno, Yasushi Onishi, Masahiro Onozawa, Makoto Onizuka, Masahide Yamamoto, Tetsuya Ishikawa, Kazuaki Inoue, Shigeru Kusumoto, Satoshi Hashino, Hidetsugu Saito, Tatsuya Kanto, Hisashi Sakamaki, Masashi Mizokami

    Bone marrow transplantation   Vol. 55 ( 7 ) page: 1388 - 1398   2020.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Hepatitis B virus (HBV) reactivation reportedly occurs frequently after hematopoietic stem cell transplantation (HSCT) in resolved HBV-infected patients. Here, 50 patients with resolved HBV infections and scheduled to undergo HSCT were enrolled; all subjects were vaccinated with three doses of hepatitis B vaccine 12 months after HSCT and the incidence of HBV reactivation was monitored. The patients' characteristics were: median age, 61 (34-72) years; male/female, 27/19; allogeneic/autologous, 40/6; bone marrow/peripheral blood stem cells/cord blood, 26/16/4. Of the 46 patients who underwent HSCT, 19 were excluded and did not make it to vaccination due to relapse of underlying disease, HBV reactivation within 12 months of HSCT, or transfer of patients. The remaining 27 were vaccinated 12 months after HSCT and monitored for 2 years. Six showed HBV reactivation, with a 2-year cumulative reactivation incidence of 22.2%; the same incidence was 27.3% only in allogeneic HSCT patients. Factors associated with HBV reactivation included the discontinuation of immunosuppressants (P = 0.0379) and baseline titers of antibody against hepatitis B surface antigen (P = 0.004). HBV reactivation with vaccination following HSCT could occur despite maintenance of serum anti-HBs at more than protective levels.

    DOI: 10.1038/s41409-020-0833-5

    Scopus

    PubMed

    researchmap

  24. Complete response of advanced hepatocellular carcinoma achieved by sorafenib dose re-escalation after failure of long-term low-dose-sorafenib treatment combined with transcatheter arterial chemoembolization: a case report. Reviewed

    Hisanori Muto, Teiji Kuzuya, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Masatoshi Ishigami, Mitsuhiro Fujishiro

    Clinical journal of gastroenterology   Vol. 13 ( 3 ) page: 397 - 402   2020.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Few reports have described dose re-escalation after long-term low-dose sorafenib leading to good outcomes. Here, we report the case of an 80-year-old woman with advanced hepatocellular carcinoma who achieved complete response from sorafenib dose re-escalation after the failure of long-term low-dose sorafenib treatment combined with transcatheter arterial chemoembolization. Sorafenib therapy was initiated at 400 mg once daily due to old age and low platelet count. 5 months later, this dose was reduced to 200 mg once daily because of adverse events. Best radiological antitumor response by sorafenib treatment alone was judged as stable disease according to the modified Response Evaluation Criteria in Solid Tumors. 1 year later, she showed progressive disease owing to the progression of intrahepatic lesions. She received combination therapy with low-dose sorafenib (200 mg every other day) and transcatheter arterial chemoembolization, which proved relatively effective for three and a half years. Antitumor response by the fourth transcatheter arterial chemoembolization and subsequent low-dose sorafenib was clearly progressive disease. At that time, sorafenib-related adverse events were well-controlled. Sorafenib dose was re-escalated to 200 mg once daily. After this re-escalation, tumor markers declined rapidly, and adverse events remained tolerable. 4 months later, complete response was achieved.

    DOI: 10.1007/s12328-019-01066-7

    Web of Science

    Scopus

    PubMed

    researchmap

  25. Correlation of serum zinc levels with pathological and laboratory findings in patients with nonalcoholic fatty liver disease. Reviewed International journal

    Takanori Ito, Masatoshi Ishigami, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Tetsuya Ishikawa, Hidenori Toyoda, Takashi Kumada, Mitsuhiro Fujishiro

    European journal of gastroenterology & hepatology   Vol. 32 ( 6 ) page: 748 - 753   2020.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: Chronic liver diseases are associated with zinc (Zn) deficiency. However, no previous studies have examined the relationship between serum Zn levels and hepatic pathological findings in patients with nonalcoholic fatty liver disease (NAFLD). The aim of this study was to investigate the serum Zn levels in NAFLD patients based on pathological/laboratory findings. METHODS: We evaluated a total of 191 NAFLD patients who underwent liver biopsy with the goal of identifying laboratory markers and pathological findings associated with serum Zn levels. RESULTS: Zn levels significantly decreased along with progression of hepatic fibrosis (P = 0.039), but there were no significant differences among inflammatory grades. Zn levels were most strongly correlated with albumin levels (r = 0.410, P < 0.001). In addition, Zn levels were significantly correlated with homeostasis model assessment of insulin resistance (HOMA-IR) (r = -0.284, P < 0.001), hyaluronic acid (r = -0.230, P < 0.001), branched chain amino acid/tyrosine molar ratio (BTR) (r = 0.278, P < 0.001), FIB-4 index (r = -0.238, P < 0.001), and NAFLD fibrosis score (NFS) (r = -0.261, P < 0.001). In multivariate analysis, albumin [odds ratio (OR), 9.244 (per 1 g/dL decrease) [95% confidence interval (CI), 2.261-32.744]; P < 0.001], BTR [OR, 1.545 (per 1 decrease) (95% CI, 1.115-2.140); P = 0.009], and HOMA-IR [OR, 1.048 (per 1 increase) (95% CI, 1.019-1.167); P = 0.028] were significantly associated with Zn deficiency. CONCLUSION: The progression of liver fibrosis, but not inflammation, is associated with lower serum Zn levels in biopsy-proven NAFLD patients. Serum Zn levels were correlated with nutrition markers and insulin resistance.

    DOI: 10.1097/MEG.0000000000001587

    Scopus

    PubMed

    researchmap

  26. Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Reviewed International journal

    Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Mitsuhiro Fujishiro

    Anticancer research   Vol. 40 ( 4 ) page: 2283 - 2290   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: We aimed to compare the outcomes between sorafenib and lenvatinib as first-line therapy for advanced hepatocellular carcinoma (HCC) with major portal vein tumor thrombosis (Vp3/4). PATIENTS AND METHODS: This retrospective study enrolled 41 HCC patients with Vp3/4 and Child-Pugh A. RESULTS: The outcomes in the lenvatinib group (n=13) were significantly better than those in the sorafenib group (n=28) [best objective response rate according to the modified Response Evaluation Criteria in Solid Tumors: 53.8% vs. 14.3%; p=0.0193, best disease control rate: 92.3% vs. 35.7%; p=0.0008, median overall survival (OS): not reached vs. 187 days; p=0.0040, respectively]. Lenvatinib treatment was the only significant predictor of better OS and time to tumor progression. No patient needed to discontinue lenvatinib treatment due to drug-related adverse events. CONCLUSION: Compared with sorafenib, lenvatinib treatment for advanced HCC with Vp3/4 may lead to more favorable outcomes.

    DOI: 10.21873/anticanres.14193

    Web of Science

    Scopus

    PubMed

    researchmap

  27. Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma. Reviewed International journal

    Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Mitsuhiro Fujishiro

    Anticancer research   Vol. 40 ( 4 ) page: 2089 - 2093   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: The outcomes of ramucirumab after lenvatinib failure for hepatocellular carcinoma (HCC) patients with alpha fetoprotein (AFP) levels of ≥400 ng/ml are unknown. PATIENTS AND METHODS: Of 12 patients treated with ramucirumab after lenvatinib failure, 10 patients were enrolled in this retrospective study. RESULTS: The disease control rate of 80% at 6 weeks and the median time to progression of 3.1 months were the same by both the Response Evaluation Criteria in Solid Tumors (RECIST) and the modified RECIST. AFP reduction was seen in 5 patients at 2 weeks and in 3 patients at 6 weeks. The incidence of grade 3 adverse events was low at 10%. The albumin-bilirubin scores within 6 weeks did not worsen. CONCLUSION: Ramucirumab might have potential therapeutic efficacy and safety in advanced HCC patients after lenvatinib failure. Further studies are needed to confirm the outcomes of ramucirumab after lenvatinib failure.

    DOI: 10.21873/anticanres.14167

    Web of Science

    Scopus

    PubMed

    researchmap

  28. Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma. Reviewed International journal

    Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Mitsuhiro Fujishiro

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 50 ( 3 ) page: 374 - 381   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    AIM: We aimed to investigate the radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma in real-world practice. METHODS: This retrospective study enrolled 40 patients who received lenvatinib. Radiological antitumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors. RESULTS: The objective response rate at 2 weeks and best overall response on confirmation of complete response, partial response (PR), and stable disease required (confirmed response) were 57.5% and 32.5%, respectively. Based on confirmed response, the overall survival rate was significantly longer in patients with an objective response rate than in those with stable disease or progressive disease after 12 months (73.2% and 54.2%, P = 0.0358). All 13 patients with an objective response rate on confirmed response were evaluated as PR at 2 weeks. The alpha-fetoprotein ratio at 2 weeks was a significant factor associated with PR of response rate at 2 weeks. The median relative dose intensity from 2 to 6 weeks was significantly lower than that from 0 to 2 weeks (69.6% vs. 100%, P < 0.0001). Stratified by the antitumor response at 6 weeks considering the image evaluation at 2 weeks, the median relative dose intensity from 2 to 6 weeks was significantly lower in patients with progressive disease than in those with PR or stable disease (45.2% vs. 72.6%, P = 0.0482). CONCLUSIONS: The radiological antitumor response at 2 weeks was favorable. Information on a favorable visible therapeutic response very early after lenvatinib initiation can help patients maintain their motivation for treatment, and allow physicians to continue treatment effectively and safely.

    DOI: 10.1111/hepr.13452

    Web of Science

    Scopus

    PubMed

    researchmap

  29. Effect of weight change and lifestyle modifications on the development or remission of nonalcoholic fatty liver disease: sex-specific analysis. Reviewed International journal

    Naoki Yoshioka, Masatoshi Ishigami, Yasuko Watanabe, Hajime Sumi, Masao Doisaki, Takeo Yamaguchi, Takanori Ito, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Tetsuya Ishikawa, Jun-Ichi Haruta, Mitsuhiro Fujishiro

    Scientific reports   Vol. 10 ( 1 ) page: 481 - 481   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The effects of changes in various lifestyle habits on nonalcoholic fatty liver disease (NAFLD) have not been well elucidated. We aimed to clarify how weight change and lifestyle modifications were associated with the development or remission of NAFLD. In this longitudinal cohort study, we reviewed the periodic health checkup data of 1,421 subjects with no causes of liver disease besides NAFLD who had received at least two health checkups between 2009 and 2018. The prevalence of NAFLD at baseline was 34.1% (484/1,421). During follow-up period (4.6 ± 2.8 years), 104 subjects developed NAFLD and 127 subjects demonstrated NAFLD remission. The frequency of NAFLD development or that of NAFLD remission significantly increased as the larger weight gain or weight loss was, respectively (both, p < 0.001). Approximately 40% of the subjects who maintained ≥ 1%/year weight loss achieved NAFLD remission. By multivariate analysis, quitting smoking were independently associated with NAFLD development (adjusted odds ratio [AOR], 2.86; 95% CI, 1.24-6.62). Subjects who quit smoking demonstrated large weight gain (≥1%/year) significantly more frequently than the other subjects (p < 0.001). In sex-specific analysis, starting to exercise was independently associated with NAFLD remission in men (AOR, 2.38; 95% CI, 1.25-4.53).

    DOI: 10.1038/s41598-019-57369-9

    Scopus

    PubMed

    researchmap

  30. Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion. International journal

    Taku Tanaka, Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Mitsuhiro Fujishiro

    Oncology   Vol. 98 ( 9 ) page: 621 - 629   2020

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    INTRODUCTION: Because the frequency of bile duct invasion in hepatocellular carcinoma (HCC) patients is very rare, there is limited clinical evidence to demonstrate the outcomes of systemic therapy in HCC with bile duct invasion. OBJECTIVE: Our aim was to clarify the efficacy and safety of sorafenib treatment in patients with unresectable advanced HCC with bile duct invasion. METHODS: One hundred and seventy-five patients with advanced HCC were enrolled in this study. We retrospectively compared the outcomes of sorafenib between patients without bile duct invasion [B (-) group, n = 165] and those with bile duct invasion [B (+) group, n = 10]. RESULTS: There were no significant differences in the confirmed objective response rate (ORR) and the confirmed disease control (DC) rate between the B (-) and the B (+) groups (13.9 vs. 20.0%, p = 0.637 for ORR; 47.2 vs. 70.0%, p = 0.202 for DC rate, respectively). There were no significant differences in median overall survival (OS) and time to progression (TTP) between the B (-) group and the B (+) group (14.8 vs. 14.1 months, p = 0.780 for OS; 3.4 vs. 5.7 months, p = 0.277 for TTP, respectively). Post-treatment factors associated with good OS were changes in albumin-bilirubin score (0-6 weeks) of <0.25, and antitumor response at 6 weeks of DC. Though 5 of 10 patients (50%) in the B (+) group had bile duct complications, such as obstructive jaundice and biliary bleeding, these 5 patients were able to recover from biliary troubles by careful and vigorous management with biliary endoscopic intervention, and were able to continue sorafenib therapy safely. CONCLUSIONS: Our present results suggest that sorafenib might have potential therapeutic efficacy and safety in advanced HCC patients with bile duct invasion. In case of biliary tract troubles before and during sorafenib treatment, early biliary management may be important to continue sorafenib therapy safely. Further studies are needed to confirm the outcomes of sorafenib in advanced HCC patients with bile duct invasion.

    DOI: 10.1159/000507051

    Scopus

    PubMed

    researchmap

  31. Serum Nutritional Markers as Prognostic Factors for Hepatic and Extrahepatic Carcinogenesis in Japanese Patients with Nonalcoholic Fatty Liver Disease. Reviewed International journal

    Takanori Ito, Masatoshi Ishigami, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Tetsuya Ishikawa, Hidenori Toyoda, Takashi Kumada, Mitsuhiro Fujishiro

    Nutrition and cancer   Vol. 72 ( 5 ) page: 884 - 891   2020

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Serum zinc (Zn) levels and the branched chain amino acid/tyrosine molar ratio (BTR) were reported to decrease with the progression of various chronic liver diseases. We investigated the impact of BTR and Zn on the incidence of malignancies in patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD). A total of 179 Japanese NAFLD patients who underwent liver biopsy were enrolled. Hepatocellular carcinoma (HCC) and extrahepatic malignancies developed in 7 (3.9%) and 10 (5.6%) patients, respectively, during the follow-up period (median 7.9 years). Patients with low BTR levels (<5.0) and Zn deficiency (<70 μg/dL) had significantly higher incidences of HCC and extrahepatic malignancies (P < 0.001 and 0.026), respectively. Multiple logistic regression analyses revealed the following risk factors: liver fibrosis (F3-4) (hazard ratio [HR] 24.292, 95% confidence interval [CI] 2.802-210.621, P = 0.004) and BTR < 5.0 (HR 5.462, 95% CI 1.095-27.253, P = 0.038) for HCC, and serum Zn level <70 μg/dL (HR 3.504, 95% CI 1.010-12.157, P = 0.048) and liver inflammation (A2-3) (HR 3.445, 95% CI 0.886-13.395, P = 0.074) for extra-hepatic malignancies. In conclusion, serum BTR and Zn levels were useful for predicting HCC and extrahepatic malignancies in NAFLD, respectively.

    DOI: 10.1080/01635581.2019.1653474

    Scopus

    PubMed

    researchmap

  32. Sarcopenia impairs health-related quality of life in cirrhotic patients. Reviewed International journal

    Yusuke Ando, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Tetsuya Ishikawa, Mitsuhiro Fujishiro

    European journal of gastroenterology & hepatology   Vol. 31 ( 12 ) page: 1550 - 1556   2019.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    AIM: Sarcopenia is associated with poor health-related quality of life (HRQOL) in the general population. However, in cirrhotic patients, as the development of sarcopenia is closely related to declined liver function, which also impairs HRQOL, whether sarcopenia deteriorates HRQOL independently from declined liver function remains unclear. The aim of this study was to clarify the impact of sarcopenia on HRQOL impairment in cirrhotic patients. PATIENTS AND METHODS: A total of 88 cirrhotic patients [median age, 69 years; range: 31-79 years; 49 male (55.7%), 45 with hepatocellular carcinoma (51.1%)] were analyzed. We measured HRQOL using the 36-item Short-Form Health Survey version 2 questionnaire and identified factors contributing to scores lower than 50 in physical component summary (PCS), mental component summary, and role-social component summary (RCS) scores. RESULTS: Twenty-four (27.2%) patients had sarcopenia. PCS and RCS scores were significantly lower in patients with sarcopenia compared with those without sarcopenia. Patients with Child-Pugh (CP) classification B or C showed significantly lower scores in PCS and RCS than those with CP classification A. On multivariate analysis, the presence of sarcopenia was the only factor associated with low PCS scores [odds ratio (OR): 11.6; P = 0.031]. Female sex (OR: 3.34; P = 0.034), CP classification B or C (OR: 3.19; P = 0.037), and presence of sarcopenia (OR: 4.64; P = 0.016) were identified as independent factors for low RCS scores. CONCLUSION: Sarcopenia independently impairs physical and role-social HRQOL in cirrhotic patients.

    DOI: 10.1097/MEG.0000000000001472

    Web of Science

    Scopus

    PubMed

    researchmap

  33. Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity. Reviewed

    Naoki Yoshioka, Teiji Kuzuya, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Masatoshi Ishigami, Mitsuhiro Fujishiro

    Internal medicine (Tokyo, Japan)   Vol. 58 ( 19 ) page: 2803 - 2808   2019.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Sorafenib and regorafenib are tyrosine kinase inhibitors that are used in the treatment of hepatocellular carcinoma and which have similar chemical structures and toxicity profiles. We herein report a case in which regorafenib treatment could be continued for 10 months and stable disease could be maintained for a long period despite the discontinuation of sorafenib due to grade 4 liver injury and grade 3 fever. The severe adverse events could be attributed to drug hypersensitivity, since a drug-induced lymphocyte stimulation test (DLST) indicated sensitivity to sorafenib. A DLST for regorafenib was negative. This is the first report showing that regorafenib could be safely administered after the discontinuation of sorafenib due to hypersensitivity.

    DOI: 10.2169/internalmedicine.2812-19

    Web of Science

    Scopus

    PubMed

    researchmap

  34. Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. Reviewed International journal

    Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Yoshiki Hirooka, Mitsuhiro Fujishiro

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 49 ( 9 ) page: 1054 - 1065   2019.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    AIM: This study aimed to investigate the clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma (HCC) after sorafenib treatment. METHODS: Of 122 patients, 103 were radiologically confirmed as progressive disease (PD) (sorafenib-refractory group), and 19 discontinued sorafenib therapy due to adverse events prior to radiologic PD (sorafenib-intolerant group). Patients in the sorafenib-refractory group were divided into two subgroups each, according to their eligibility for second-line treatment (second-line-in and -out group), regorafenib (RESORCE-in and -out group), or ramucirumab (REACH-2-in and -out group). RESULTS: Patients included in the non-candidate group were those with α-fetoprotein level <400 ng/mL (n = 51, 49.5%), daily sorafenib dose <400 mg (n = 44, 42.7%), Child-Pugh B or C (n = 40, 38.8%), and Eastern Cooperative Oncology Group performance status score ≥2 (n = 24, 23.3%). The percentages of candidates were 57.3% for second-line, 35.0% for regorafenib, and 23.3% for ramucirumab. The median post-progression survival (PPS) was significantly longer for the second-line-in and the RESORCE-in groups than in the non-candidate groups (12.6 and 11.0 months vs. 3.0 and 6.1 months, respectively). The PPS was not significantly different between the REACH-2-in and -out groups. A significant predictor of candidates for second-line treatment at sorafenib initiation was a Child-Pugh score of 5 (A5). CONCLUSIONS: Not all patients refractory to sorafenib were candidates for second-line therapy. A Child-Pugh score of A5 at sorafenib initiation was an important and favorable factor related to eligibility for second-line therapy and good outcomes.

    DOI: 10.1111/hepr.13358

    Web of Science

    Scopus

    PubMed

    researchmap

  35. Induction of humoral and cellular immune response to HBV vaccine can be up-regulated by STING ligand. Reviewed International journal

    Hiroyasu Ito, Ayumu Kanbe, Akira Hara, Tetsuya Ishikawa

    Virology   Vol. 531   page: 233 - 239   2019.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A persistent hepatitis B virus (HBV) infection is characterized by a lack of or a weak immune response to HBV. Efficient induction of the HBV-specific immune response leads to the clearance of HBV. Stimulator of interferon (IFN) genes (STING) is a cytoplasmic sensor of intracellular DNA from microbes and host cells. In the present study, we examined the efficacy of cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) that is a ligand of the STING pathway as an HBV vaccine adjuvant. Wild-type (WT) mice and HBV-transgenic (HBV-Tg) mice were immunized with hepatitis B surface antigen (HBsAg) and cGAMP. The vaccination with HBsAg and cGAMP significantly enhanced the humoral and cellular immune response to HBsAg in WT and HBV-Tg mice. Cytokine production related to Th1 and Th2 responses and the activation of antigen-presenting cells in lymphoid tissues were induced by cGAMP. Vaccination using cGAMP may overcome tolerance in patients with chronic HBV infection.

    DOI: 10.1016/j.virol.2019.03.013

    Scopus

    PubMed

    researchmap

  36. In utero exposure to di(2-ethylhexyl)phthalate suppresses blood glucose and leptin levels in the offspring of wild-type mice. Reviewed International journal

    Yumi Hayashi, Yuki Ito, Hisao Naito, Hazuki Tamada, Nozomi Yamagishi, Takaaki Kondo, Tetsuya Ishikawa, Frank J Gonzalez, Tamie Nakajima

    Toxicology   Vol. 415   page: 49 - 55   2019.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Exposure of pregnant mice to di(2-ethylhexyl)phthalate (DEHP) induces maternal lipid malnutrition and decreases the number of live fetuses/pups. In this study, we aimed to clarify the relationship between maternal lipid malnutrition and the nutritional status of the neonatal, lactational, and adult offspring, as well as the role of peroxisome proliferator-activated receptor α (PPARα) in these relationships. Sv/129 wild-type (mPPARA), Ppara-null, and PPARα-humanized (hPPARA) mice were fed diets containing 0, 0.01, 0.05, or 0.1% DEHP in utero and/or during the lactational stage. The male offspring were killed on postnatal day 2 or 21, or after 11 weeks. Exposure to either 0.05% or 0.1% DEHP during both the in utero and lactational periods decreased serum glucose concentrations in 2-day-old mPPARA offspring. These dosages also decreased both serum and plasma leptin levels in both 2- and 21-day-old mPPARA offspring. In contrast, exposure to DEHP only during the lactational period did not decrease leptin levels, suggesting the importance of in utero exposure to DEHP. Exposure to 0.05% DEHP during the in utero and lactational periods also increased food consumption after weaning in both mPPARA and hPPARA mice; this was not observed in Ppara-null offspring. In conclusion, in utero exposure to DEHP induces neonatal serum glucose malnutrition via PPARα. DEHP also decreases serum and plasma leptin concentrations in offspring during the neonatal and weaning periods, in association with PPARα, which presumably results in increased of food consumption after weaning.

    DOI: 10.1016/j.tox.2019.01.008

    Scopus

    PubMed

    researchmap

  37. Corrigendum to "Intact metabolite profiling of mouse brain by probe electrospray ionization/triple quadrupole tandem mass spectrometry (PESI/MS/MS) and its potential use for local distribution analysis of the brain" [ACA 983 (2017) 160-165]. International journal

    Yumi Hayashi, Kei Zaitsu, Tasuku Murata, Tomomi Ohara, Stéphane Moreau, Maiko Kusano, Hiroshi Tanihata, Hitoshi Tsuchihashi, Akira Ishii, Tetsuya Ishikawa

    Analytica chimica acta   Vol. 1031   page: 196 - 196   2018.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.aca.2018.08.001

    Scopus

    PubMed

    researchmap

  38. Effective Transplantation of 2D and 3D Cultured Hepatocyte Spheroids Confirmed by Quantum Dot Imaging Reviewed

    Hiroki Okumura, Eri Nanizawa, Anna Nakanishi, Hiroshi Yukawa, Tadahiro Hashita, Takahiro Iwao, Yoshinobu Baba, Tetsuya Ishikawa, Tamihide Matsunaga

    Advanced Biosystems   Vol. 2 ( 8 )   2018.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Liver transplantation is the most effective treatment for patients with end-stage liver diseases, but hepatocyte transplantation using spheroids is expected to become an alternative strategy owing to the limited number of liver donors. However, the effects of the transplantation route and spheroid size on cell dynamics and the organ-specific accumulation of hepatocytes are not well characterized. In this study, the influence of three delivery routes (tail vein, portal vein, and spleen) and three spheroid sizes (50, 100, and 150 µm in diameter) on the accumulation of human fetal hepatocytes labeled with quantum dots in the liver and other organs (heart, lung, kidney, and spleen) of recipient mice is investigated. Ex vivo fluorescence imaging reveals that the accumulation of transplanted cells in the liver is highest for transplantation via the portal vein compared with other routes. The accumulation efficiency depends on spheroid size, and spheroids with a diameter of 50 µm display greater accumulation than that of spheroids of other sizes. It is concluded that hepatocyte transplantation via the portal vein using small spheroids of 50 µm in diameter may be effective for clinical applications.

    DOI: 10.1002/adbi.201800137

    Scopus

    researchmap

  39. (-)-Epigallocatechin-3-gallate Down-regulates Doxorubicin-induced Overexpression of P-glycoprotein Through the Coordinate Inhibition of PI3K/Akt and MEK/ERK Signaling Pathways

    Satonaka Hana, Ishida Kumiki, Takai Miho, Koide Ryoji, Shigemasa Ryota, Ueyama Jun, Ishikawa Tetsuya, Hayashi Kazuhiko, Goto Hidemi, Wakusawa Shinya

    ANTICANCER RESEARCH   Vol. 37 ( 11 ) page: 6071-6077   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.12055

    Web of Science

    PubMed

  40. Effects of Ursodeoxycholic Acid and Insulin on Palmitate-Induced ROS Production and Down-Regulation of PI3K/Akt Signaling Activity

    Yokoyama Kunihiro, Tatsumi Yasuaki, Hayashi Kazuhiko, Goto Hidemi, Ishikawa Tetsuya, Wakusawa Shinya

    BIOLOGICAL & PHARMACEUTICAL BULLETIN   Vol. 40 ( 11 ) page: 2001-2004   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  41. Utility of Doppler ultrasonography for diagnosing and assessing treatment effects in liver compartment syndrome. Reviewed

    Yusuke Ando, Masatoshi Ishigami, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Kazuhiko Hayashi, Tetsuya Ishikawa, Hidemi Goto, Yoshiki Hirooka

    Clinical journal of gastroenterology   Vol. 10 ( 3 ) page: 265 - 269   2017.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Liver compartment syndrome is a life-threatening complication of hepatic subcapsular hematoma; diagnosis and assessment of treatment effects are therefore important. We report a rare case of liver compartment syndrome due to spontaneous hepatic subcapsular hematoma without any underlying conditions, in which Doppler ultrasonography (US) proved useful in both diagnosis and assessment of treatment effects. A 32-year-old woman experienced sudden epigastralgia and was diagnosed with hepatic subcapsular hematoma in the right lobe, based on contrast-enhanced computed tomography. Hepatic arteriography showed active hemorrhage and Doppler US showed retrograde flow in the right portal vein. From these findings, we diagnosed hepatic subcapsular hematoma complicated with liver compartment syndrome, and performed embolization of the bleeding point and percutaneous hematoma drainage. After these medical procedures, normalized antegrade flow in the right portal vein was observed on Doppler US. No underlying conditions contributing to hematoma were identified. In this case, Doppler US was useful for both diagnosis and assessment of treatment effects in liver compartment syndrome. When we examine patients with hepatic subcapsular hematoma, Doppler US should be used to diagnose the presence of liver compartment syndrome and assess treatment effects.

    DOI: 10.1007/s12328-017-0741-4

    Web of Science

    PubMed

    researchmap

  42. Coexistence of Copper in the Iron-Rich Particles of Aceruloplasminemia Brain. Reviewed International journal

    Kunihiro Yoshida, Hisao Hayashi, Shinya Wakusawa, Ryota Shigemasa, Ryoji Koide, Tetsuya Ishikawa, Yasuaki Tatsumi, Koichi Kato, Shinji Ohara, Shu-Ichi Ikeda

    Biological trace element research   Vol. 175 ( 1 ) page: 79 - 86   2017.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The interaction between iron and copper has been discussed in association with human health and diseases for many years. Ceruloplasmin, a multi-copper oxidase, is mainly involved in iron metabolism and its genetic defect, aceruloplasminemia (ACP), shows neurological disorders and diabetes associated with excessive iron accumulation, but little is known about the state of copper in the brain. Here, we investigated localization of these metals in the brains of three patients with ACP using electron microscopes equipped with an energy-dispersive x-ray analyzer. Histochemically, iron deposition was observed mainly in the basal ganglia and dentate nucleus, and to lesser degree in the cerebral cortex of the patients, whereas copper grains were not detected. X-ray microanalysis identified two types of iron-rich particles in their brains: dense bodies, namely hemosiderins, and their aggregated inclusions. A small number of hemosiderins and most inclusions contained a significant amount of copper which was enough for distinct Cu x-ray images. These copper-containing particles were observed more frequently in the putamen and dentate nucleus than the cerebral cortex. Coexistence of iron and copper was supported by good correlations in the molecular ratios between these two metals in iron-rich particles with Cu x-ray image. Iron-dependent copper accumulation in iron-rich particles may suggest that copper recycling is enhanced to meet the increased requirement of cuproproteins in iron overload brain. In conclusion, the iron-rich particles with Cu x-ray image were found in the ACP brain.

    DOI: 10.1007/s12011-016-0744-x

    Web of Science

    PubMed

    researchmap

  43. 近赤外バイオイメージング-NIR-II:第2の生体の窓 NIR-II近赤外領域における移植幹細胞in vivo蛍光イメージング

    湯川博, 小林香央里, 湯川博, 小林香央里, 新岡宏彦, 亀山達矢, 佐藤和秀, 鳥本司, 石川哲也, 馬場嘉信, 馬場嘉信

    Bio Industry   Vol. 34 ( 1 ) page: 113 - 113   2017

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:日本バイオマテリアル学会  

    J-GLOBAL

    researchmap

  44. Metabolome analysis revealed that abnormal muscular contraction is related to both metabolic alterations and hyper-thermogenesis in the serotonin syndrome

    ZAITSU Kei, NODA Saki, HAYASHI Yumi, OHARA Tomomi, IGUCHI Akira, KUSANO Maiko, SATO Takako, TSUCHIHASHI Hitoshi, ISHIKAWA Tetsuya, SUZUKI Koichi, ISHII Akira

    Annual Meeting of the Japanese Society of Toxicology   Vol. 44.1 ( 0 ) page: O-38   2017

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Toxicology  

    DOI: 10.14869/toxpt.44.1.0_o-38

    CiNii Research

  45. Secreted Ectodomain of Sialic Acid-Binding Ig-Like Lectin-9 and Monocyte Chemoattractant Protein-1 identified from Dental Pulp Stem Cells Synergistically Resolve Acute Liver Failure in Rats by Altering Macrophage Polarity Reviewed

    Takanori Ito, Akihito Yamamoto, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Tetsuya Ishikawa, Masatoshi Ishigami, Yoshiki Hirooka, Hidemi Goto

    HEPATOLOGY   Vol. 64   page: 515A - 515A   2016.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY  

    Web of Science

    researchmap

  46. Investigation of cocaine-induced hepatic injury in PPARα-null mice on the basis of lipid mediators and metabolome analyses

    SHINODA Satoshi, HAYASHI Yumi, ZAITSU Kei, SAKAI Yuichiro, YAMANAKA Mayumi, NASU Tamie, ISHIKAWA Tetsuya, YOSHIMOTO Takashi, KUSANO Maiko, TSUCHIHASHI Hitoshi, ISHII Akira

    Annual Meeting of the Japanese Society of Toxicology   Vol. 43.1 ( 0 ) page: P-90   2016

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Toxicology  

    DOI: 10.14869/toxpt.43.1.0_p-90

    CiNii Research

  47. [Pathogenesis and disease state in hepatitis B virus infection].

    Ishikawa T

    Nihon rinsho. Japanese journal of clinical medicine   Vol. 73 Suppl 9   page: 429 - 33   2015.12

     More details

    Publishing type:Research paper (scientific journal)  

    PubMed

  48. C型肝炎治療の現状 Invited

    石川哲也

    明日の臨床   Vol. 27 ( 1 ) page: 29-34   2015.6

     More details

    Authorship:Lead author   Language:Japanese  

  49. Kynurenine production mediated by indoleamine 2,3-dioxygenase aggravates liver injury in HBV-specific CTL-induced fulminant hepatitis. Reviewed

    OHTAKI Hirofumi, ITO Hiroyasu, ANDO Kazuki, ISHIKAWA Tetsuya, HOSHI Masato, ANDO Tatsuya, TAKAMATSU Manabu, HARA Akira, MORIWAKI Hisataka, SAITO Kuniaki, SEISHIMA Mitsuru

    Biochim Biophys Acta   Vol. 1842 ( 9 ) page: 1464–1471   2014.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Indoleamine 2,3-dioxygenase (IDO), an enzyme that is ubiquitously distributed in mammalian tissues and cells, converts tryptophan to kynurenine, and is also known as a key molecule that promotes apoptosis in lymphocytes and neurons. In this study, we established hepatitis B virus (HBV)-transgenic (Tg)/IDO-knockout (KO) mice and examined the influence of IDO in a murine fulminant hepatitis model induced by HBV-specific cytotoxic T lymphocytes (CTL). An increase of IDO expression in the livers of HBV-Tg/IDO-wild-type (WT) mice administered HBV-specific CTL was confirmed by real-time polymerase chain reaction, western blotting, and evaluating IDO activity. Plasma alanine aminotransferase (ALT) levels in HBV-Tg/IDO-KO mice after HBV-specific CTL injection significantly decreased compared with those in HBV-Tg/IDO-WT mice. An inhibitor of IDO, 1-methyl-D-tryptophan (1-MT), could also attenuated the observed liver injury induced by this HBV-specific CTL. The expression levels of cytokine and chemokine mRNAs in the livers of HBV-Tg/IDO-WT mice were higher than those in the livers of HBV-Tg/IDO-KO mice. The administration of kynurenine aggravated the liver injury in HBV-Tg/IDO-KO mice injected with HBV-specific CTL. Simultaneous injection of recombinant murine interferon (IFN-γ) and kynurenine also increased the ALT levels in HBV-Tg/IDO-KO mice. The liver injury
    induced by IFN-γ and kynurenine was improved in HBV-Tg/tumor necrosis factor-α-KO mice. Conclusion:
    Kynurenine and IFN-γ induced by the administration with HBV-specific CTL are cooperatively involved in the
    progression of liver injury in acute hepatitis model. Our results may lead to a new therapy for the acute liver injury caused by HBV infection.

  50. Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2, 3-dioxygenase activity. Reviewed

    ITO Hiroyasu, ANDO Tatsuya, ANDO Kazuki, ISHIKAWA Tetsuya, SAITO Kuniaki, MORIWAKI Hisataka, SEISHIMA Mitsuru

    Immunology   Vol. 142 ( 4 ) page: 614–623   2014.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cytotoxic T lymphocytes (CTLs) are thought to be major effectors involved in viral clearance during acute infections, including hepatitis B virus (HBV) infection. A persistent HBV infection is characterized by a lack of or a weak CTL response to HBV, which may be reflective of tolerance to HBV. Efficient induction of HBV-specific CTLs leads to the clearance of HBV in patients with a chronic HBV infection. Previously, we
    reported that a-galactosylceramide (a-GalCer), a specific natural killer T (NKT) cell agonist, enhanced the induction of HBV surface antigen (HBsAg)-specific CTLs. In the present study, we found that inhibition of
    indoleamine 2,3-dioxygenase (IDO) activity enhanced the induction of HBsAg-specific CTLs after immunization with HBsAg and a-GalCer. The administration of HBsAg and a-GalCer increased the production of interleukin-2 and interleukin-12b, which are crucial for the induction of HBsAg-specific CTLs. The production of these cytokines was more strongly enhanced in IDO knockout mice compared with wild-type mice. In addition, a-GalCer induced the production of IDO in CD11b+ cells, and these cells inhibited proliferation of HBsAg-specific CTLs. Our results lead to strategies for improving the induction of HBsAg-specific CTLs.

  51. Ursodeoxycholic acid inhibits overexpression of P-glycoprotein induced bydoxorubicin in HepG2 cells. Reviewed

    KOMORI Yuki, ARISAWA Sakiko, TAKAI Miho, YOKOYAMA Kunihiro, HONDA Minako, HAYASHI Kazuhiko, ISHIGAMI Masatoshi, KATANO Yoshiaki, GOTO Hidemi, UEYAMA Jun, ISHIKAWA Tetsuya, WAKUSAWA Shinya.

    European JournalofPharmacology   Vol. 724   page: 161-167   2014.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  52. 進行肝細胞癌に対するソラフェニブ投与後2週間以内の発熱と造影CT上の阻血性変化との関係 Reviewed

    葛谷貞二、石上雅敏、新家卓郎、今井則博、阿知波宏一、荒川恭宏、山田恵一、中野聡、石津洋二、本多隆、林和彦、石川哲也、中野功、片野義明、伊藤彰浩、廣岡芳樹、後藤秀実.

    肝臓   Vol. 54 ( 7 ) page: 505-506   2013.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  53. 満腹感を伴う便秘症状の原因にvildagliptinの関与が示唆された糖尿病合併末期腎不全の1例 Reviewed

    綾田穣、森弘卓延、加藤ふみ、堀田直樹、黒川剛、中野達徳、石川哲也

    腎と透析   Vol. 74 ( 3 ) page: 470-474   2013.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  54. Clinical trial of percutaneous radio frequency ablation therapy by two-step insertion method using VirtuTRAX<sup>TM</sup> instrument navigator Reviewed

    Kuzuya Teiji, Hayashi Kazuhiko, Ishigami Masatoshi, Ishikawa Tetsuya, Nakano Isao, Katano Yoshiaki, Itoh Akihiro, Hirooka Yoshiki, Izumi Namiki, Goto Hidemi, Ishizu Yoji, Niinomi Takurou, Imai Norihiro, Achiwa Kouichi, Arakawa Takahiro, Yamada Keiichi, Nakano Satoshi, Honda Takashi

    Kanzo   Vol. 54 ( 12 ) page: 850 - 853   2013

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japan Society of Hepatology  

    We performed percutaneous radio frequency ablation (RFA) therapy by two-step insertion method using VirtuTRAX<sup>TM</sup> (GE Healthcare, USA) instrument navigator. Subjects were 16 patients (23 nodules) with hepatocellular carcinoma. VirtuTRAX<sup>TM</sup> position sensor was attached to the hilt of 14-gauge outer needle. In all cases, we could perform 17- gauge Cool-tip RFA without the positional gap between the virtual tract and the actual needle which was caused by the deflection of the needle. The reasons without causing the positional gap were that the outer needle was more rigid than Cool-tip needle, and that it was inserted using initial insertion of a 21-gauge guided needle. RFA by two-step insertion method using VirtuTRAX<sup>TM</sup> is suggested to be more safe and effective than conventional RFA.

    DOI: 10.2957/kanzo.54.850

    Scopus

    CiNii Books

    J-GLOBAL

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2014089120

  55. Quantum dots conjugated with transferrin for brain tumor cell imaging.

    Yukawa H, Tsukamoto R, Kano A, Okamoto Y, Tokeshi M, Ishikawa T, Mizuno M, Baba Y

    Journal of Cell Science and Therapy   Vol. 4 ( 3 ) page: 1   2013

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  56. Immunoregulation of hepatitis B virus infection -rationale and clinical application- Invited

    ISHIKAWA Tetsuya

    Nagoya J Med Sci   Vol. 74   page: 217-232   2012.8

     More details

    Authorship:Lead author   Language:English  

    Hepatitis B virus (HBV) is susceptible to the cellular immune responses, especially to the signal of interferon (IFN)-g. The action of IFN-g is pleiotropic, and causes downregulation of HBV in protein, RNA, and possibly DNA levels. Therefore, therapeutic vaccination to induce cellular immune responses to HBV is a promising approach for controlling chronic HBV infection. A number of clinical trials with this approach have been conducted to date, however, they have not been as successful as initially expected. T-cell exhaustion induced by the excessive HBV antigens caused by persistent infection is thought to be one of the main causes of poor responses to therapeutic vaccination. In this review, the mechanisms behind immunoregulation of HBV replication and immunodysfunction during chronic HBV infection are summarized, and novel approaches to improve the efficacy of therapeutic vaccination, from basic research to clinical trials, are introduced.

  57. 機能性胃疾患診療における不安抑うつスコアの有用性と機能性胃疾患の発症および増悪因子としての心配性の関与について

    洪繁、松浦俊博、木村宏之、石川哲也、京兼和宏、山田理

    消化器内科   Vol. 55 ( 1 ) page: 42-49   2012.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    HADS(Hospital Anxiety Depression Scale)スコアに本人の主観的性格分類(楽天的か心配性か)を組み合わせて解析することで、機能性胃腸症発症、増悪と心配性の性格の関わりについて解析した。職域検診を受診した健常者の解析からは、心配性の性格とHADSスコアが正に相関していた。更に、機能性胃腸症患者では、うつ病で治療中の患者と同様に心配性の患者の割合が非常に高く、患者の心配性の性格が機能性胃腸症発症及び増悪因子であることが疑われた。機能性胃腸症の診療においては、多くの患者が過度に心配性であり、胃腸症状の出現により更に心配性の度合いが高じていることを考慮し、患者の不安を取り除く診療を行うことが、患者の愁訴を減少させ、治療満足度を向上させる方法であると考えられる。

  58. 瀉血による慢性肝炎の進展予防

    伊東和樹, 石川哲也

    medicina   Vol. 48 ( 7 ) page: 1176-1178   2011.7

     More details

    Language:Japanese  

    1-110//2-0//3-石川哲也

  59. 今月の主題 内科疾患の予防戦略 消化器疾患の予防戦略 瀉血による慢性肝炎の進展予防

    伊東 和樹, 石川 哲也

    medicina   Vol. 48 ( 7 ) page: 1176 - 1178   2011.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:株式会社医学書院  

    DOI: 10.11477/mf.1402105262

    CiNii Research

  60. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy. Reviewed

    HAYASHI Kazuhiko, KATANO Yoshiaki, HONDA Takashi, ISHIGAMI Masatoshi, ITOH Akihiro, HIROOKA Yoshiki, ISHIKAWA Tetsuya, NAKANO Isao, YOSHIOKA Kentaro, TOYODA Hidenori, KUMADA Takashi, GOTO Hidemi

    Liver Int     page: 1359-1365   2011.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background and aims: Mutations in the core and NS5A region of hepatitis C virus (HCV) genotype 1b have been associated with response to interferon (IFN) therapy. Genome-wide association studies have revealed that the singlenucleotide polymorphism (SNP) of interleukin 28B (IL28B) contributes to IFN response. The aim of this study was to investigate whether the SNP of IL28B (rs8099917) and amino acid substitutions in the core and NS5A region affect the response to IFN therapy. Methods: A total of 299 patients (157 men, 142 women; mean age, 55.910.3 years) infected with HCV genotype 1b were studied. The fibrosis stage was diagnosed as F0 (n = 23), F1 (n = 121), F2 (n = 62), F3 (n = 32) and F4 (n = 7) by liver biopsy. Results: Of the 299 patients, 138 achieved sustained virological response (SVR). On univariate analysis, predictors of SVR were age o60 years, male gender, higher platelet count, lack of fibrosis, non-Q at core 70, mutant-type interferon sensitivitydetermining region (ISDR) and IL28B genotype TT. The factors related to SVR on multivariate analysis were IL28B (P = 0.0001), fibrosis (P = 0.0111) and mutations in the core region70 (P = 0.0267) and ISDR (P = 0.0408). The best SVR was achieved in patients with non-Q70, mutant-type ISDR and T allele (74.5%), and the worst was achieved in patients with Q70, wild-type
    ISDR and G allele (8.1%). Conclusions: The SNP of IL28B and mutations in the core region and NS5A are associated with IFN responsiveness. Both host and viral factors might be useful for predicting IFN response.

    DOI: 10.1111/j.1478-3231.2011.02571.x.

  61. バンコマイシン投与によって難治性肝性脳症が改善し肝細胞癌に対する肝動脈化学塞栓療法が可能となった1例

    葛谷 貞二, 竹田 欽一, 宇都宮 節夫, 多賀 雅浩, 川田 登, 池田 誉, 今井 則博, 水谷 佳貴, 広瀬 健, 石川 哲也

    癌と化学療法   Vol. 38 ( 6 ) page: 995 - 1001   2011.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:(株)癌と化学療法社  

    症例は80歳、男性。C型肝硬変、肝細胞癌で通院していた。2007年秋ごろから肝性脳症を繰り返すようになり、頻回の外来通院と入院加療を必要とした。肝予備能の低下により、肝細胞癌に対する治療は不可能となった。肝性脳症に対して緩下剤、ラクツロース、カナマイシン内服などの投与を行ったが、脳症のコントロールは困難であった。血中アンモニア値は130μg/dL前後で、時に200μg/dL以上となった。12月よりバンコマイシン内服(0.5g/回、3日に1回投与)を追加したところ、アンモニア値は速やかに50μg/dL低下となり、意識レベルの正常化、ADL、QOLの改善など著明な効果が得られた。バンコマイシン内服開始3ヵ月後には、Child C(10点)からChild B(7点)と肝予備能も改善、肝細胞癌に対し肝動脈化学塞栓療法が可能となった。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2011&ichushi_jid=J00296&link_issn=&doc_id=20110629470023&doc_link_id=%2Fab8gtkrc%2F2011%2F003806%2F025%2F0995-0997%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2011%2F003806%2F025%2F0995-0997%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  62. Liver stiffness in extrahepatic cholestasis correlates positively with bilirubin and negatively with alanime aminotransferase

    HARATA Masao, HASHIMOTO Senju, KAWABE Naoto, NITTA Yoshifumi, MURAO Michihito, NAKANO Takuji, ARIMA Yuko, SHIMAZAKI Hiroaki, ISHIKAWA Tetsuya, OKUMURA Akihiko, ICHINO Naohiro, OSAKABE Keisuke, NISHIKAWA Toru, YOSHIOKA Kentaro

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 41 ( 5 ) page: 423 - 429   2011.5

     More details

    Publishing type:Research paper (scientific journal)  

  63. 沈降型B型肝炎ワクチン Invited

    石川哲也

    肝胆膵   Vol. 61 ( 6 ) page: 1088-1094   2010.12

     More details

    Authorship:Lead author   Language:Japanese  

  64. Hypofractionated stereotactic body radiotherapy for primary and metastatic liver tumors using the novalis image-guided system: preliminary results regarding efficacy and toxicity. Reviewed International journal

    Hiromitsu Iwata, Yuta Shibamoto, Chisa Hashizume, Yoshimasa Mori, Tatsuya Kobayashi, Naoki Hayashi, Katsura Kosaki, Tetsuya Ishikawa, Teiji Kuzuya, Setsuo Utsunomiya

    Technology in cancer research & treatment   Vol. 9 ( 6 ) page: 619 - 27   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    www.tcrt.org The purpose of this study was to evaluate the efficacy and toxicity of stereotactic body radiotherapy (SBRT) for primary and metastatic liver tumors using the Novalis image-guided radiotherapy system. After preliminarily treating liver tumors using the Novalis system from July 2006, we started a protocol-based study in February 2008. Eighteen patients (6 with primary hepatocellular carcinoma and 12 with metastatic liver tumor) were treated with 55 or 50 Gy, depending upon their planned dose distribution and liver function, delivered in 10 fractions over 2 weeks. Four non-coplanar and three coplanar static beams were used. Patient age ranged from 54 to 84 years (median: 72 years). The Child-Pugh classification was Grade A in 17 patients and Grade B in 1. Tumor diameter ranged from 12 to 35 mm (median: 23 mm). Toxicities were evaluated according to the Common Terminology Criteria of Adverse Events version 4.0, and radiation-induced liver disease (RILD) was defined by Lawrence's criterion. The median follow-up period was 14.5 months. For all patients, the 1-year overall survival and local control rates were 94% and 86%, respectively. A Grade 1 liver enzyme change was observed in 5 patients, but no RILD or chronic liver dysfunction was observed. SBRT using the Novalis image-guided system is safe and effective for treating primary and metastatic liver tumors. Further investigation of SBRT for liver tumors is warranted. In view of the acceptable toxicity observed with this protocol, we have moved to a new protocol to shorten the overall treatment time and escalate the dose.

    PubMed

    researchmap

  65. Ability of IDO to attenuate liver injury in α-galactosylceramide- induced hepatitis model Reviewed

    Hiroyasu Ito, Masato Hoshi, Hirofumi Ohtaki, Ayako Taguchi, Kazuki Ando, Tetsuya Ishikawa, Yosuke Osawa, Akira Hara, Hisataka Moriwaki, Kuniaki Saito, Mitsuru Seishima

    Journal of Immunology   Vol. 185 ( 8 ) page: 4554 - 4560   2010.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER ASSOC IMMUNOLOGISTS  

    IDO converts tryptophan to L-kynurenine, and it is noted as a relevant molecule in promoting tolerance and suppressing adaptive immunity. In this study, we examined the effect of IDO in α-galactosylceramide (α-GalCer)-induced hepatitis. The increase in IDO expression in the liver of wild-type (WT) mice administered α-GalCer was confirmed by real-time PCR, Western blotting, and IDO immunohistochemical analysis. The serum alanine aminotransferase levels in IDO-knockout (KO) mice after α-GalCer injection significantly increased compared with those in WT mice. 1-Methyl-D-tryptophan also exacerbated liver injury in this murine hepatitis model. In α-GalCer-induced hepatitis models, TNF-α is critical in the development of liver injury. The mRNA expression and protein level of TNF-α in the liver from IDO-KO mice were more enhanced compared with those in WT mice. The phenotypes of intrahepatic lymphocytes from WT mice and IDO-KO mice treated with α-GalCer were analyzed by flow cytometry, and the numbers of CD49b+ and CD11b+ cells were found to have increased in IDO-KO mice. Moreover, as a result of the increase in the number of NK cells and macrophages in the liver of IDO-KO mice injected with α-GalCer, TNF-α secretion in these mice was greater than that in WT mice. Deficiency of IDO exacerbated liver injury in α-GalCer-induced hepatitis. IDO induced by proinflammatory cytokines may decrease the number of TNF-α-producing immune cells in the liver. Thus, IDO may suppress overactive immune response in the α-GalCer-induced hepatitis model. Copyright © 2010 by The American Association of Immunologists, Inc.

    DOI: 10.4049/jimmunol.0904173

    Web of Science

    Scopus

    PubMed

    researchmap

  66. Role of tumor necrosis factor-α in acute hepatitis B virus infection

    Ito Hiroyasu, Ando Kazuki, Ishikawa Tetsuya, SEISHIMA Mitsuru

    炎症・再生 : 日本炎症・再生医学会雑誌 = Inflammation and regeneration   Vol. 30 ( 5 ) page: 445 - 450   2010.9

     More details

    Publishing type:Research paper (scientific journal)   Publisher:日本炎症・再生医学会  

  67. PEG後栄養管理中の義歯誤嚥に対しネット鉗子とオーバーチューブを用い安全に異物除去が可能であった1例 Reviewed

    綾田穣, 堀田直樹, 中野達徳, 内村正史, 花井恵美, 伊藤陽子, 徳永有姫, 吉田篤生, 石川哲也, 増子和郎

    在宅医療と内視鏡治療   Vol. 14 ( 1 ) page: 46-51   2010.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  68. A case of erythropoietic protoporphyria with severe liver damage Reviewed

    SHIMAZAKI Hiroaki, ARIMA Yuko, NAKANO Takuji, MURAO Michihito, NITTA Yoshifumi, HARATA Masao, KAWABE Naoto, HASHIMOTO Senju, NAGANO Kenichi, ISHIKAWA Tetsuya, OKUMURA Akihiko, HAYASHI Kazuhiko, KATANO Yoshiaki, KURODA Makoto, YOSHIOKA Kentaro

    Kanzo   Vol. 51 ( 4 ) page: 175 - 182   2010.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japan Society of Hepatology  

    Case is a 29-yr-old man, whose complaint was abdominal pain. He had photosensitivity since childhood. The paternal grandfather and the younger brother have photosensitivity. In November 2001, he admitted in the other hospital with liver dysfunction and was diagnosed as erythropoietic protoporphyria (EPP). In August 2005, he admitted with abdominal pain and jaundice and recovered with antibiotics. In January 2006, he was referred to our hospital with mild elevation of ALT. In November 2006 and in May 2007, he admitted in our hospital with abdominal pain and jaundice, and recovered with antibiotics. In August 2008, he admitted with the same symptoms. Erythrocyte protoporphyrin and total bilirubin continually elevated. He died from liver failure in November 2008. A small portion of EPP patients suffer from liver failure. The only effective treatment for liver failure of EPP is liver transplantation, which should be considered at appropriate timing of the disease course.<br>

    DOI: 10.2957/kanzo.51.175

    Scopus

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2010194025

  69. A case of metastatic pancreatic cancer with a remarkable response to to combination therapy of gemcitabine and adoptive immune cell therapy. Reviewed

      Vol. 37 ( 3 ) page: 527-529   2010.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  70. B型肝炎に対する免疫療法 Invited

    石川哲也

    medicina   Vol. 47 ( 3 ) page: 487-490   2010.3

     More details

    Authorship:Lead author   Language:Japanese  

  71. [A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy]. Reviewed

    Norihiro Imai, Kinichi Takeda, Setsuo Utsunomiya, Masahiro Taga, Noboru Kawata, Takashi Ikeda, Yoshitaka Mizutani, Ken Hirose, Tetsuya Ishikawa, Shonen Yoshida

    Gan to kagaku ryoho. Cancer & chemotherapy   Vol. 37 ( 3 ) page: 527 - 9   2010.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    A 52-year-old woman with a chief complaint of epigastric distress was diagnosed as having pancreatic cancer with multiple liver metastases. After insertion of a metallic stent for biliary stenosis, combination therapy of gemcitabine (GEM) and adoptive immune cell therapy (AICT) was initiated. GEM 1,000 mg/m2 was administered on day 1, 8 and 15 every 4 weeks, while AICT using MUC1 peptide-pulsed dendritic cells (DC) and anti-CD3-activated T lymphocytes (CAT) was given biweekly. After 6 courses of GEM and 9 courses of DC-CAT, the patient was considered to have a complete response (CR) on CT and MRI examination. CR has still been maintained by the continuous administration of GEM and CAT. The combination therapy of GEM and AICT was suggested to be effective against advanced pancreatic cancer.

    PubMed

    researchmap

  72. Role of tumor necrosis factor-a in acute hepatitis B virus infection.

    ITO Hiroyasu, ANDO Kazuki, ISHIKAWA Tetsuya, SEISHIMA Mitsuru.

    Inflammation and Regeneration   Vol. 30 ( 5 ) page: 445 - 450   2010

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Access below to see full text:
    http://www.jstage.jst.go.jp/article/inflammregen/30/5/445/_pdf

    DOI: 10.2492/inflammregen.30.445

  73. Interaction between LPS-induced NO production and IDO activity in mouse peritoneal cells in the presence of activated Va14 NKT cells. Reviewed

    Ohtaki H, Ito H, Ando K, Ishikawa T, Hoshi M, Tanaka R, Osawa Y, Yokochi T, Moriwaki H, Saito K, Seishima M.

    Biochem Biophys Res Com   Vol. 389 ( 2 ) page: 229-234   2009.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  74. BSCガストロストミーシステムを用いた胃瘻交換時における患者に与える影響についての検討

    綾田 穣, 堀田 直樹, 中野 達徳, 鮫島 庸一, 吉田 篤生, 花井 恵美, 伊藤 陽子, 徳永 有姫, 石川 哲也, 増子 和郎

    在宅医療と内視鏡治療   Vol. 13 ( 1 ) page: 19 - 24   2009.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:PEG・在宅医療研究会  

    BSCガストロストミーシステム:BSC gastrostomy system(以下BSCGSと略す)は、ガイドワイヤーを用いずに胃瘻造設後のカテーテル交換を行うことができるバンパータイプ・ボタン型カテーテルキットである。今回BSCGSに改良が加えられたため、交換に要する時間や、バイタルサインの変化について、ガイドワイヤーを用いる同タイプのキットとの比較検討を行った。BSCGSでは、有意に交換時間が短縮され(p&lt;0.01)、バイタルサインの変化に有意差は認めず、有用かつ安全と考えられた。(著者抄録)

    researchmap

  75. Inflammatory cytokines modulate chemokine production patterns of HepG2 cells toward initially inclined direction. Reviewed

    Ohashi T, Tanabe J, Ishikawa T, Okumura A, Sato K, Ayada M, Hotta N, Kuzuya K, Ito H, Nakao H, Yoneda M, Kakumu S.

    Hepatol Res   Vol. 39 ( 5 ) page: 510-519   2009.5

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  76. V alpha14 NKT cells activated by alpha-galactosylceramide augment lipopolysaccharide-induced nitric oxide production in mouse intra-hepatic lymphocytes. Reviewed

    Ohtaki H, Ito H, Ando K, Ishikawa T, Saito K, Imawari M, Yokochi T, Moriwaki H, Seishima M

    Biochem Biophys Res Com   Vol. 378 ( 3 ) page: 579-583   2009.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  77. Role of TNF-alpha produced by nonantigen-specific cells in a fulminant hepatitis mouse model. Reviewed

    Ito H, Ando K, Ishikawa T, Saito K, Takemura M, Imawari M, Moriwaki H, Seishima M.

    J Immunol   Vol. 182 ( 1 ) page: 391-397   2009.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  78. Usefulness of radiofrequency ablation with micro-convex probe for hepatocellular carcinoma. Reviewed

    HOTTA Naoki, AYADA Minoru, MATSUMOTO Eiji, OKUMURA Akihiko, ISHIKAWA Tetsuya, SATO Ken, OOHASHI Tomohiko, KAKUMU Shinichi

    Hepato-gastroenterology   Vol. 56 ( 93 ) page: 1127-1132   2009

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background/Aims: It was aimed to assess whether a micro-convex probe is superior to the present conventional probe for ultrasonography from the points of safety and efficacy during percutaneous radiofrequency ablation therapy for hepatocellular carcinoma. Methodology: Twenty-one patients with 23 hepatocellular carcinoma lesions who had one or 2 lesions, each 4 cm or less in diameter, and liver function of Child-Pugh class A or B were enrolled. All the patients except for 2 patients were seropositive for hepatitis C virus. Radiofrequency ablation was carried out under a real-time US guidance. The cooled-tip electrodes used were single and clustered. Results: It was possible to perform safe and accurate percutaneous radiofrequency ablation procedure using micro-convex probes for the treatment of all hepatocellular carcinoma nodules. It was also possible to treat hepatocellular carcinoma located in the right subphrenic region without artificial pleural effusion under intercostal ultrasonography guide. Improved clustered needles were successfully applied to treat the nodules more than 3 cm in diameter with less resistance for penetration compared with the conventional needle. The findings of advanced dynamic flow image on ultrasonography to assess the therapeutic efficacy indicated the consistency with those of dynamic CT which was done 3 to 5 days later radiofrequency ablation. Major complication of radiofrequency ablation procedure was noted in none. Conclusions: These results suggest that micro-convex probe with clustered tips is superior to conventional probe for ultrasonography from the points of safety and efficacy during radiofrequency ablation for hepatocellular carcinoma nodule located in the right subphrenic region and for larger sized nodule more than 3 cm.

  79. A patient with Gilbert's syndrome complicated with drug-induced liver injury by the over-the-counter drug and Fluvastatin Sodium: A case report Reviewed

    Minoru Ayada, Tetsuya Ishikawa, Akihiko Okumura, Naoki Hotta, Akinori Hirose, Kazuo Masuko, Shinichi Kakumu

    Acta Hepatologica Japonica   Vol. 50 ( 3 ) page: 139 - 144   2009

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japan Society of Hepatology  

    A 56-year-old female was admitted to our hospital because of epigastralgia, vomiting, hyperbilirubinemia, and abnormalities in the hepatic function tests. After the discontinuation of an over-the-counter drug, her symptoms and the abnormalities in the blood tests were improved. Thus she was diagnosed as drug-induced liver injury by the over-the-counter drug. The second episode of drug-induced liver injury occurred when she took Fluvastatin Sodium for her hyperlipemia. The liver injury was improved by the discontinuation of the drug
    however, only serum indirect bilirubin level remained abnormal. She was suspected to have constitutional jaundice, and diagnosed as Gilbert's syndrome by the analysis of gene polymorphism for UDP-glucuronyl transferase (UGT1A1). The polymorphism of UGT1A1 affects the efficiency of the lipophilic drug metabolism, and the activity of UGT1A1 is known to be low in the patients with Gilbert's syndrome Therefore the present case suggests that the recurrent drug-induced liver injury might be related to the low UGT1A1 activity due to Gilbert's syndrome. We here report the case with Gilbert's syndrome complicated with the recurrent drug-induced liver injuries. © 2009 The Japan Society of Hepatology.

    DOI: 10.2957/kanzo.50.139

    Scopus

    CiNii Research

    researchmap

  80. Deficiency of forkhead box P3 and cytotoxic T-lymphocyte-associated antigen-4 gene expressions and impaired suppressor function of CD4+CD25+ T cells in patients with autoimmune hepatitis

    OKUMURA Akihiko, ISHIKAWA Tetsuya, SATO Sayaka, YAMAUCHI Taeko, OSHIMA Hisae, OHASHI Tomohiko, SATO Ken, AYADA Minoru, HOTTA Naoki, KAKUMU Shinichi

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 38 ( 9 ) page: 896 - 903   2008.9

     More details

    Publishing type:Research paper (scientific journal)  

  81. Deficiency of forkhead box P3 and cytotoxic T-lymphocyte-associated antigen-4 gene expressions and impaired suppressor function of CD4+CD25+ T cells in patients with autoimmune hepatitis. Reviewed

    Okumura A, Ishikawa T, Sato S, Yamauchi T, Oshima H, Ohashi T, Sato K, Ayada M, Hotta N, Kakumu S.

    Hepatol Res   Vol. 38 ( 9 ) page: 896-903   2008.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  82. Role of V alpha14+ NKT cells in the development of hepatitis B virus-specific CTL: Activation of V alpha14+ NKT cells promotes the breakage of CTL tolerance. Reviewed

    Ito H, Ando K, Ishikawa T, Nakayama T, Taniguchi M, Saito K, Imawari M, Moriwaki H, Yokochi T, Kakumu S, Seishima M.

    Int Immunol   Vol. 20 ( 7 ) page: 869-879   2008.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  83. Use of the Model for End-Stage Liver Disease (MELD) score to predict 1-year survival of Japanese patients with cirrhosis and to determine who will benefit from living donor liver transplantation. Reviewed

    Ishigami M, Honda T, Okumura A, Ishikawa T, Kobayashi M, Katano Y, Fujimoto Y, Kiuchi T, Goto H.

    J Gastroenterol   Vol. 43 ( 5 ) page: 363-368   2008.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  84. Upregulation of indoleamine 2,3-dioxygenase in hepatocyte during acute hepatitis caused by hepatitis B virus-specific cytotoxic T lymphocytes in vivo. Reviewed

    Iwamoto N, Ito H, Ando K, Ishikawa T, Hara A, Taguchi A, Saito K, Takemura M, Imawari M, Moriwaki H, Seishima M.

    Liv Int   Vol. 29 ( 2 ) page: 277-283   2008.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  85. Use of hepatitis B vaccine for the treatment of chronic hepatitis B

    ISHIKAWA Tetsuya, KAKUMU Shinichi

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 37   page: S347 - S350   2007.10

     More details

    Publishing type:Research paper (scientific journal)  

  86. B型肝炎の新たな治療展開 B型肝炎の治療戦略 Adefovir pivoxil

    石川 哲也, 各務 伸一

    内科   Vol. 100 ( 4 ) page: 677 - 682   2007.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:南江堂  

    DOI: 10.15106/j00974.2007346151

    CiNii Research

  87. Expression of Toll-like receptors in chronic hepatitis C virus infection. Reviewed

    Sato K, Ishikawa T, Okumura A, Yamauchi T, Sato S, Ayada M, Matsumoto E, Hotta N, Ohashi T, Fukuzawa Y, Kakumu S.

    J Gastroenterol Hepatol   Vol. 22 ( 10 ) page: 1627-1632   2007.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  88. Use of HB vaccine for the treatment of chronic hepatitis B. Invited

    Ishikawa T, Kakumu S.

    Hepatol Res   Vol. 37 ( S3 ) page: S347-S350   2007.10

     More details

    Authorship:Lead author   Language:English  

  89. Effect of Vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Reviewed

    Hotta N, Ayada M, Sato K, Ishikawa T, Okumura A, Matsumoto E, Ohashi T, Kakumu S.

    Hepato-gastroenterology   Vol. 54 ( 79 ) page: 2073-2077   2007.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  90. 今月の主題 消化器薬の使い方Update 消化器疾患の薬物治療 自己免疫性肝炎(AIH)

    石川 哲也

    medicina   Vol. 44 ( 9 ) page: 1713 - 1715   2007.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:株式会社医学書院  

    DOI: 10.11477/mf.1402102933

    CiNii Research

  91. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load

    FUJIWARA Kenji, KANEKO Shuichi, KAKUMU Shinichi, SATA Michio, HIGE Shuhei, TOMITA Eiichi, MOCHIDA Satoshi, IDE T., NISHIDA H., YOKOYAMA H., YAMASHITA T., MORIWAKI H., NAGAKI M., SUGIHARA J., TAKAHASHI H., ISHIKAWA T., MIYATA M., NISHIKAWA K., NAGOSHI S., SUGAHARA S., YAMAMOTO K., MIZUTA T., ANDO T., TAKEI Y., ENOMOTO N., TSUDA H., SUMINO Y., ISHII K., SAISHO H., YOKOSUKA O., EGUCHI K., HAMASAKI K., SAWADA K., FUKUNAGA K., ARAKAWA Y., MORIYAMA M., IMAWARI M., ITO T.

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 37 ( 9 ) page: 701 - 710   2007.9

     More details

    Publishing type:Research paper (scientific journal)  

  92. Combination therapy with lamivudine and HB vaccine on chronic hepatitis B

    ISHIKAWA Tetsuya, KAKUMU Shinichi

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 37   page: S62 - S66   2007.7

     More details

    Publishing type:Research paper (scientific journal)  

  93. Combination thearpy with lamivudine and HB vaccine on chronic heaptitis B. Invited

    Ishikawa T, Kakumu S.

    Hepatol Res   Vol. 37 ( S1 ) page: S62-S66   2007.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  94. 今月の主題 ウイルス肝炎 実地診療A to Z 扉

    石川 哲也

    medicina   Vol. 44 ( 5 ) page: 847 - 847   2007.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:株式会社医学書院  

    DOI: 10.11477/mf.1402102722

    CiNii Research

  95. 今月の主題 ウイルス肝炎 実地診療A to Z 座談会 外来で診るウイルス肝炎-効果的な病診連携のために

    八橋 弘, 伊東 和樹, 柴田 実, 石川 哲也

    medicina   Vol. 44 ( 5 ) page: 972 - 983   2007.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:株式会社医学書院  

    DOI: 10.11477/mf.1402102753

    CiNii Research

  96. 今月の主題 ウイルス肝炎 実地診療A to Z ウイルス肝炎の的確な診断のために 肝障害患者の診断の進め方

    各務 伸一, 石川 哲也

    medicina   Vol. 44 ( 5 ) page: 848 - 851   2007.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:株式会社医学書院  

    DOI: 10.11477/mf.1402102723

    CiNii Research

  97. Usefulness of a Bloodflow Diagnosis at Liver Tumors Using Sonazoid

    AYADA Minoru, HOTTA Naoki, OKUMURA Akihiko, ISHIKAWA Tetsuya, KIBA Kumiko, KURODA Yasuko, NIWA Sachiyo, IDO Makoto, KAKUMU Sinichi

      Vol. 34   2007.4

     More details

    Publishing type:Research paper (scientific journal)  

  98. Four-Dimensional Ultrasonography for Therapeutic Radiofrequency Ablation for Hepatocellular Carcinoma

    HOTTA Naoki, AYADA Minoru, HIJIKATA Yasutaka, OOHASHI Tomohiko, SATO Ken, OKUMURA Akihiko, ISHIKAWA Tetsuya, OONO Nagayuki, KAKUMU Shinichi

      Vol. 34   2007.4

     More details

    Publishing type:Research paper (scientific journal)  

  99. Usefulness of ultrasonography to Liver Tumor in Live 3D

    HOTTA Naoki, AYADA Minoru, OOHASHI Tomohiko, SATO Ken, OKUMURA Akihiko, ISHIKAWA Tetsuya, KOSAKI Masahiro, KAKUMU Shinichi

      Vol. 34   2007.4

     More details

    Publishing type:Research paper (scientific journal)  

  100. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma

    Hotta Naoki, Ayada Minoru, Sato Ken, Ishikawa Tetsuya, Ohumura Ahihiko, Matsumoto Eiji, Ohashi Tomohiko, Kakumu Shinichi

    HEPATO-GASTROENTEROLOGY   Vol. 54 ( 79 ) page: 2073 - 2077   2007

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  101. Management of imatinib mesilate (IM)-related hepatic injury by adjusting the dose of the drug in a patient with chronic myelogenous leukemia (CML): A case report

    Ayada Minoru, Ishikawa Tetsuya, Okumura Akihiko, Hotta Naoki, Furuta Keiko, Yamauchi Taeko, Hijikata Yasutaka, Ohashi Tomohiko, Sato Ken, Kakumu Shinichi

    Kanzo   Vol. 48 ( 10 ) page: 505 - 510   2007

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japan Society of Hepatology  

    A 72-year-old female, with chronic myelogenous leukemia (CML) treated successfully with 400mg/day of imatinib mesilate (IM), developed laboratory signs of a cholestatic type of liver injury after one-year administration of IM, and was admitted to our hospital. We decided to stop the administration of IM to the patient. Thereafter the abnormalities in liver function tests recovered to the normal level promptly. However, with a necessity to use IM for preventing the recurrence of CML, we re-started administration of IM at a lower dose, by weighing the risk for liver injury and the benefit for CML in a balance. With careful monitoring of liver function tests, the dose of IM was gradually increased and reached 300mg/d, and the recurrence of liver injury or CML has not been observed. Here, we report the case of IM-related liver injury, controlled well after the re-administration of IM with the lower dose.<br>

    DOI: 10.2957/kanzo.48.505

    CiNii Research

  102. Combination therapy with lamvudine and HB vaccine on chronic hepatitis B.

    石川 哲也

    Hepatology Research 37     2007

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    CiNii Research

  103. A CASE OF HEMORRHAGIC GASTRIC VASCULAR ECTASIA TO BE ACCOMPANIED BY IDIOPATHIC PULMONARY FIBROSIS : SUCCESSFULLY TREATED BY ENDOSCOPIC BAND LIGATION

    AYADA Minoru, NAKANO Tatsunori, HOTTA Naoki, OKUMURA Akihiko, ISHIKAWA Tetsuya, OHASHI Tomohiko, MATSUMOTO Eiji, SATO Ken, YOSIDA Kagumi, KAKUMU Shinichi

    Gastroenterol Endosc   Vol. 48 ( 11 ) page: 2626 - 2631   2006.11

     More details

    Publishing type:Research paper (scientific journal)  

  104. Role of toll-like receptors in hepatitis C virus-infected chronic liver disease

    Kakumu Shinichi, Okumura Akihiko, Ishikawa Tetsuya, Yamauchi Taeko, Sato Sayaka, Sato Ken, Ohashi Tomohiko, Ayada Minoru, Hotta Naoki, Fukuzawa Yoshitaka

    HEPATOLOGY   Vol. 44 ( 4 ) page: 300A - 300A   2006.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  105. Efficacy of non-invasive hepatic fibrosis quantificated-evaluation by liver elasticity measurement in nonalcoholic steatohepatitis (NASH) - Comparison of ultrasonic transient elastography and histopathological diagnosis

    Fukuzawa Yoshitaka, Kizawa Senji, Ohashi Tomohiko, Matsumoto Eiji, Sato Ken, Ayada Minoru, Hotta Naoki, Okumura Akihiko, Ishikawa Tetsuya, Kakumu Shinichi

    HEPATOLOGY   Vol. 44 ( 4 ) page: 649A - 650A   2006.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  106. Expression of toll-like receptor family on regulatory T cells in the patients with autoimmune hepatitis

    Okumura Akihiko, Ishikawa Tetsuya, Sato Sayaka, Yamauchi Taeko, Ohashi Tomohiko, Sato Ken, Ayada Minoru, Hotta Naoki, Fukuzawa Yoshitaka, Kakumu Shinichi

    HEPATOLOGY   Vol. 44 ( 4 ) page: 640A - 641A   2006.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  107. Four-dimensional ultrasonography for therapeutic radiofrequency ablation for heaptocellular carcinoma. Reviewed

    Hotta N, Maeno T, Ayada M, Sato K, Ishikawa T, Okumura A, Matsumoto E, Fukuzawa Y, Kakumu S.

    Hepato-gastroenterology   Vol. 53 ( 70 ) page: 521-525   2006.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  108. TRIALS OF PERCUTANEOUS ENDOSCOPIC GASTROSTOMY BY TRANSNASAL ENDOSCOPY USING A SMALL-CALIBER ENDOSCOPE

    AYADA Minoru, NAKANO Tatsunori, HOTTA Naoki, NAKAE Harumichi, KUNII Shin, YOSHIDA Kagumi, OKUMURA Akihiko, ISHIKAWA Tetsuya, FUKUZAWA Yoshitaka, KAKUMU Shinichi

    GASTROENTEROLOGICAL ENDOSCOPY   Vol. 48 ( 7 ) page: 1425 - 1430   2006.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Japan Gastroenterological Endoscopy Society  

    We performed percutaneous endoscopic gastrostomy (PEG) by transnasal endoscopy using a small-caliber endoscope for the purpose of relieving the pain and stress of gastrointestinal endoscopy and PEG without conscious cedation. The usefulness and safety were compared between cases performed PEG by transnasal endoscopy and those by transoral endoscopy. Cases with dysphagia by neurological diseases were divided into two groups randomly. The pull technique was used for both groups. We observed vital signs etc to compare pain and stress in transnasal insertion group and transoral insertion group. An increase in blood pressure and pulse rate was significantly small during PEG in the transnasal insertion group compared to the transoral group. There was no major complication in the transnasal insertion group as well as the transoral group. Our experience suggested that PEG by transnasal endoscopy using a smallcaliber endoscope is more useful than PEG by transoral endoscopy to relieve the pain and stress, and PEG by transnasal endoscopy is a safe method as well as PEG by transoral endoscopy.

    DOI: 10.11280/gee1973b.48.1425

    CiNii Research

    researchmap

  109. Alteration of serum cytokine balances among different phases of chronic hepatitis B virus infection. Reviewed

    Ayada M, Ishikawa T, Okumura A, Tanabe J, Ito H, Ohashi T, Matsumoto E, Sato K, Hotta N, Fukuzawa Y, Kakumu S.

    Hepatol Res   Vol. 34 ( 4 ) page: 214-221   2006.4

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  110. 慢性肝疾患の病態にせまる免疫学的アプローチ 自己免疫性肝炎(AIH)における制御性T細胞(Tr)の機能低下

    奥村 明彦, 石川 哲也, 伊藤 弘康, 佐藤 さやか, 山内 妙子, 大橋 知彦, 松本 英司, 佐藤 顕, 綾田 穣, 堀田 直樹, 福澤 嘉孝, 各務 伸一

    消化器と免疫   Vol. 42 ( 42 ) page: 29 - 32   2006.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:日本消化器免疫学会  

    自己免疫性肝炎患者の制御性T細胞(Tr)について,Trの機能を調節しているFoxp3,TNF-R-SF18,CTLA-4,CD28の各遺伝子の発現を調べ調べ,自己免疫性肝炎(AIH)患者と健常者のTrのサイトカイン産生能を比較し,TrがAIHの病態に関与している可能性について検討した.AIH 15例,コントロールとしてC型慢性肝炎(CH-C)患者26例と健常人12例を対象とした.AIHではFoxp3,CTLA-4のmRNA量が減少し,TrによるIL-10の産生能が低下していることが明らかとなった.Trの機能異常が病態に関与している可能性が示唆された

    researchmap

  111. Plasma amino acid profiles applied for diagnosis of advanced liver fibrosis in patients with chronic hepatitis C infection. Reviewed

    Zhang Q, Takahashi M, Noguchi Y, Sugimoto T, Kimura T, Okumura A, Ishikawa T, Kakumu S.

    Hepatol Res   Vol. 34 ( 3 ) page: 170-177   2006.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  112. The SHAP-hyaluronan complex in serum from patients with chronic liver diseases caused by hepatitis virus infection. Reviewed

    Shen L, Zhuo L, Okumura A, Ishikawa T, Miyachi M, Owa Y, Ishizawa T, Sugiura N, Nagata Y, Nonami T, Kakumu S, Kimata K.

    Hepatol Res   Vol. 34 ( 3 ) page: 178-186   2006.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  113. 肝癌局所療法における超音波ドプラ法の新展開 Real Time 4D Ultrasoundを用いた肝細胞癌のラジオ波焼灼療法の有用性-マイクロコンベックスプローブ使用における検討も含めて

    堀田 直樹, 大橋 知彦, 松本 英司, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 各務 伸一

    Rad Fan   Vol. 4 ( 3 ) page: 116 - 119   2006.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:(株)メディカルアイ  

    従来の2D modeのエコーではなく,Real Time 4D Ultrasound systemsを用いて肝細胞癌に対しラジオ波焼灼療法(RFA)を施行し,その有用性について検討した.また,マイクロコンベックスプローブにおいても検討した.肝細胞癌22例25結節を対象とした.RFA施行22例25結節において,全症例Real Time 4D Ultrasound systemにて穿刺可能であった.Real Time 4D Ultrasound使用によるRFAは多方向より針の留置部位を確認することができ,より正確に経皮的治療を施行することができた

    researchmap

  114. Cholestatic hepatic injury related to administration of sodium risedronate hydrate. A case report with distinctive histological findings

    AYADA Minoru, ISHIKAWA Tetsuya, OKUMURA Akihiko, OHASHI Tomohiko, MATSUMOTO Eiji, SATO Ken, HOTTA Naoki, FUKUZAWA Yoshitaka, KAKUMU Shinichi

    Kanzo   Vol. 47 ( 1 ) page: 10 - 15   2006.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japan Society of Hepatology  

    A 53-year-old woman was hospitalized because of general fatigue, jaundice, and the elevation of serum hepatic and biliary enzymes. She was suffering from osteoporosis, and had undergone treatment with oral administration of sodium risedronate hydrate (SRH) for 6 months before admission. Liver injury related to SRH was suspected, and the medication was stopped. After cessation of the medication, she recovered from her illness, and the elevated enzymes gradually declined. According to the diagnostic scale for drug-induced hepatic injury at the workshop in Digestive Disease Week-Japan 2004, her liver injury was classified into cholestatic type and judged “highly possible.” Liver biopsy showed the distinctive findings, such as diffuse rosette formations of hepatocytes in liver parenchyma, and strongly supported the diagnosis.<br>Liver biopsy gives us important, sometimes critical information as the present case, thus it should be considered for execution as an auxiliary measure for accurate diagnosis of drug-related liver injury.

    DOI: 10.2957/kanzo.47.10

    CiNii Research

    researchmap

  115. Four-dimensional ultrasonography for therapeutic radiofrequency ablation for hepatocellular carcinoma

    Hotta Naoki, Maeno Tadashi, Ayada Minoru, Sato Ken, Ishikawa Tetsuya, Okumura Akihiko, Matsumoto Eiji, Fukuzawa Yoshitaka, Kakumu Shinichi

    HEPATO-GASTROENTEROLOGY   Vol. 53 ( 70 ) page: 521 - 525   2006

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  116. Rebamipide enemas-New effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis-

    Miyata M, Kasugai K, Ishikawa T, Kakumu S, Onishi M, Mori T.

    Dig Dis Sci   Vol. 50 ( S1 ) page: S119-S123   2005.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  117. Assessment of hepatic fibrosis in chronic liver disease - Usefulness of the strain rate imaging method

    Hotta N, Okumura A, Ishikawa T, Kakumu S

    HEPATOLOGY   Vol. 42 ( 4 ) page: 342A - 342A   2005.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  118. 出血性胃vascular ectasiaに対し内視鏡的結紮術が有効であった2例

    綾田 穣, 堀田 直樹, 石川 哲也, 奥村 明彦, 恒川 明久, 井澤 晋也, 大橋 知彦, 松本 英司, 佐藤 顕, 福沢 嘉孝, 各務 伸一

    Gastroenterological Endoscopy   Vol. 47 ( Suppl.2 ) page: 1971 - 1971   2005.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  119. Four-dimensional ultrasonogaraphy for therapeutic radiofrequency ablation for hepatocellular carcinoma

    Hotta N, Okumura A, Ishikawa T, Fukuzawa Y, Kakumu S

    AMERICAN JOURNAL OF GASTROENTEROLOGY   Vol. 100 ( 9 ) page: S106 - S106   2005.9

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  120. 門脈圧亢進症の新しい薬物療法 難治性腹水に対するdocarpamineの有用性と安全性

    綾田 穣, 石川 哲也, 堀田 直樹, 奥村 明彦, 大橋 知彦, 松本 英司, 佐藤 顕, 福沢 嘉孝, 各務 伸一

    日本門脈圧亢進症学会雑誌   Vol. 11 ( 1 ) page: 43 - 43   2005.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:(一社)日本門脈圧亢進症学会  

    researchmap

  121. B型肝炎ウイルス(HBV)関連抗原が肝炎進展過程に与える影響について

    佐藤 顕, 石川 哲也, 田邊 純一, 大橋 知彦, 松本 英司, 前野 禎, 綾田 穣, 堀田 直樹, 宮田 充樹, 奥村 明彦, 福沢 嘉孝, 各務 伸一

    消化器と免疫   Vol. 41 ( 41 ) page: 159 - 162   2005.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:日本消化器免疫学会  

    標題の影響を明らかにするため,concanavalin A(Con A)を投与されたHBVトランスジェニックマウスの肝臓におけるサイトカイン,ケモカインの発現パターンを解析し,同系正常マウスと比較した.結果,トランスジェニックマウスではCon A投与後2時間から24時間にかけてIL-18,TGF-β,GM-CSF,fractalkineの発現が正常マウスよりも強く,24時間後にはTNF-αとINF-γの発現が強かった.これは,HBV関連抗原が免疫応答を制御あるいは修飾することで何らかの免疫異常を引き起こしている可能性を示すと考えられた

    researchmap

  122. Changes in natural killer T cells subsets during therapy in type C hepatitis and hepatocellular carcinoma. Reviewed

    Okumura A, Ishikawa T, Maeno T, Sato K, Ayada M, Hotta N, Yamauchi T, Fukuzawa Y, Kakumu S.

    Hepatol Res   Vol. 32 ( 4 ) page: 213-217   2005.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  123. マイクロコンベックス使用におけるラジオ波焼灼療法の経験

    堀田 直樹, 綾田 穣, 佐藤 顕, 松本 英司, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 高橋 忍, 各務 伸一

    超音波医学   Vol. 32 ( Suppl. ) page: S409 - S409   2005.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:(公社)日本超音波医学会  

    researchmap

  124. A CASE OF HEMORRHAGIC DUODENAL VASCULAR ECTASIA : SUCCESSFULLY TREATED BY ENDOSCOPIC VARICEAL LIGATION

    AYADA Minoru, FUKUZAWA Yoshitaka, HOTTA Naoki, MATSUMOTO Eiji, MAENO Tadashi, SATO Ken, OKUMURA Akihiko, ISHIKAWA Tetsuya, KAKUMU Shinichi

    Gastroenterol Endosc   Vol. 47 ( 1 ) page: 15 - 21   2005.1

     More details

    Publishing type:Research paper (scientific journal)  

  125. Advanced dynamic flow imaging with contrast-enhanced ultrasonography for the evaluation of tumor vascularity in liver tumors. Reviewed

    Hotta N, Tagaya T, Maeno T, Ayata M, Sato K, Ishikawa T, Okumura A, Fukuzawa Y, Kakumu S.

    Clin Imaging   Vol. 29 ( 1 ) page: 34-41   2005.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  126. A CASE OF HEMORRHAGIC DUODENAL VASCULAR ECTASIA: SUCCESSFULLY TREATED BY ENDOSCOPIC VARICEAL LIGATION

    AYADA Minoru, FUKUZAWA Yoshitaka, HOTTA Naoki, MATSUMOTO Eiji, MAENO Tadashi, SATO Ken, OKUMURA Akihiko, ISHIKAWA Tetsuya, KAKUMU Shinichi

    GASTROENTEROLOGICAL ENDOSCOPY   Vol. 47 ( 1 ) page: 15 - 21   2005.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Japan Gastroenterological Endoscopy Society  

    A 82-year-old-woman was hospitalized because of the hemorrhagic small intestinal an-giodysplasia with general malaise. On emergent gastrointestinal fiberscopy, we formed a duodenal vascular ectasia with two bleeding spots among several vascular ectasia at the superior duodenal angle. We successfully treated the two hemorrhagic vascular ectasia using a ligating device for endoscopic variceal ligation (EVL). Permanent hemostasis was obtained with one procedure with out side effects. EVL appeared to be useful for small hemorrhagic lesions of small intestine.

    DOI: 10.11280/gee1973b.47.15

    CiNii Research

    researchmap

  127. A case of hepatocellular carcinoma (HCC) treated with radiofrequency ablation (RFA) using 4D real-time ultrasound system

    Hotta N, Fukuzawa Y, Ayada M, Sato K, Maeno T, Tagaya T, Okumura A, Ishikawa T, Ito Y, Kakumu S

    HEPATO-GASTROENTEROLOGY   Vol. 52 ( 64 ) page: 1224-1227   2005

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  128. Changes in natural killer T cell subsets during therapy in type C hepatitis and hepatocellular carcinoma.

    石川 哲也

    Hepatol Res 32     page: 213 - 217   2005

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    CiNii Research

  129. 【内科診療最前線2005 この1年の動向を踏まえて】 肝疾患

    各務 伸一, 福沢 嘉孝, 石川 哲也, 奥村 明彦, 堀田 直樹, 綾田 穣

    内科   Vol. 94 ( 6 ) page: 1030 - 1038   2004.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:南江堂  

    DOI: 10.15106/j00974.2005057442

    CiNii Research

  130. 【内科診療最前線2005 この1年の動向を踏まえて】肝疾患

    各務 伸一, 福沢 嘉孝, 石川 哲也, 奥村 明彦, 堀田 直樹, 綾田 穣

    内科   Vol. 94 ( 6 ) page: 1030 - 1038   2004.12

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:(株)南江堂  

    researchmap

  131. Usefulness of contrast-enhanced ultrasonography to evaluate therapeutic effects for hepatocellular carcinoma

    Hotta N, Okumura A, Ishikawa T, Kakumu S

    AMERICAN JOURNAL OF GASTROENTEROLOGY   Vol. 99 ( 10 ) page: S69 - S69   2004.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  132. Dynamics of CD8(+)T cells, CD4(+)T cells, and CD4(+)CD25(+) regulatory T cells in the liver with autoimmune hepatitis(AIH) - Analysis using mice model for AIH type 2

    Okumura A, Ishikawa T, Ito H, Sato K, Maeno T, Ayada M, Hotta N, Matsumoto E, Ohashi T, Fukuzawa Y, Kakumu S

    HEPATOLOGY   Vol. 40 ( 4 ) page: 421A - 421A   2004.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  133. Nutrition assessment and management in outpatients with liver cirrhosis caused by HCV (LC-C) - Usefulness of a branched chain amino acid (BCAA)-rich product as late evening snacks (LES)

    Fukuaawa Y, Hotta N, Ayada M, Ohashi T, Matsumoto E, Sato K, Maeno T, Okumura A, Ishikawa T, Kakumu S

    HEPATOLOGY   Vol. 40 ( 4 ) page: 512A - 512A   2004.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  134. 2) DFPPによるウイルス除去療法 : DFPPによるC型肝炎ウイルス減量療法の効果(日本アフェレシス学会第13回関東甲信越地方会抄録)

    西川 和裕, 宮田 充樹, 奥村 明彦, 石川 哲也, 各務 伸一

    日本アフェレシス学会雑誌   Vol. 23 ( 3 ) page: 289-290   2004

     More details

    Language:Japanese  

  135. 内科診療最前線2005-この1年の動向を踏まえて-非アルコール性脂肪性肝炎 (NASH),アルコール性肝障害 (ALD). Reviewed

    各務伸一, 福沢嘉孝, 石川哲也, 奥村明彦, 堀田直樹, 綾田穣

    内科   Vol. 94   page: 1823 - 1829   2004

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    researchmap

  136. Successful treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration (B-RTO) for a patient with Wilson disease Reviewed

    Japanese Journal of Portal Hypertension   Vol. 10 ( 10 ) page: 132 - 136   2004

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japan Society for Portal Hypertension  

    DOI: 10.11423/jsph1999.10.3-4_132

    researchmap

  137. Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic heaptitis C virus infection. Reviewed

    Maeno T, Okumura A, Ishikawa T, Kato K, Sakakibara F, Sato K, Ayada M, Hotta N, Tagaya T, Fukuzawa Y, Kakumu S.

    J Gastroenterol Hepatol   Vol. 18 ( 12 ) page: 1358-1363   2003.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  138. 生活習慣病を合併した著明な脂肪肝症例に対して茵ちん蒿湯・防風通聖散併用療法が奏効した1例

    福沢 嘉孝, 堀田 直樹, 佐藤 顕, 前野 禎, 綾田 穣, 多賀谷 恒明, 奥村 明彦, 石川 哲也, 各務 伸一, 加藤 勝久

    漢方医学   Vol. 27 ( 5 ) page: 221 - 224   2003.12

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:(株)協和企画  

    53歳女.全身倦怠感,後頭部不快感を主訴とした.身長161cm,体重81kg,普段から暑がりで便秘傾向があり,熱実証,腹壁が厚く弾力があった.臨床データは異常値を示し,臨床データ及び腹部超音波検査より,高脂血症,高血圧,肥満,耐糖能障害(IGT)を合併する著明な脂肪肝と診断した.高血圧にはアンジオテンシンII受容体拮抗薬バルサルタンを投与し,コントロール良好となった.肥満・高脂血症・脂肪肝・IGTに対しては食事・運動療法を開始したが,各種データの改善は乏しかった.その後,生活習慣の乱れによりデータが悪化し,体重も治療前値付近に戻ったため,従来法を継続しながら,茵ちん蒿湯を新たに処方し,強化療法も同時に行った.約5ヵ月後,各種データは改善傾向を示したが,体重は殆ど変化しなかった.患者が減量を切望したこと等より,10月末から防風通聖散を併用した.治療開始から漢方薬併用投与約3.5ヵ月後迄に体重は74kgになり,各種データも改善し,自覚症状も殆ど消失した.現在,大きな副作用は認めず,生活習慣病に対する病識も向上してきた.従来法は継続中である

    researchmap

  139. Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection

    Maeno T, Okumura A, Ishikawa T, Kato K, Sakakibara F, Sato K, Ayada M, Hotta N, Tagaya T, Fukuzawa Y, Kakumu S

    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   Vol. 18 ( 12 ) page: 1358 - 1363   2003.12

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  140. Usefulness of contrast-enhanced ultrasonography with dynamic flow imaging to evaluated therapeutic effects for hepatocellular carcinoma. Reviewed

    Hotta N, Tagaya T, Maeno T, Ishikawa T, Okumura A, Fukuzawa Y, Kakumu S.

    Hepato-gastroenterology   Vol. 50 ( 54 ) page: 1867-1871   2003.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  141. Combination therapy of lamivudine and HB vaccine for the treatment of chronic hepatitis B.

    Ishikawa T, Okumura A, Maeno T, Sato K, Ayada M, Hotta N, Tagaya T, Fukuzawa Y, Kakumu S

    HEPATOLOGY   Vol. 38 ( 4 ) page: 717A - 717A   2003.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  142. Nutrition is more important than Th1-dominated condition for better response in interferon alpha-2b/ribavirin therapy.

    Okumura A, Ishikawa T, Ayada M, Sato K, Maeno T, Hotta N, Tagaya T, Fukuzawa Y, Kakumu S

    HEPATOLOGY   Vol. 38 ( 4 ) page: 314A - 314A   2003.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  143. Involvement of CD4+ CD25+ regulatory T cells as immune modulators in chronic hepatitis C virus (HCV) infection.

    Okumura A, Ishikawa T, Yamauchi T, Maeno T, Sato K, Ayada M, Hotta N, Tagaya T, Fukuzawa Y, Kakumu S

    HEPATOLOGY   Vol. 38 ( 4 ) page: 463A - 463A   2003.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  144. Establishment of a novel mouse model for AIH type 2.

    Okumura A, Ishikawa T, Sato K, Ayada M, Maeno T, Hotta N, Tagaya T, Fukuzawa Y, Kakumu S

    HEPATOLOGY   Vol. 38 ( 4 ) page: 485A - 485A   2003.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  145. 肝細胞癌におけるFas/Fas Lの発現と浸潤リンパ球との関係

    福澤 嘉孝, 堀田 直樹, 佐藤 顕, 前野 禎, 綾田 穣, 多賀谷 恒明, 奥村 明彦, 石川 哲也, 各務 伸一

    愛知医科大学医学会雑誌   Vol. 31 ( 2 ) page: 106 - 107   2003.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:愛知医科大学医学会  

    researchmap

  146. Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. Reviewed

    Arao M, Murase K, Kusakabe A, Yoshioka K, Fukuzawa Y, Ishikawa T, Tagaya T, Yamanouchi K, Ichimiya H, Sameshima Y, Kakumu S.

    J Gastroenterol   Vol. 38 ( 4 ) page: 355-360   2003.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  147. Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. Reviewed

    Kasahara S, Ando K, Saito K, Sekikawa K, Ito H, Ishikawa T, Ohnishi H, Seishima M, Kakumu S, Moriwaki H.

    J Virol   Vol. 77 ( 4 ) page: 2469-2476   2003.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  148. Levels of SHAP-HA complex in the sera of patients with chronic liver diseases -Usefulness as an indicator for diagnosis of hepatocellular carcinoma-

    Shen L., Zhou L., Okumura A., Ishikawa T., Kakumu S., Kimata K.

    Japan Journal of Molecular Tumor Marker Research   Vol. 19 ( 19 ) page: 70 - 71   2003

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Japanese Society for Molecular Tumor Marker Research  

    DOI: 10.11241/jsmtmr.19.70

    CiNii Research

  149. Usefulness of contrast-enhanced ultrasonography with dynamic flow imaging to evaluate therapeutic effects for hepatocellular carcinoma

    Hotta N, Tagaya T, Maeno T, Ishikawa T, Okumura A, Fukuzawa Y, Kakumu S

    HEPATO-GASTROENTEROLOGY   Vol. 50 ( 54 ) page: 1867 - 1871   2003

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  150. 3. B型慢性肝炎へのラミブジン+HBワクチン併用療法

    石川 哲也, 奥村 明彦, 各務 伸一

    肝臓   Vol. 43 ( 10 ) page: 470-471   2002.10

     More details

    Language:Japanese  

  151. Usefulness of contrast-enhanced ultrasonography with dynamic flow imaging to evaluate therapeutic effects for hepatocelluiar carcinoma.

    Hotta N, Maeno T, Tagaya T, Ayata M, Satoh K, Okumura A, Fukuzawa Y, Ishikawa T, Kakumu S

    HEPATOLOGY   Vol. 36 ( 4 ) page: 687A - 687A   2002.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  152. Combination of HB vaccine with lamivudine for the treatment of chronic hepatitis B.

    Ishikawa T, Okumura A, Maeno T, Sato K, Ayada Y, Hotta N, Tagaya T, Fukuzawa Y, Kakumu S

    HEPATOLOGY   Vol. 36 ( 4 ) page: 643A - 643A   2002.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  153. Expression of glypican-3 (GPC 3) and its significance as a novel marker of the degree of dedifferentiation in hepatocellular carcinoma

    Fukuzawa Y, Furuta K, Tagaya T, Sato K, Maeno T, Ayada M, Hotta N, Okumura A, Ishikawa T, Kakumu S

    HEPATOLOGY   Vol. 36 ( 4 ) page: 691A - 691A   2002.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  154. Different distribution of antigenic B cell and T cell epitopes within HBV core region

    Okumura A, Ishikawa T, Sato K, Maeno T, Ayada M, Hotta N, Tagaya T, Fukuzawa Y, Kakumu S

    HEPATOLOGY   Vol. 36 ( 4 ) page: 620A - 620A   2002.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  155. 慢性肝疾患と免疫 B型慢性肝炎患者におけるHBc抗原領域のエピトープの同定とそれに対する免疫応答の質的解析

    石川 哲也, 田邊 純一, 佐藤 顕, 前野 禎, 綾田 穣, 堀田 直樹, 多賀谷 恒明, 奥村 明彦, 福沢 嘉孝, 各務 伸一

    消化器と免疫   ( 38 ) page: 20 - 23   2002.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:日本消化器免疫学会  

    B型慢性肝炎患者(B-CH)におけるHBc抗原特異的免疫応答の標的部位の解析,免疫応答の質的評価を行った.B-CH患者23例を対象に,HBc抗原領域をカバーする13〜15merのペプタイドを作製し,患者末梢血単核球を刺激後,細胞内サイトカイン/ケモカイン発現パターンをflow cytometry(FACS)及びRT-PCRにて解析した.FACS解析では,HBc91-105(p19)での刺激時に,FN-γ+細胞,IL-4+細胞とも有意な増加がみられた.また,RT-PCRを用いた解析ではp19による刺激で11例中8例で,多くの場合,同時に複数のサイトカイン/ケモカインの発現増強がみられた.これらのことから,B-CH患者においてはp19に主要なエピトープが存在している可能性が示唆された

    researchmap

  156. Expression of Fas/Fas ligand (FasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC)

    FUKUZAWA Yoshitaka, TAKAHASHI Kiyoshi, FURUTA Keiko, TAGAYA Tsuneaki, ISHIKAWA Tetsuya, WADA Kaori, OMOTO Yasukazu, KOJI Takehiko, KAKUMU Shinichi

    Journal of gastroenterology   Vol. 36 ( 10 ) page: 681 - 688   2001.10

     More details

    Publishing type:Research paper (scientific journal)  

  157. Expression of Fas/Fas ligand (FasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC). Reviewed

    Fukuzawa Y, Takahashi K, Furuta K, Tagaya T, Ishikawa T, Wada K, Omoto Y, Koji T, Kakumu S.

    J Gastroenterol   Vol. 36 ( 10 ) page: 178-186   2001.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  158. Expression of Fas/Fas ligand (FasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC) Reviewed

    Y Fukuzawa, K Takahashi, K Furuta, T Tagaya, T Ishikawa, K Wada, Y Omoto, T Koji, S Kakumu

    JOURNAL OF GASTROENTEROLOGY   Vol. 36 ( 10 ) page: 681 - 688   2001.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER-VERLAG  

    Background. This study was conducted to examine the expression of Fas/Fas ligand (FasL), to elucidate its relationship with tumor-infiltrating lymphocytes (TILs), and to detect possible gene mutation of Fas/FasL in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). Methods. Indirect immunohistochemical staining was performed on formalin-fixed, paraffin-embedded sections of liver biopsy and surgery specimens from five normal livers, and from the livers of 30 patients with HCC. Fas/FasL mRNA-expressing cells and apoptotic cells were detected by in situ hybridization and DNA nick end labeling (TUNEL), respectively. We also performed polymerase chain reaction (PCR) -amplifying and direct sequencing for the Fas/FasL gene. Results. Fas/FasL and its mRNA were localized on the, membrane or in the cytoplasm in some HCC cells, as well as hepatocytes. Their expression was enhanced in areas with infiltrating inflammatory cells in the noncancerous regions of liver tissue and on the margins of the cancerous tissue. The positivity rate for TUNEL was elevated along these margins. The labeling index of Fas/FasL was lower in the cancerous liver tissue than in the surrounding noncancerous region (P &lt; 0.01), and tended to decrease in proportion to the malignancy of tumor cells; Fas/FasL expression was not found on poorly differentiated type cancer cells. Fas(-)/FasL(+), FasL-mRNA(+) HCC cells were seen in one specimen of moderately differentiated type. Some CD8+T lymphocytes were TUNEL-positive around the cancerous region. In this study, cancerous and noncancerous tissues in HCC revealed no genetic mutations in any exons of Fas/FasL. Conclusions. These findings suggest that Fas/FasL expression was decreased in proportion to the malignancy of tumor cells, and that infiltrating CD8+T lymphocytes play a role in apoptosis in HCC. The apoptosis in HCC could be regulated by the suppression of Fas/FasL expression, or, sometimes, by the enhancement of FasL expression.

    DOI: 10.1007/s005350170031

    Web of Science

    researchmap

  159. Expression of Fas/Fas ligand (FasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC)

    Fukuzawa Y, Takahashi K, Furuta K, Tagaya T, Ishikawa T, Wada K, Omoto Y, Koji T, Kakumu S

    JOURNAL OF GASTROENTEROLOGY   Vol. 36 ( 10 ) page: 681 - 688   2001.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  160. Identification of highly immunogenic T cell epitope within HBV core region and immune response triggered by the activation of HBV core specific T cells.

    Ishikawa T, Tanabe J, Okumura A, Maeno T, Yamamoto K, Hotta N, Yoshida K, Ito M, Tagaya T, Fukuzawa Y, Kakumu S

    HEPATOLOGY   Vol. 34 ( 4 ) page: 312A - 312A   2001.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  161. Crosstalk between oxidative stress and apoptosis in hepatocellular carcinoma (HCC).

    Fukuzawa Y, Hotta N, Furuta K, Maeno T, Yamamoto K, Yoshida K, Ito M, Tagaya T, Okumura A, Ishikawa T, Kakumu S

    HEPATOLOGY   Vol. 34 ( 4 ) page: 515A - 515A   2001.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  162. Experimental autoimmune hepatitis in mice following immunization with cytochrome P450IID6.

    Ishikawa T, Tanabe JC, Okumura A, Ito M, Maeno T, Yamamoto K, Yoshida K, Hotta N, Tagaya T, Fukuzawa Y, Miyakawa H, Kakumu S

    HEPATOLOGY   Vol. 34 ( 4 ) page: 286A - 286A   2001.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  163. Increased insulin resistance in the patients with chronic HCV infection is mediated by elevated serum TNF alpha.

    Maeno T, Okumura A, Ishikawa T, Yamamoto K, Hotta N, Yoshida K, Ito M, Tagaya T, Fukuzawa Y, Kakumu S

    HEPATOLOGY   Vol. 34 ( 4 ) page: 552A - 552A   2001.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  164. Impaired function of peripheral blood dendritic cell subsets of hepatitis C virus-infected patients.

    Sobue S, Nomura T, Nakao H, Okumura A, Ishikawa T, Kakumu S, Itoh M

    HEPATOLOGY   Vol. 34 ( 4 ) page: 482A - 482A   2001.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  165. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. Reviewed

    Sobue S, Nomura T, Ishikawa T, Ito S, Saso K, Ohara H, Joh T, Itoh M, Kakumu S.

    J Gastroenterol   Vol. 36 ( 8 ) page: 544-551   2001.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  166. 消化器疾患の病態とTh1/Th2バランス 肝細胞のケモカイン産生とTh1/Th2バランスへの影響

    石川 哲也, 田邊 純一, 伊東 正道, 奥村 明彦, 多賀谷 恒明, 福澤 嘉孝, 各務 伸一

    消化器と免疫   ( 37 ) page: 5 - 8   2001.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:日本消化器免疫学会  

    肝細胞の炎症及びTh1/Th2 cytokine刺激に対する反応,その後のTh1/Th2バランスに与える影響を,肝細胞のchemokine産生を測定することにより検討した.肝細胞はIFN-γ(Th1)刺激により,更にTh1反応を促進する方向に働くこと,IL-4(Th2)刺激によりTh1反応を抑制し,Th2反応を間接的に促進する方向に働くことがわかった.IL-1O(Th2)刺激はTh2反応を間接的に促進する方向に働いた.肝炎においては肝細胞自身が免疫応答の方向性を制御している可能性が示された

    researchmap

  167. Apoptosis is induced by caspase activation and cytochrome c release in photodynamic therapy (PDT) of human hepatocellular carcinoma cells.

    Okumura A, Hamblin MR, Hasan T, Ishikawa T, Kakumu S, Takahashi H

    GASTROENTEROLOGY   Vol. 120 ( 5 ) page: A363 - A363   2001.4

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  168. 最近の癌の動向 当科における肝癌患者の実態

    福沢 嘉孝, 堀田 直樹, 前野 禎, 山本 賢一, 吉田 香果, 吉田 篤生, 伊東 正道, 多賀谷 恒明, 奥村 明彦, 石川 哲也

    愛知医科大学医学会雑誌   Vol. 29 ( 2 ) page: 148 - 150   2001.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:愛知医科大学医学会  

    researchmap

  169. Mutation at codon 130 in hepatitis B virus (HBV) core region increases markedly during acute exacerbation of hepatitis in chronic HBV carriers. Reviewed

    Okumura A, Ishikawa T, Yoshioka K, Yuasa R, Fukuzawa Y, Kakumu S.

    J Gastroenterol   Vol. 36 ( 2 ) page: 103-110   2001.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  170. Update of liver disease related to chronic hepatitis B virus infection. Invited

    Ishikawa T, Kakumu S.

    Int Med   Vol. 40 ( 2 ) page: 178-179   2001.2

     More details

    Authorship:Lead author   Language:English  

  171. Symposium on Clinical Aspects in Hepatitis Virus Infection, Update of Liver Disease Related to Chronic Hepatitis B Virus Infection

    ISHIKAWA Tetsuya, KAKUMU Shinichi

    Internal medicine   Vol. 40 ( 2 ) page: 178 - 179   2001.2

     More details

    Publishing type:Research paper (scientific journal)   Publisher:一般社団法人 日本内科学会  

    DOI: 10.2169/internalmedicine.40.178

  172. 学会記”肝臓学会” Reviewed

    各務伸一, 福沢嘉孝, 石川哲也, 奥村明彦

    日本醫亊新報   ( 4033 ) page: 40 - 42   2001

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    researchmap

  173. Randomized controlled trial of twice-a-day administration of natural interferon β for chronic hepatitis C

    YOSHIOKA Kentaro, YANO Motoyoshi, HIROFUJI Hideo, ARAO Motohiro, KUSAKABE Atsuhiko, SAMESHIMA Yoichi, KURIKI Junsuke, KUROKAWA Susumu, MURASE Kenichi, ISHIKAWA Tetsuya, KAKUMU Shinichi

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 18 ( 3 ) page: 310 - 319   2000.11

     More details

    Publishing type:Research paper (scientific journal)  

  174. Randomized controlled trial of twice-a-day administration of natural interferon beta for chronic hepatitis C. Reviewed

    Yoshioka K, Yano M, hirohuji H, Arao M, Kusakabe A, Sameshima Y, Kuriki J, Kurokawa S, Murase K, Ishikawa T, Kakumu S, IFN Treatment Group of Affiliated Hospitals of Third Department of Internal Medicine at Nagoya University School of Medicine.

    Hepatol Res   Vol. 18 ( 3 ) page: 310-319   2000.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  175. Roles of hepatocytes in regulating inflammatory reactions.

    Tanabe J, Ishikawa T, Ito M, Maeno T, Tagaya T, Fukuzawa Y, Kakumu S

    HEPATOLOGY   Vol. 32 ( 4 ) page: 202A - 202A   2000.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  176. Association of chronic HCV infection and diabetes mellitus among Japanese populations.

    Kakumu S, Tagaya T, Fukuzawa Y, Ishikawa T, Arao M, Murase K, Kusakabe A, Yoshioka K

    HEPATOLOGY   Vol. 32 ( 4 ) page: 543A - 543A   2000.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  177. Comparison of serum cytokine levels between type C cirrhotic patients with and without hepatocellular carcinoma.

    Ito M, Ishikawa T, Tanabe J, Hotta N, Yoshida K, Tagaya T, Fukuzawa Y, Kakumu S

    HEPATOLOGY   Vol. 32 ( 4 ) page: 620A - 620A   2000.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  178. Influence of hepatitis B core protein and its defective mutants on growth and gene expression of hepatocytes.

    Tanabe J, Ishikawa T, Ito M, Yoshida A, Tagaya T, Fukuzawa Y, Kakumu S

    HEPATOLOGY   Vol. 32 ( 4 ) page: 393A - 393A   2000.10

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  179. Decreased function of peripheral blood dendritic cell in patients with hepatocellular carcinoma with hepatitis B and C virus infection. Reviewed

    Kakumu S, Ito S, Ishikawa T, Mita Y, Tagaya T, Fukuzawa Y, Yoshioka K.

    J Gastroenterol Hepatol   Vol. 61 ( 1 ) page: 23-28   2000.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  180. Properties of hepatitis B virus genome recovered from Vietnamese patients with fulminant hepatitis in comparison with those from acute hepatitis. Reviewed

    Yuasa R, Takahashi K, Dien BV, Binh NH, Morishita T, Sato K, Yamamoto N, Isomura S, Yoshioka K, Ishikawa T, Mishiro S, Kakumu S.

    J Med Virol   Vol. 61 ( 1 ) page: 23-28   2000.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  181. Properties of hepatitis B virus genome recovered from Vietnamese patients with fulminant hepatitis in comparison with those of acute hepatitis

    Yuasa R, Takahashi B, Dien BV, Binh NH, Morishita T, Sato K, Yamamoto N, Isomura S, Yoshioka K, Ishikawa T, Mishiro S, Kakumu S

    JOURNAL OF MEDICAL VIROLOGY   Vol. 61 ( 1 ) page: 23 - 28   2000.5

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  182. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection

    Kakumu S, Ito S, Ishikawa T, Mita Y, Tagaya T, Fukuzawa Y, Yoshioka K

    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   Vol. 15 ( 4 ) page: 431 - 436   2000.4

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  183. 肝炎ウイルスの臨床  3 B型慢性肝疾患の話題

    石川 哲也, 各務 伸一

    日本内科学会雑誌   Vol. 89 ( 9 ) page: 1845 - 1849   2000

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:一般社団法人 日本内科学会  

    DOI: 10.2169/naika.89.1845

    PubMed

    CiNii Research

  184. Elevated intracellular IFN-gamma levels in circulating CD8+ lymphocytes in patients with fulminant hepatitis. Reviewed

    Kimura K, Ando K, Ohnishi H, Tomita E, Muto Y, Moriwaki H, Ishikawa T, Kakumu S.

    J Hepatol   Vol. 31 ( 4 ) page: 579-583   1999.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  185. Immuno-pathogenesis of hepatic fibrosis in chronic liver injury induced by repeatedly administered concanavalin A. Reviewed

    Kimura K, Ando K, Ohnishi H, Takemura M, Muto Y, Moriwaki H, Ishikawa T, Kakumu S.

    Int Immunol   Vol. 11 ( 9 ) page: 1491-1500   1999.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  186. Gene mutation of transforming growth factor beta1 type II receptor in hepatocellular carcinoma. Reviewed

    Furuta K, Misao S, Takahashi K, Tagaya T, Fukuzawa Y, Ishikawa T, Yoshioka K, Kakumu S.

    Int J Cancer   Vol. 81 ( 6 ) page: 851-853   1999.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  187. Polyclonality and multispecificity of the CTL response to a single viral epitope. Reviewed

    Ishikawa T, Kakumu S, Kono D, Chung J, Fowler P, Theofilopoulos A, Chisari FV.

    J Immunol   Vol. 161 ( 11 ) page: 5842-5850   1998.12

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  188. Different constitution of hepatitis C virus population in peripheral blood mononuclear cells and plasma in patients with type C chronic liver disease. Reviewed

    Okumura A, Yoshioka K, Aiyama T, Takayanagi M, Iwata K, Ishikawa T, Kakumu S.

    Dig Dis Sci   Vol. 43 ( 2 ) page: 377-383   1998.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  189. Serum levels of IL-10, IL-15 and soluble tumor necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Reviewed

    Kakumu S, Okumura A, Ishikawa T, Yano M, Enomoto A, Nishimura H, Yoshioka K, Yoshikai Y.

    Clin Exp Immunol   Vol. 109 ( 3 ) page: 458-463   1997.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  190. Serial quantitation of serum core protein and viral RNA of hepatitis C virus after interferon therapy: Increase in viral load in biochemical responders. Reviewed

    Yoshioka K, Aiyama T, Iwata K, Yano M, Okumura A, Ishikawa T, Kakumu S.

    Am J Gastroenterol   Vol. 92 ( 8 ) page: 1305-1309   1997.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  191. Interleukin 2 and gamma/delta T-cell receptors in peripheral blood of patients with chronic hepatitis C virus infection. Reviewed

    Kakumu S, Ishikawa T, Okumura A, Yoshioka K.

    Hepatol Res   Vol. 7 ( 2 ) page: 83-93   1997.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  192. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. Reviewed

    Kakumu S, Aiyama T, Okumura A, Iwata K, Ishikawa T, Yoshioka K.

    J Gastroenterol Hepatol   Vol. 12 ( 6 ) page: 468-472   1997.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  193. Production of interleukins 10 and 12 by peripheral blood mononuclear cells (PBMC) in chronic hepatitis C virus (HCV) infection. Reviewed

    Kakumu S, Okumura A, Ishikawa T, Iwata K, Yano M, Yoshioka K.

    Clin Exp Immunol   Vol. 108 ( 1 ) page: 138-143   1997.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  194. Humoral immune response to the hypervariable region of hepatitis C virus differs between genotype 1b and 2a. Reviewed

    Yoshioka K, Aiyama T, Okumura A, Takayanagi M, Iwata K, Ishikawa T, Nagai Y, Kakumu S.

    J Infect Dis   Vol. 175 ( 3 ) page: 505-510   1997.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  195. Cyclosporine therapy affects amino-transferase activity but not hepatitis C virus RNA levels in chronic hepatitis C. Reviewed

    Kakumu S, Takayanagi M, Iwata K, Okumura A, Aiyama T, Ishikawa T, Nadai M, Yoshioka K.

    J Gastroenterol Hepatol   Vol. 12 ( 1 ) page: 62-66   1997.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  196. Hypervariable region sequence in cryoglobulin-associated hepatitis C virus in sera of patients with chronic hepatitis C: relationship to antibody response against hypervariable region genome. Reviewed

    Aiyama T, Yoshioka K, Okumura A, Takayanagi M, Iwata K, Ishikawa T, Kakumu S.

    Hepatology   Vol. 24 ( 6 ) page: 1346-1350   1996.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  197. Sequence analysis of hypervariable region of hepatitis C virus (HCV) associated with immune complex in patients with chronic HCV infection. Reviewed

    Aiyama T, Yoshioka K, Okumura A, Takayanagi M, Iwata K, Ishikawa T, Kakumu S.

    J Infect Dis   Vol. 174 ( 6 ) page: 1316-1320   1996.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  198. Serial analysis of hepatitis B virus core nucleotide sequence of patients with acute exacerbation during chronic infection. Reviewed

    Okumura A, Takayanagi M, Aiyama T, Iwata K, Wakita T, Ishikawa T, Yoshioka K, Kakumu S.

    J Med Virol   Vol. 49 ( 2 ) page: 103-109   1996.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  199. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Reviewed

    Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber RD, Chisari FV.

    Immunity   Vol. 4 ( 1 ) page: 25-36   1996.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  200. Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Reviewed

    Tsui LV, Guidotti LG, Ishikawa T, Chisari FV.

    Proc Natl Acad Sci USA   Vol. 92 ( 26 ) page: 12398-12402   1995.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  201. CTL access to tissue antigen is restricted in vivo. Reviewed

    Ando K, Guidotti LG, Cerny A, Ishikawa T, Chisari FV.

    J Immunol   Vol. 153 ( 2 ) page: 482-488   1994.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  202. ClassⅠrestricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. Reviewed

    Ando K, Guidotti LG, Wirth S, Ishikawa T, Missale G, Moriyama T, Schreiber RD, Schricht HJ, Huang S, Chisari FV.

    J Immunol   Vol. 152 ( 7 ) page: 3245-3253   1994.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  203. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Reviewed

    Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel RD, Schreiber RD, Chisari FV.

    Proc Natl Acad Sci USA   Vol. 91 ( 9 ) page: 3764-3768   1994.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  204. Hepatitis C virus genotypes are not responsible for development of serious liver disease. Reviewed

    Yamada M, Kakumu S, Yoshioka K, Higashi Y, Tanaka K, Ishikawa T, Takayanagi M.

    Dig Dis Sci   Vol. 39 ( 2 ) page: 234-239   1994.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  205. Interferon-gamma production specific for hepatitis B virus antigen by intrahepatic T lymphocytes in patients with acute and chronic hepatitis B. Reviewed

    Kakumu S, Ishikawa T, Wakita T, Yoshioka K, Takayanagi M, Tahara H, Kusakabe A.

    Am J Gastroenterol   Vol. 89 ( 1 ) page: 92-96   1994.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  206. Dynamics of genome change in the E2/NS1 region of hepatitis C virus in vivo. Reviewed

    Higashi Y, Kakumu S, Yoshioka K, Wakita T, Mizokami M, Ohba K, Ito Y, Ishikawa T, Takayanagi M, Nagai Y.

    Virology   Vol. 197 ( 2 ) page: 659-668   1993.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  207. Cytotoxic T lymphocyte activity to hepatitis B virus DNA-transfected HepG2 cells in patients with chronic hepatitis B. Reviewed

    Ito Y, Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Koike K.

    J Gastroenterol   Vol. 28 ( 5 ) page: 657-665   1993.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  208. Relative immunogenicity of hepatitis B virus-encoded antigens as targets for cytotoxic T cell response. Reviewed

    Ishikawa T, Kakumu S, Yoshioka K, Yamada Y, Tanaka K, Higashi Y, Takayanagi M, Okumura A, Kojima A, Tamura S.

    Immunology   Vol. 80 ( 2 ) page: 313-318   1993.10

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  209. Comparison of envelope and precore/core variants of hepatitis B virus (HBV) during chronic HBV infection. Reviewed

    Takayanagi M, Kakumu S, Wakita T, Ishikawa T, Yoshioka Y, Higashi Y.

    Virology   Vol. 196 ( 1 ) page: 138-145   1993.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  210. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Reviewed

    Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y.

    Gastroenterology   Vol. 105 ( 2 ) page: 507-512   1993.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  211. Pilot study of ribavirin and interferon-beta for chronic hepatitis B. Reviewed

    Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y.

    Hepatology   Vol. 18 ( 2 ) page: 258-263   1993.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  212. Effects of interferon-alpha treatment on hepatitis B virus antigen-specific immunologic responses in patients with chronic hepatitis B. Reviewed

    Ishikawa T, Kakumu S, Yoshioka K, Kurokawa S, Kusakabe A, Tahara H, Hirofuji H, Kawabe M.

    Liver   Vol. 13 ( 2 ) page: 95-101   1993.4

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  213. Effect of recombinant human transforming growth factor beta1 on immune responses in patients with chronic hepatitis B. Reviewed

    Kakumu S, Ito Y, Takayanagi M, Yoshioka K, Wakita T, Ishikawa T, Higashi Y, Yang ZQ.

    Liver   Vol. 13 ( 2 ) page: 62-68   1993.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  214. Effects of transforming growth factor-beta1 against the inhibitory action of interferon on DNA synthesis and viral replication in hepatitis B virus DNA-transfected cells. Reviewed

    Kakumu S, Ito Y, Wakita T, Yoshioka K, Ishikawa T, Tkayanagi M, Higashi Y, Yang ZQ.

    J Med Virol   Vol. 38 ( 1 ) page: 62-66   1992.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  215. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: Relation to genotype of hepatitis C virus. Reviewed

    Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Ito Y, Takayanagi M, Higashi Y, Shibata M, Morishima T.

    Hepatology   Vol. 16 ( 2 ) page: 293-299   1992.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  216. Cellular immune response of peripheral blood mononuclear cells to HBV antigens during chronic and acute HBV infection. Reviewed

    Wakita T, Kakumu S, Yoshioka K, Ishikawa T, Ito Y, Shinagawa T.

    Digestion   Vol. 52 ( 1 ) page: 26-33   1992.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  217. Immune response of peripheral blood mononuclear cells to antigenic determinants within hepatitis B core antigen in HB virus-infected man. Reviewed

    Ishikawa T, Kakumu S, Yoshioka K, Wakita T, Takayanagi M, Orido E.

    Liver   Vol. 12 ( 2 ) page: 100-105   1992.4

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  218. Interleukin 6 production by peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection and primary biliary cirrhosis. Reviewed

    Kakumu S, Shinagawa T, Ishikawa T, Yoshioka K, Wakita T, Ida N.

    J Gastroenterol   Vol. 28 ( 1 ) page: 18-24   1992.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  219. Detection of pre-C and core region mutants of hepatitis B virus (HBV) in chronic HBV carriers. Reviewed

    Wakita T, Kakumu S, Shibata M, Yoshioka K, Ito Y, Shinagawa T, Ishikawa T, Takayanagi M, Morishima T.

    J Clin Invest   Vol. 88 ( 6 ) page: 1793-1801   1991.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  220. Serum interleukin 6 levels in patients with chronic hepatitis B. Reviewed

    Kakumu S, Shinagawa T, Ishikawa T, Yoshioka K, Wakita T, Ito Y, Takayanagi M, Ida N.

    Am J Gastroenterol   Vol. 86 ( 12 ) page: 1804-1808   1991.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  221. Apoptosis in cultured rat hepatocytes: The effects of tumor necrosis factor alpha and interferon gamma. Reviewed

    Shinagawa T, Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Ito Y, Takayanagi M.

    J Pathol   Vol. 165 ( 3 ) page: 247-253   1991.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  222. Anti-hepatitis C antibodies in patients with chronic non-A, non-B hepatitis: relation to disease progression and effect of interferon alpha. Reviewed

    Yoshioka K, Kakumu S, Hayashi H, Shinagawa T, Wakita T, Ishikawa T, Ito Y, Takayanagi M.

    Am J Gastroenterol   Vol. 86 ( 10 ) page: 1495-1499   1991.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  223. Treatment with human gamma interferon of chronic hepatitis B: Comparative study with alpha interferon. Reviewed

    Kakumu S, Ishikawa T, Mizokami M, Orido E, Yoshioka K, Wakita T, Yamamoto M.

    J Med Virol   Vol. 35 ( 1 ) page: 32-37   1991.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  224. Effect of sizofiran, a polysaccharide, on interferon gamma, antibody and lymphocyte proliferation specific for hepatitis B virus antigen in patients with chronic hepatitis B. Reviewed

    Kakumu S, Ishikawa T, Wakita T, Yoshioka K, Ito Y, Shinagawa T.

    Int J Immunopharm   Vol. 13 ( 7 ) page: 969-976   1991.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  225. In vitro production of anti-mitochondrial antibody by peripheral blood mononuclear cells in patients with primary biliary cirrhosis. Reviewed

    Ishikawa T, Kakumu S, Wakita T, Takayanagi M, Yoshioka K.

    J Clin Lab Immunol   Vol. 35 ( 1 ) page: 17-25   1991.5

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  226. T cell lines reactive with hepatitis B core and e antigens in patients with chronic hepatitis B. Reviewed

    Ishikawa T, Kakumu S, Yoshioka K, Wakita T, Shinagawa T, Ito Y.

    J Clin Lab Immunol   Vol. 34 ( 4 ) page: 151-156   1991.4

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  227. Effects of TJ-9 Sho-saiko-to (Kampo Medicine) on interferon gamma and antibody production specific for hepatitis B virus antigen in patients with type B chronic hepatitis. Reviewed

    Kakumu S, Yoshioka K, Wakita T, Ishikawa T.

    Int J Immunopharm   Vol. 13 ( 2/3 ) page: 141-146   1991.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  228. Comparison of peripheral blood and hepatic lymphocyte subpopulations and interferon production in chronic viral hepatitis. Reviewed

    Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Murase A, Kusakabe A, Kurokawa S.

    J Clin Lab Immunol   Vol. 33 ( 1 )   1990.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  229. Immunohistochemical studies of intrahepatic tumor necrosis factor alpha in chronic liver disease. Reviewed

    Yoshioka K, Kakumu S, Arao M, Tsutsumi Y, Inoue M, Wakita T, Ishikawa T, Mizokami M.

    J Clin Pathol   Vol. 43 ( 4 ) page: 298-302   1990.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  230. In vitro production of antibody to hepatitis B core and e antigen by prepheral blood mononuclear cells in patients with chronic hepatitis B virus infection. Reviewed

    Tsutsumi Y, Kakumu S, Wakita T, Yoshioka K, Ishikawa T.

    J Immunol   Vol. 144 ( 6 ) page: 2389-2393   1990.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

▼display all

Books 47

  1. 必ず役立つ! 肝炎診療バイブル

    三田英治、平松直樹 他( Role: Contributor ,  アルコール性肝障害の診断と治療)

    メディカ出版  2021.7  ( ISBN:978-4840475679

     More details

    Total pages:384   Responsible for pages:196 - 205   Language:Japanese Book type:Textbook, survey, introduction

  2. B型肝炎ワクチンとアジュバント 「次世代アジュバント開発のためのメカニズム解明と安全性」

    伊藤弘康、石川哲也

    シーエムシー出版  2017 

     More details

    Responsible for pages:309-315   Language:Japanese

  3. 血液検査:免疫学的検査、一般検査 「ここまできた肝臓病診療」

    石川哲也( Role: Contributor)

    中山書店  2017 

     More details

    Responsible for pages:114-120   Language:Japanese

  4. ウイルス肝炎の発症機序肝臓専門医テキスト 改訂第2版(日本肝臓学会編)

    石川哲也( Role: Contributor)

    南江堂  2016 

     More details

    Responsible for pages:36-39   Language:Japanese

  5. C型肝炎治療の現状について

    石川哲也( Role: Contributor)

    明日の臨床  2015 

     More details

    Responsible for pages:29 - 34   Language:Japanese

  6. B型肝炎 病態 B型肝炎の発症機序と病態

    石川哲也( Role: Contributor)

    日本臨床  2015 

     More details

    Responsible for pages:429 - 433   Language:Japanese

  7. ウイルス肝炎の発症機序 「肝臓専門医テキスト 日本肝臓学会編」

    石川哲也( Role: Sole author)

    南江堂  2013.3  ( ISBN:978-4-524-26812-2

     More details

    Language:Japanese

  8. B型肝炎についての最近の話題

    石川哲也( Role: Sole author)

    健康文化振興財団  2012.10 

     More details

    Language:Japanese

  9. B型慢性肝炎 「肝疾患レジデントマニュアル」

    石川哲也( Role: Sole author)

    医学書院  2008.10 

     More details

    Language:Japanese

  10. 画像検査所見、病理検査所見 「重篤副作用疾患別対応マニュアル 第2集」

    石川哲也( Role: Sole author)

    日本医薬情報センター  2008.7 

     More details

    Language:Japanese

  11. 肝疾患レジデントマニュアル

    柴田 実, 八橋 弘, 石川 哲也, 伊東 和樹( Role: Joint author)

    医学書院  2008  ( ISBN:9784260006408

     More details

  12. C型急性肝炎 「消化器疾患最新の治療2007-2008」

    石川哲也( Role: Sole author)

    南江堂  2007.3 

     More details

    Language:Japanese

  13. HCVキャリアの指導、管理および院内感染事故対策 「今日の治療指針 2007年度版」

    石川哲也( Role: Sole author)

    医学書院  2007.1 

     More details

    Language:Japanese

  14. B型肝炎 -急性肝炎- 「肝臓病学」

    各務伸一,石川哲也( Role: Joint author)

    朝倉書店  2006.8 

     More details

    Language:Japanese

  15. 慢性肝炎 「ガイドライン外来診療2006」

    石川哲也( Role: Sole author)

    日経メディカル開発  2006.3 

     More details

    Language:Japanese

  16. HBVキャリアの指導、管理および院内感染事故対策 「今日の治療指針 2006年度版」

    石川哲也( Role: Sole author)

    医学書院  2006.1 

     More details

    Language:Japanese

  17. サルコイドーシスにおけるプロピオニバクテリア属の関与の解明とその診断法の開発

    片岡 幹男, 石川 哲也( Role: Joint author)

    片岡幹男  2006 

     More details

    Language:Japanese

    CiNii Books

  18. 概説-肝疾患- 「中高年・疾病予防(健康づくり)のための運動の実際」

    石川哲也( Role: Sole author)

    全日本病院出版会  2005.10 

     More details

    Language:Japanese

  19. 急性ウイルス肝炎:B型肝炎 「臨床消化器病学」

    各務伸一,石川哲也( Role: Joint author)

    朝倉書店  2005.9 

     More details

    Language:Japanese

  20. 慢性ウイルス肝炎:B型肝炎 「臨床消化器病学」

    各務伸一,石川哲也( Role: Joint author)

    朝倉書店  2005.9 

     More details

    Language:Japanese

  21. B型肝炎 「肝疾患と免疫」

    石川哲也( Role: Sole author)

    医薬ジャーナル社  2005.3 

     More details

    Language:Japanese

  22. B型肝炎の発症機序とHBV持続感染 「ウイルス性肝炎 消化器3」

    石川哲也,各務伸一( Role: Joint author)

    最新医学社  2005.2 

     More details

    Language:Japanese

  23. B型肝炎:ウイルス、病態、診断 「Annual Review 消化器2005」

    各務伸一,奥村明彦,石川哲也( Role: Joint author)

    中外医薬社  2005.1 

     More details

    Language:Japanese

  24. ラミブジンとHBワクチン併用療法の効果と問題点 「ウイルス性肝炎 下- 基礎・臨床研究の進歩-」

    石川哲也,各務伸一( Role: Joint author)

    日本臨床社  2004.8 

     More details

    Language:Japanese

  25. B型慢性肝炎 「消化器病診療 -良きインフォームド・コンセントに向けて-」

    各務伸一,石川哲也,奥村明彦( Role: Joint author)

    医学書院  2004.5 

     More details

    Language:Japanese

  26. B型肝炎 免疫療法 「コンセンサス 肝疾患 治療 2004」

    石川哲也( Role: Sole author)

    アークメディア  2003.12 

     More details

    Language:Japanese

  27. 慢性肝炎,肝硬変の治療;ワクチン治療 「消化器病セミナー91 -ウイルス肝炎の治療はどのように変わったか-」

    石川哲也,各務伸一( Role: Joint author)

    へるす出版  2003.6 

     More details

    Language:Japanese

  28. 肝細胞のケモカイン産生が炎症の方向性に与える影響について 「再生・増殖・分化と消化器病」

    田邊純一,石川哲也,奥村明彦,前野禎,佐藤顕,綾田穣,堀田直樹,多賀谷恒明,福沢義孝,吉岡健太郎.各務伸( Role: Joint author)

    アークメディア  2002.10 

     More details

    Language:Japanese

  29. B型慢性肝炎におけるラミブジンとワクチンの併用療法 「B型・C型肝炎治療の新しい展開」

    各務伸一,石川哲也( Role: Joint author)

    犬山シンポジウム記録刊行会、アークメディア  2002.10 

     More details

    Language:Japanese

  30. B型肝炎 病態 「コンセンサス肝疾患2002 診断・治療と病態」

    石川哲也( Role: Sole author)

    日本メディカルセンター  2002.3 

     More details

    Language:Japanese

  31. 肝と免疫 「Annual Review 消化器2002」

    各務伸一,奥村明彦,石川哲也( Role: Joint author)

    中外医薬社  2002.1 

     More details

    Language:Japanese

  32. The mechanism of liver injury in hepatitis B virus infection. “Molecular Biology and Immunology in Hepatology-Advances in the Treatment of Intractable Liver Diseases-“

    Ishikawa T, Kakumu S.( Role: Joint author)

    Elsevier Science B.V.  2002 

     More details

    Language:English

  33. B型肝炎の免疫学的治療の検討-HBVトランスジェニックマウスを用いて- 「肝臓フォーラム '01記録集」

    石川哲也( Role: Sole author)

    2002 

     More details

    Language:Japanese

  34. B型慢性肝炎に対するワクチン+ラミブジン併用療法 「B型肝炎の新しい展開」

    各務伸一,石川哲也( Role: Joint author)

    犬山シンポジウム記録刊行会、アークメディア  2001.10 

     More details

    Language:Japanese

  35. ウイルス肝炎:B型 「消化器疾患の分子医学」

    石川哲也,各務伸一( Role: Joint author)

    日本メディカルセンター  2001.5 

     More details

    Language:Japanese

  36. B型肝炎とは 「慢性肝疾患診療マニュアル」

    石川哲也,各務伸一( Role: Joint author)

    2001.5 

     More details

    Language:Japanese

  37. 肝細胞のケモカイン産生に対するサイトカインの影響 「肝の生化学」

    石川哲也,田邊純一,各務伸一( Role: Joint author)

    箱根シンポジウム記録刊行会  2000.7 

     More details

    Language:Japanese

  38. The mechanism of liver injury and viral clearance in hepatitis B virus infection. “Progress in Hepatology”

    Ishikawa T, Kakumu S( Role: Joint author)

    Elsevier Science B.V.  1999.12 

     More details

    Language:English

  39. ウイルス抗原に対する免疫応答の多様性と変異によるウイルス逃避の可能性について 「消化器疾患と細胞内情報伝達」

    石川哲也( Role: Sole author)

    アークメディア  1999.10 

     More details

    Language:Japanese

  40. B型肝炎 「医学のあゆみ 消化器疾患 Ver.2 II. 肝・胆・膵」

    石川哲也,各務伸一( Role: Joint author)

    1999.6 

     More details

    Language:Japanese

  41. 肝炎慢性化におけるcostimulatory moleculeの関与 -CD8+細胞障害性Tリンパ球(CTL)の機能に与える影響について- 「肝免疫の最前線」

    石川哲也,景山正之,奥村明彦,各務伸一( Role: Joint author)

    マイライフ社  1999 

     More details

    Language:Japanese

  42. 発症機序と診断(B型肝炎) 「肝臓病 今日の診断と最新の治療」

    各務伸一,石川哲也( Role: Joint author)

    国際医書出版  1997.12 

     More details

    Language:Japanese

  43. Role of immune response on liver cell injury and regulation of the virus.“Frontier in Hepatology '97”

    Ishikawa T, Chisari FV, Kakumu S.( Role: Joint author)

    Axel Springer Japan Publishing Inc.  1997.7 

     More details

    Language:English

  44. マウスHBs抗原特異的CTLのレパトア解析とその意義 「肝臓病学の最前線 1997」

    各務伸一,石川哲也( Role: Joint author)

    中外医薬社  1997.7 

     More details

    Language:Japanese

  45. ウイルソン病 「肝臓病の原因と治療」

    石川哲也( Role: Sole author)

    PHP研究所  1997.3 

     More details

    Language:Japanese

  46. B型肝炎 -肝細胞障害のメカニズム-「消化器診療プラクティス 14 自己免疫性肝炎」

    石川哲也,各務伸一( Role: Joint author)

    文光堂  1996.8 

     More details

    Language:Japanese

  47. B型肝炎 「肝と免疫」

    石川哲也( Role: Sole author)

    医薬ジャーナル社  1996.8 

     More details

    Language:Japanese

▼display all

MISC 309

  1. HBs抗原のヒト肝細胞への取込み機序とその意義について

    堀純子, 玉置優貴, 内藤沙妃, 柴田ゆりあ, 池田悠馬, 池田悠馬, 名仁澤英里, 林由美, 石川哲也

    日本臨床検査医学会誌   Vol. 69   2021

  2. AMINO ACID POLYMORPHISM IN HEPATITIS B VIRUS ASSOCIATED WITH NATURAL CLEARANCE OF HBV DNA AND HBsAg

    Takashi Honda, None Yamada, Asako Murayama, Asuka Kato, Takanori Ito, Yoji Ishizu, Teiji Kuzuya, Masatoshi Ishigami, Yoshiki Murakami, Tetsuya Ishikawa, Mitsuhiro Fujishiro, Takanobu Kato

    HEPATOLOGY   Vol. 72   page: 508A - 509A   2020.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  3. 肝細胞キメラマウス作製系における移植肝細胞の生着、拒絶の動態と拒絶回避のための治療について

    玉置 優貴, 堀 純子, 名仁澤 英里, 林 由美, 石川 哲也

    臨床病理   Vol. 68 ( 補冊 ) page: 193 - 193   2020.10

     More details

    Language:Japanese   Publisher:(一社)日本臨床検査医学会  

    researchmap

  4. 非肝癌症例と肝発癌症例の違いに関与する腸内細菌の検討

    本多 隆, 石上 雅敏, 山本 崇文, 犬飼 庸介, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 石津 洋二, 葛谷 貞二, 石川 哲也, 藤城 光弘

    肝臓   Vol. 61 ( Suppl.2 ) page: A701 - A701   2020.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  5. 腫瘍肝占拠率50%以上の高度進行肝細胞癌に対する分子標的治療薬の治療効果の検討~ソラフェニブとレンバチニブの比較~

    武藤久哲, 葛谷貞二, 杉山由晃, 吉岡直輝, 水野和幸, 横山晋也, 田中卓, 山本健太, 伊藤隆徳, 石津洋二, 本多隆, 石川哲也, 石上雅敏, 藤城光弘

    肝臓   Vol. 61 ( Supplement 1 ) page: A371 - A371   2020

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  6. Complete response by vitamin K2 analog monotherapy in sorafenib-failure advanced hepatocellular carcinoma: A case report. International journal

    Teiji Kuzuya, Masatoshi Ishigami, Yoji Ishizu, Takashi Honda, Kazuhiko Hayashi, Tetsuya Ishikawa, Yoshiki Hirooka, Hidemi Goto

    Hepatology research : the official journal of the Japan Society of Hepatology   Vol. 49 ( 3 ) page: 360 - 364   2019.3

     More details

    Language:English  

    There have been reports that a vitamin K2 (VK2) analog is beneficial for the prevention of recurrence in hepatocellular carcinoma (HCC) patients after curative therapy. However, the VK2 analogs in current use do not appear to show dramatic antitumor effects when given alone. Here, we report the case of a 67-year-old male patient with sorafenib-failure advanced HCC who achieved complete response (CR) after VK2 analog monotherapy. At the time of sorafenib failure confirmation, the patient had multiple intrahepatic tumors, multiple lung metastases, and Vp3 portal vein tumor thrombosis. He had poor liver function (Child-Pugh score of 9, Child-Pugh class B) and poor performance status (Eastern Cooperative Oncology Group performance status 2). Both serum α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) levels were elevated (558 900 ng/mL and 917 300 mAU/mL, respectively). Treatment with VK2 analog was initiated at 45 mg/day. Five months later, both tumor markers had decreased to normal levels (AFP 8 ng/mL and DCP 10 mAU/mL). Contrast-enhanced computed tomography showed that all intrahepatic tumors had shrunk, there was no enhancement of tumor staining in the arterial phase, and all lung metastases and portal vein tumor thromboses had disappeared. We considered that CR was achieved according to the modified Response Evaluation Criteria in Solid Tumors. Eighteen months after the start of VK2 analog administration, the patient continues to receive treatment and has remained in CR without adverse events. Here, we report a rare case of sorafenib-failure advanced HCC in which sustained CR was achieved by VK2 analog monotherapy.

    DOI: 10.1111/hepr.13237

    Scopus

    PubMed

    researchmap

  7. 肝細胞キメラマウス作製系を用いたアロ肝細胞に対する免疫拒絶反応の解析

    玉置優貴, 名仁澤英里, 宮下凛太朗, 園玲華, 林由美, 石川哲也

    臨床病理   Vol. 67 ( 補冊 ) page: 166 - 166   2019

     More details

    Language:Japanese   Publisher:(一社)日本臨床検査医学会  

    J-GLOBAL

    researchmap

  8. B型肝炎ウイルスの生活環におけるエンドサイトーシス経路の役割

    宮下凜太郎, 名仁澤英里, 園玲華, 玉置優貴, 林由美, 石川哲也

    臨床病理   Vol. 67 ( 補冊 ) page: 257 - 257   2019

     More details

    Language:Japanese   Publisher:(一社)日本臨床検査医学会  

    J-GLOBAL

    researchmap

  9. B型肝炎ウイルストランスジェニックマウスにおける肝細胞の小胞体ストレスと肝障害重症化機序

    園玲華, 石川哲也, 林由美, 名仁澤英里, 玉置優貴, 宮下凛太郎

    臨床病理   Vol. 67 ( 補冊 ) page: 258 - 258   2019

     More details

    Language:Japanese   Publisher:(一社)日本臨床検査医学会  

    J-GLOBAL

    researchmap

  10. 新規HBV感染マウスモデル作製と宿主免疫応答の解析

    神戸歩, 伊藤弘康, 石川哲也

    肝臓   Vol. 60 ( Supplement 1 )   2019

  11. マウス肝障害モデルにおけるトロンボモジュリン遺伝子導入脂肪由来幹細胞の炎症軽減効果について

    山本 万智, 名仁澤 英里, 今井田 藍, 山崎 花那子, 園 玲華, 玉置 優貴, 宮下 凛太郎, 林 由美, 石川 哲也

    臨床病理   Vol. 66 ( 補冊 ) page: 233 - 233   2018.10

     More details

    Language:Japanese   Publisher:日本臨床検査医学会  

    researchmap

  12. B型肝炎ウイルス粒子の蛍光ラベルによる可視化と細胞内取込み機構の解析

    山崎 花那子, 今井田 藍, 名仁澤 英里, 山本 万智, 宮下 凛太郎, 玉置 優貴, 園 玲華, 林 由美, 石川 哲也

    臨床病理   Vol. 66 ( 補冊 ) page: 251 - 251   2018.10

     More details

    Language:Japanese   Publisher:日本臨床検査医学会  

    researchmap

  13. B型肝炎ウイルス粒子可視化技術を用いたウイルス生活環の解析

    今井田 藍, 山崎 花那子, 山本 万智, 名仁澤 英里, 玉置 優貴, 宮下 凛太郎, 園 玲華, 林 由美, 石川 哲也

    臨床病理   Vol. 66 ( 補冊 ) page: 251 - 251   2018.10

     More details

    Language:Japanese   Publisher:日本臨床検査医学会  

    researchmap

  14. 量子ドットを用いた移植幹細胞・免疫細胞間interaction蛍光イメージング

    北村 晃大, 湯川 博, 佐藤 和秀, 有本 知子, 小野島 大介, 石川 哲也, 馬場 嘉信

    バイオイメージング   Vol. 27 ( 2 ) page: 83 - 83   2018.8

     More details

    Language:Japanese   Publisher:日本バイオイメージング学会  

    researchmap

  15. 探針エレクトロスプレーイオン化タンデム質量分析(PESI/MS/MS)を用いたin vivoリアルタイム・モニタリングシステムの構築

    林 由美, 財津 桂, 村田 匡, 土橋 均, 石井 晃, 緒方 是嗣, 石川 哲也

    JSBMS Letters   Vol. 43 ( Suppl. ) page: 144 - 144   2018.8

     More details

    Language:Japanese   Publisher:(一社)日本医用マススペクトル学会  

    researchmap

  16. 量子ドットによる移植幹細胞・免疫細胞間インターラクションin vivo蛍光イメージング

    北村 晃大, 湯川 博, 佐藤 和秀, 有本 知子, 小野島 大介, 石川 哲也, 馬場 嘉信

    日本DDS学会学術集会プログラム予稿集   Vol. 34回 ( 2 ) page: 156 - 156   2018.5

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)   Publisher:日本DDS学会  

    researchmap

  17. 進行肝細胞癌に対するソラフェニブ投与後の肝予備能推移 初回画像PD判定時にレゴラフェニブへの切り替え条件を満たすかにも着目して

    葛谷 貞二, 石上 雅敏, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 安田 諭, 石津 洋二, 本多 隆, 林 和彦, 石川 哲也, 廣岡 芳樹, 後藤 秀実

    日本消化器病学会雑誌   Vol. 115 ( 臨増総会 ) page: A283 - A283   2018.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  18. 肝硬変患者におけるサルコペニアと栄養状態・QOLとの関連性

    安藤 祐資, 石上 雅敏, 石津 洋二, 葛谷 貞二, 本多 隆, 林 和彦, 石川 哲也, 廣岡 芳樹, 後藤 秀実

    日本消化器病学会雑誌   Vol. 115 ( 臨増総会 ) page: A297 - A297   2018.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  19. C型慢性肝炎・肝硬変患者に対するDAAs治療が血球数に与える影響

    石津 洋二, 石上 雅敏, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 安田 諭, 葛谷 貞二, 本多 隆, 林 和彦, 廣岡 芳樹, 石川 哲也, 後藤 秀実

    日本消化器病学会雑誌   Vol. 115 ( 臨増総会 ) page: A313 - A313   2018.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  20. 進行肝細胞癌に対するレゴラフェニブの投与後早期(6週間以内)の治療成績-ソラフェニブ導入時との比較-

    葛谷貞二, 石上雅敏, 武藤久哲, 横山晋也, 田中卓, 山本健太, 安藤祐資, 伊藤隆徳, 安田諭, 石津洋二, 本多隆, 林和彦, 石川哲也, 廣岡芳樹, 後藤秀実

    肝臓   Vol. 59 ( Supplement 1 ) page: A509 - A509   2018

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  21. 探針エレクトロスプレーイオン化タンデム質量分析(PESI/MS/MS)とScheduled SRM法を用いた生体組織のインタクト・メタボロミクス法の構築

    近藤健太, 林由美, 林由美, 村田匡, 土屋弥月, 大原倫美, 石川哲也, 緒方是嗣, 土橋均, 石井晃, 財津桂, 財津桂

    JSBMS Letters   Vol. 43 ( Supplement ) page: 143 - 143   2018

     More details

    Language:Japanese   Publisher:(一社)日本医用マススペクトル学会  

    J-GLOBAL

    researchmap

  22. 3年半ぶりのソラフェニブ増量にて完全奏功が得られた進行肝細胞癌の1例

    武藤久哲, 葛谷貞二, 横山晋也, 田中卓, 山本健太, 安藤祐資, 伊藤隆徳, 安田諭, 石津洋二, 本多隆, 林和彦, 石上雅敏, 石川哲也, 廣岡芳樹, 後藤秀実

    Liver Cancer Journal   ( Suppl.1 ) page: 52 - 53   2018

     More details

    Language:Japanese   Publisher:(株)メディカルレビュー社  

    J-GLOBAL

    researchmap

  23. 量子ドットイメージング技術を用いた移植幹細胞に対する細胞間interaction機構解明(一般研究発表用)

    北村晃大, 湯川博, 湯川博, 佐藤和秀, 有本知子, 小野島大介, 小野島大介, 石川哲也, 馬場嘉信, 馬場嘉信, 馬場嘉信, 馬場嘉信

    中部化学関係学協会支部連合秋季大会講演予稿集   Vol. 49th   2018

  24. 量子ドットイメージング技術を用いた移植幹細胞と免疫細胞のinteraction機構解明

    北村晃大, 湯川博, 佐藤和秀, 有本知子, 小野島大介, 小野島大介, 石川哲也, 馬場嘉信, 馬場嘉信, 馬場嘉信, 馬場嘉信

    日本再生医療学会総会(Web)   Vol. 17th   2018

  25. 量子ドットによる移植幹細胞・免疫細胞間インターラクションin vivo蛍光イメージング

    北村晃大, 湯川博, 佐藤和秀, 有本知子, 小野島大介, 小野島大介, 石川哲也, 馬場嘉信, 馬場嘉信, 馬場嘉信, 馬場嘉信

    日本化学会春季年会講演予稿集(CD-ROM)   Vol. 98th   2018

  26. 進行肝細胞癌に対するソラフェニブ投与後の肝予備能推移-初回画像PD判定時にレゴラフェニブへの切り替え条件を満たすかにも着目して-

    葛谷貞二, 石上雅敏, 武藤久哲, 横山晋也, 田中卓, 山本健太, 安藤祐資, 伊藤隆徳, 安田諭, 石津洋二, 本多隆, 林和彦, 石川哲也, 廣岡芳樹, 後藤秀実

    日本消化器病学会雑誌(Web)   Vol. 115   2018

  27. 肝硬変患者におけるサルコペニアと栄養状態・QOLとの関連性

    安藤祐資, 石上雅敏, 石津洋二, 葛谷貞二, 本多隆, 林和彦, 石川哲也, 廣岡芳樹, 後藤秀実

    日本消化器病学会雑誌(Web)   Vol. 115   2018

  28. 探針エレクトロスプレータンデム質量分析(PESI/MS/MS)を用いた簡便かつ超迅速な血中シアン化物スクリーニング法の構築

    久恒一晃, 久恒一晃, 林由美, 林由美, 村田匡, 大原倫美, 肥田宗政, 土橋均, 石川哲也, 石井晃, 緒方是嗣, 財津桂, 財津桂

    日本法科学技術学会誌   Vol. 23 ( Supplement )   2018

  29. 分子動力学法を用いたpregenome RNAを内包したB型肝炎ウイルスの物性解明

    山口陽平, 今井甫, 藤本和士, 浦野諒, 篠田渉, 尾曲克己, 田中靖人, 石川哲也, 中川敦史, 岡崎進

    分子シミュレーション討論会講演要旨集   Vol. 32nd   2018

  30. 量子ドットによる増殖癌細胞・免疫細胞in vivo蛍光イメージング技術の構築

    北村 晃大, 湯川 博, 佐藤 和秀, 有本 知子, 小野島 大介, 石川 哲也, 馬場 嘉信

    Organ Biology   Vol. 24 ( 3 ) page: 93 - 93   2017.11

     More details

    Language:Japanese   Publisher:(一社)日本臓器保存生物医学会  

    researchmap

  31. 線維化進展例におけるIFNフリー抗HCV治療の効果 IFN時代と比較して何が変わったか?

    石上 雅敏, 安藤 祐資, 林 和彦, 本多 隆, 葛谷 貞二, 石津 洋二, 伊藤 隆徳, 安田 諭, 山本 健太, 田中 卓, 横山 晋也, 中野 功, 石川 哲也, 後藤 秀実

    肝臓   Vol. 58 ( Suppl.2 ) page: A628 - A628   2017.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  32. 好酸球増多症を合併したBudd Chiari症候群の1例

    石津 洋二, 石上 雅敏, 横山 晋也, 田中 卓, 安藤 祐資, 伊藤 隆徳, 安田 諭, 野村 彩, 葛谷 貞二, 本多 隆, 林 和彦, 廣岡 芳樹, 石川 哲也, 後藤 秀実

    日本門脈圧亢進症学会雑誌   Vol. 23 ( 3 ) page: 135 - 135   2017.8

     More details

    Language:Japanese   Publisher:(一社)日本門脈圧亢進症学会  

    researchmap

  33. 量子・磁気ナノハイブリッド粒子による幹細胞イメージングおよびハイパーサーミア効果

    小林 香央里, 湯川 博, 村田 勇樹, 城 潤一郎, 小野島 大介, 山本 雅哉, 石川 哲也, 田畑 泰彦, 馬場 嘉信

    日本DDS学会学術集会プログラム予稿集   Vol. 33回   page: 235 - 235   2017.6

     More details

    Language:Japanese   Publisher:日本DDS学会  

    researchmap

  34. セロトニン症候群モデルラットにおける筋肉の異常収縮と血漿メタボローム・プロファイルの関連性

    財津 桂, 野田 沙樹, 林 由美, 大原 倫美, 井口 亮, 草野 麻衣子, 佐藤 貴子, 土橋 均, 石川 哲也, 鈴木 廣一, 石井 晃

    The Journal of Toxicological Sciences   Vol. 42 ( Suppl. ) page: S197 - S197   2017.6

     More details

    Language:Japanese   Publisher:(一社)日本毒性学会  

    researchmap

  35. 細胞トレーシングのためのDDS 量子ドットによる移植幹細胞in vivo蛍光イメージング

    湯川 博, 石川 哲也, 田畑 泰彦, 馬場 嘉信

    日本DDS学会学術集会プログラム予稿集   Vol. 33回   page: 90 - 90   2017.6

     More details

    Language:Japanese   Publisher:日本DDS学会  

    researchmap

  36. 門脈腫瘍栓を伴う進行肝細胞癌に対するソラフェニブの治療成績 6週PD判定の有無に着目して

    葛谷 貞二, 石上 雅敏, 横山 晋也, 田中 卓, 山本 健太, 安藤 祐資, 伊藤 隆徳, 安田 諭, 野村 彩, 石津 洋二, 本多 隆, 林 和彦, 石川 哲也, 廣岡 芳樹, 後藤 秀実

    肝臓   Vol. 58 ( Suppl.1 ) page: A275 - A275   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  37. 慢性肝疾患患者における生活習慣による腸内細菌への影響

    山本 健太, 石上 雅敏, 田中 卓, 安藤 祐資, 伊藤 隆徳, 安田 諭, 野村 彩, 加藤 幸一郎, 石津 洋二, 葛谷 貞二, 本多 隆, 林 和彦, 廣岡 芳樹, 石川 哲也, 後藤 秀実

    肝臓   Vol. 58 ( Suppl.1 ) page: A237 - A237   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  38. 歯髄幹細胞無血清培養上清による難治性肝疾患での有用性の検討 急性・慢性肝炎動物モデルにおける効果発現メカニズムの違いに着目して

    伊藤 隆徳, 田中 卓, 山本 健太, 安藤 祐資, 安田 諭, 野村 彩, 加藤 幸一郎, 石津 洋二, 葛谷 貞二, 本多 隆, 林 和彦, 石上 雅敏, 廣岡 芳樹, 石川 哲也, 後藤 秀実

    肝臓   Vol. 58 ( Suppl.1 ) page: A256 - A256   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  39. C型慢性肝炎における線維化進展例(Fib4 index≧3.25)におけるウイルス消失後の肝予備能の変化

    石上 雅敏, 林 和彦, 本多 隆, 葛谷 貞二, 石津 洋二, 野村 彩, 伊藤 隆徳, 安田 諭, 安藤 祐資, 山本 健太, 田中 卓, 横山 晋也, 石川 哲也, 中野 功, 廣岡 芳樹, 後藤 秀実

    肝臓   Vol. 58 ( Suppl.1 ) page: A311 - A311   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  40. メタボロミクスによる妊娠期DEHP曝露における胎児低生存率の解析

    林 由美, 財津 桂, 名仁澤 英里, 平野 文香, 大原 倫美, 野田 沙樹, 石井 晃, 伊藤 由起, 那須 民江, 石川 哲也

    日本衛生学雑誌   Vol. 72 ( Suppl. ) page: S198 - S198   2017.3

     More details

    Language:Japanese   Publisher:(一社)日本衛生学会  

    researchmap

  41. BIOINDUSTRY・NIR-II近赤外領域における移植幹細胞in vivo蛍光イメージング

    BIOINDUSTRY・NIR-II近赤外領域における移植幹細胞in vivo蛍光イメージング   Vol. 34 ( 1 ) page: 27 - 34   2017.1

     More details

    Language:Japanese  

    researchmap

  42. Epstein-Barr virusの再燃により胃瘻からの経腸栄養再開を躊躇した一例

    綾田穣, 綾田穣, 中野達徳, 石川哲也, 松家健一, 坂井圭介, 小野幸矢, 廣岡正史, 牛山知己, 大場浩次, 中村昌樹

    在宅医療と内視鏡治療   Vol. 21 ( 1 )   2017

  43. pgRNAを内包したB型肝炎ウイルスの全原子分子動力学シミュレーション

    山口陽平, 今井甫, 藤本和士, 浦野諒, 篠田渉, 尾曲克己, 田中靖人, 石川哲也, 中川敦史, 岡崎進

    分子シミュレーション討論会講演要旨集   Vol. 31st   2017

  44. DDS・イメージング 量子ドットによる移植幹細胞in vivo蛍光イメージング手法の構築

    湯川 博, 石川 哲也, 馬場 嘉信

    日本バイオマテリアル学会大会予稿集   Vol. シンポジウム2016   page: 215 - 215   2016.11

     More details

    Language:Japanese   Publisher:日本バイオマテリアル学会  

    researchmap

  45. 再生医療 いま見えてきた課題 量子ドットによる移植幹細胞in vivo蛍光リアルタイムイメージング

    湯川 博, 有本 知子, 吉住 寧真, 荻原 裕佑, 石川 哲也, 馬場 嘉信

    Organ Biology   Vol. 23 ( 3 ) page: 60 - 60   2016.10

     More details

    Language:Japanese   Publisher:(一社)日本臓器保存生物医学会  

    researchmap

  46. 肝臓特異的UBXD8ノックアウトは脂質負荷・コリン欠乏に対し線維化形成を促進する

    今井 則博, 山本 健太, 安藤 祐資, 伊藤 隆徳, 安田 諭, 野村 彩, 加藤 幸一郎, 新家 卓郎, 石津 洋二, 葛谷 貞二, 本多 隆, 林 和彦, 石上 雅敏, 廣岡 芳樹, 石川 哲也, 後藤 秀実

    肝臓   Vol. 57 ( Suppl.2 ) page: A553 - A553   2016.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  47. 新規M2マクロファージ誘導因子を用いた難治性肝疾患治療法の開発

    伊藤 隆徳, 山本 朗仁, 山本 健太, 安藤 祐資, 安田 諭, 野村 彩, 加藤 幸一郎, 新家 卓郎, 石津 洋二, 葛谷 貞二, 本多 隆, 林 和彦, 石上 雅敏, 廣岡 芳樹, 石川 哲也, 日比 英晴, 後藤 秀実

    肝臓   Vol. 57 ( Suppl.2 ) page: A550 - A550   2016.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  48. 肝硬変患者におけるpresarcopeniaが推算糸球体濾過量(eGFR)に与える影響

    石津 洋二, 石上 雅敏, 山本 健太, 安藤 祐資, 伊藤 隆徳, 安田 諭, 野村 彩, 加藤 幸一郎, 新家 卓郎, 葛谷 貞二, 本多 隆, 林 和彦, 廣岡 芳樹, 石川 哲也, 後藤 秀実

    肝臓   Vol. 57 ( Suppl.2 ) page: A607 - A607   2016.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  49. B型慢性肝炎におけるインターフェロン治療によるCoreI97の変化と肝炎沈静化

    本多 隆, 石上 雅敏, 山本 健太, 安藤 佑資, 安田 諭, 伊藤 隆徳, 野村 彩, 加藤 幸一郎, 新家 卓郎, 石津 洋二, 葛谷 貞二, 林 和彦, 廣岡 芳樹, 石川 哲也, 中野 功, 後藤 秀実

    肝臓   Vol. 57 ( Suppl.2 ) page: A530 - A530   2016.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  50. 脂質メディエーターとメタボローム解析によるPPARαノックアウトマウスを用いたコカイン誘発性肝障害の解析

    篠田 諭, 林 由美, 財津 桂, 酒井 佑一朗, 山中 麻友美, 那須 民江, 石川 哲也, 吉本 高士, 草野 麻衣子, 土橋 均, 石井 晃

    The Journal of Toxicological Sciences   Vol. 41 ( Suppl. ) page: S258 - S258   2016.6

     More details

    Language:Japanese   Publisher:(一社)日本毒性学会  

    researchmap

  51. ダクラタスビル+アスナプレビル治療症例におけるHCV抗原特異的免疫応答の変化について

    加藤 幸一郎, 石川 哲也, 石津 洋二, 荒川 恭宏, 安藤 祐資, 伊藤 隆徳, 安田 諭, 川口 彩, 新家 卓郎, 今井 則博, 葛谷 貞二, 本多 隆, 林 和彦, 石上 雅敏, 後藤 秀実

    肝臓   Vol. 57 ( Suppl.1 ) page: A324 - A324   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  52. B型肝炎研究のUp-To-Date B型肝炎ウイルス粒子可視化による細胞内侵入機構の解析

    石川 哲也, 湯川 博

    肝臓   Vol. 57 ( Suppl.1 ) page: A25 - A25   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  53. 肝細胞癌合併血友病患者に対するラジオ波焼灼術の安全性についての検討

    石津 洋二, 石上 雅敏, 安藤 祐資, 伊藤 隆徳, 安田 諭, 川口 彩, 加藤 幸一郎, 新家 卓郎, 今井 則博, 阿知波 宏一, 葛谷 貞二, 本多 隆, 林 和彦, 廣岡 芳樹, 石川 哲也, 後藤 秀実

    日本消化器病学会雑誌   Vol. 113 ( 臨増総会 ) page: A272 - A272   2016.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  54. HBs抗原消失がみられI97L変異の長期観察ができた症例の検討

    本多 隆, 石上 雅敏, 安藤 祐資, 安田 諭, 伊藤 隆徳, 川口 彩, 加藤 幸一郎, 新家 卓郎, 今井 則博, 阿知波 宏一, 石津 洋二, 葛谷 貞二, 林 和彦, 中野 功, 石川 哲也, 後藤 秀実

    日本消化器病学会雑誌   Vol. 113 ( 臨増総会 ) page: A392 - A392   2016.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  55. 遷延する肝障害にEpstein-Barr virusの再活性の関与が示唆されたStevens-Johnson症候群と薬剤性過敏症症候群と考えられた薬物性肝障害の1例

    綾田穣, 森下宗自, 中野達徳, 石川哲也

    肝臓   Vol. 57 ( Supplement 3 )   2016

  56. 生体イメージングを目指した近赤外発光性AgInTe<sub>2</sub>量子ドットの開発

    亀山達矢, 石神裕二郎, 湯川博, 嶋田泰佑, 馬場嘉信, 石川哲也, 桑畑進, 鳥本司

    日本化学会春季年会講演予稿集(CD-ROM)   Vol. 96th   2016

  57. 反復する尿路感染症と一過性頻脈・振戦により経管栄養の再開時期を躊躇した薬物性過敏症症候群の一例

    綾田穣, 中野達徳, 石川哲也, 中村昌樹

    PEG・在宅医療研究会学術集会プログラム抄録集   Vol. 21st   2016

  58. カドミウムフリー量子ドットを用いた生体内深部イメージング

    荻原裕佑, 湯川博, 小野島大介, 亀山達矢, 林由美, 鳥本司, 石川哲也, 馬場嘉信

    日本化学会春季年会講演予稿集(CD-ROM)   Vol. 96th   2016

  59. B型肝炎ウイルス粒子の可視化による細胞内侵入機構の解析

    石川哲也, 湯川博, 馬場嘉信, 馬場嘉信

    肝細胞研究会プログラム・抄録集   Vol. 23rd   2016

  60. HBV疑似ウィルス可視化による感染機構の解明と高効率回収デバイスの開発

    平川真志, 湯川博, 小野島大介, 石川哲也, 馬場嘉信

    日本化学会春季年会講演予稿集(CD-ROM)   Vol. 96th   2016

  61. 【新ウイルス性肝炎学-最新の基礎・臨床研究情報-】B型肝炎 病態 B型肝炎の発症機序と病態

    石川 哲也

    日本臨床   Vol. 73 ( 増刊9 新ウイルス性肝炎学 ) page: 429 - 433   2015.12

     More details

    Language:Japanese   Publisher:(株)日本臨床社  

    researchmap

  62. 高齢者C型慢性肝炎におけるDaclatasvir/Asunaprevir併用療法の早期反応と治療効果

    本多 隆, 石上 雅敏, 安藤 祐資, 安田 諭, 伊藤 隆徳, 川口 彩, 加藤 幸一郎, 新家 卓郎, 今井 則博, 阿知波 宏一, 石津 洋二, 葛谷 貞二, 林 和彦, 石川 哲也, 中野 功, 後藤 秀実

    肝臓   Vol. 56 ( Suppl.3 ) page: A1046 - A1046   2015.11

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  63. ダクラタスビル+アスナプレビル治療中のHCV抗原特異的免疫応答の変化について

    加藤 幸一郎, 荒川 恭宏, 石川 哲也, 安藤 祐資, 伊藤 隆徳, 安田 諭, 川口 彩, 新家 卓郎, 今井 則博, 阿知波 宏一, 石津 洋二, 葛谷 貞二, 本多 隆, 林 和彦, 石上 雅敏, 脇田 隆字, 後藤 秀実

    肝臓   Vol. 56 ( Suppl.3 ) page: A995 - A995   2015.11

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  64. バルーン閉塞下逆行性経静脈的塞栓術後の肝予備能の変化と肝臓体積の関連性

    石津 祥二, 石上 雅敏, 安藤 祐資, 伊藤 隆徳, 安田 諭, 川口 彩, 加藤 幸一郎, 新家 卓郎, 今井 則博, 阿知波 宏一, 葛谷 貞二, 本多 隆, 林 和彦, 廣岡 芳樹, 石川 哲也, 後藤 秀実

    肝臓   Vol. 56 ( Suppl.3 ) page: A1031 - A1031   2015.11

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  65. 超低毒性量子ドットによる幹細胞標識及び3D in vivoイメージング

    荻原 裕佑, 湯川 博, 小野島 大介, 亀山 達也, 林 由美, 鳥本 司, 石川 哲也, 馬場 嘉信

    日本バイオマテリアル学会大会予稿集   Vol. 37回   page: 338 - 338   2015.11

     More details

    Language:Japanese   Publisher:日本バイオマテリアル学会  

    researchmap

  66. CA19-9高値で見つかった進行肝細胞癌に対しソラフェニブが奏功した一例

    安田 諭, 葛谷 貞二, 安藤 祐資, 伊藤 隆徳, 川口 彩, 加藤 幸一郎, 新家 卓郎, 今井 則博, 阿知波 宏一, 石津 洋二, 本多 隆, 林 和彦, 石上 雅敏, 廣岡 芳樹, 石川 哲也, 後藤 秀実

    肝臓   Vol. 56 ( Suppl.3 ) page: A1051 - A1051   2015.11

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  67. M2マクロファージ誘導因子を用いた肝細胞保護効果の検討

    伊藤 隆徳, 松下 嘉泰, 安田 諭, 川口 彩, 加藤 幸一郎, 新家 卓郎, 今井 則博, 阿知波 宏一, 石津 洋二, 葛谷 貞二, 本多 隆, 林 和彦, 石上 雅敏, 廣岡 芳樹, 石川 哲也, 山本 朗仁, 後藤 秀実

    肝臓   Vol. 56 ( Suppl.3 ) page: A930 - A930   2015.11

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  68. 脂肪由来幹細胞が細胞傷害性Tリンパ球機能に与える影響について

    中切 健太, 大原 倫美, 平野 文香, 名仁澤 英里, 林 由美, 石川 哲也

    臨床病理   Vol. 63 ( 補冊 ) page: 216 - 216   2015.10

     More details

    Language:Japanese   Publisher:日本臨床検査医学会  

    researchmap

  69. レプチンが脂肪由来幹細胞の分化能に与える影響について

    大原 倫美, 中切 健太, 名仁澤 英里, 平野 文香, 林 由美, 石川 哲也

    臨床病理   Vol. 63 ( 補冊 ) page: 215 - 215   2015.10

     More details

    Language:Japanese   Publisher:日本臨床検査医学会  

    researchmap

  70. 進行肝細胞癌に対するソラフェニブ投与後早期のPIVKA-2値の推移と抗腫瘍効果との関係

    葛谷 貞二, 石上 雅敏, 伊藤 隆徳, 安田 諭, 川口 彩, 加藤 幸一郎, 新家 卓郎, 今井 則博, 阿知波 宏一, 石津 洋二, 本多 隆, 林 和彦, 石川 哲也, 後藤 秀実

    肝臓   Vol. 56 ( Suppl.2 ) page: A748 - A748   2015.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  71. バイポーラ電極針を用いたラジオ波焼灼術におけるDexmedetomidineを用いた鎮静法の検討

    石津 洋二, 石上 雅敏, 伊藤 隆徳, 安田 諭, 川口 彩, 加藤 幸一郎, 新家 卓郎, 今井 則博, 阿知波 宏一, 葛谷 貞二, 本多 隆, 林 和彦, 石川 哲也, 後藤 秀実

    肝臓   Vol. 56 ( Suppl.2 ) page: A740 - A740   2015.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  72. 肝再生 基礎から臨床 マウス急性肝障害モデルにおける移植後脂肪由来幹細胞の生体内動態解析

    石川 哲也, 吉住 寧真, 湯川 博

    肝臓   Vol. 56 ( Suppl.2 ) page: A653 - A653   2015.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  73. 進行肝細胞癌に対するソラフェニブ不応後TACEを組み合わせた症例の治療成績

    葛谷 貞二, 石上 雅敏, 伊藤 隆徳, 安田 諭, 川口 彩, 加藤 幸一郎, 新家 卓郎, 今井 則博, 阿知波 宏一, 石津 洋二, 本多 隆, 林 和彦, 石川 哲也, 後藤 秀実

    日本消化器病学会雑誌   Vol. 112 ( 臨増大会 ) page: A871 - A871   2015.9

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  74. DC beadを用いたTACEの臨床的検討 cTACEとの比較

    今井 則博, 石上 雅敏, 伊藤 隆徳, 安田 諭, 川口 彩, 加藤 幸一郎, 新家 卓郎, 阿知波 宏一, 石津 洋二, 葛谷 貞二, 本多 隆, 林 和彦, 石川 哲也, 廣岡 芳樹, 後藤 秀実

    肝臓   Vol. 56 ( Suppl.2 ) page: A737 - A737   2015.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  75. 探針エレクトロスプレー/タンデム質量分析(PESI/MS/MS)によるマウス肝臓内のメタボローム直接分析法(インタクト・メタボローム分析法)の構築

    林 由美, 財津 桂, 村田 匡, 大原 倫美, 中切 健太, 草野 麻衣子, 那須 民江, 中島 宏樹, 石川 哲也, 土橋 均, 石井 晃

    JSBMS Letters   Vol. 40 ( Suppl. ) page: 65 - 65   2015.8

     More details

    Language:Japanese   Publisher:(一社)日本医用マススペクトル学会  

    researchmap

  76. C型肝炎治療の現状について

    石川 哲也

    明日の臨床   Vol. 27 ( 1 ) page: 29 - 34   2015.6

     More details

    Language:Japanese   Publisher:愛知県保険医協会  

    researchmap

  77. 高齢者C型肝炎におけるDaclatasvir・Asunaprevir併用療法の治療早期の効果

    本多 隆, 石上 雅敏, 伊藤 隆徳, 安田 諭, 川口 彩, 加藤 幸一郎, 新家 卓郎, 今井 則博, 阿知波 宏一, 石津 洋二, 葛谷 貞二, 林 和彦, 中野 功, 石川 哲也, 後藤 秀実

    肝臓   Vol. 56 ( Suppl.1 ) page: A504 - A504   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  78. コリン欠乏高脂肪食によるNASHマウスモデルにおける高血糖を伴わない脂質、分岐鎖アミノ酸代謝の検討

    本多 隆, 石上 雅敏, 馬 凌云, 安田 諭, 川口 彩, 加藤 幸一郎, 新家 卓郎, 今井 則博, 阿知波 宏一, Luo Fangqiong, 山田 恵一, 石津 洋二, 葛谷 貞二, 林 和彦, 中野 功, 石川 哲也, 後藤 秀実

    糖尿病   Vol. 58 ( Suppl.1 ) page: S - 481   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本糖尿病学会  

    researchmap

  79. 当院におけるDC Beadの初期使用経験

    今井 則博, 石上 雅敏, 安田 諭, 川口 彩, 加藤 幸一郎, 新家 卓郎, 阿知波 宏一, 山田 恵一, 石津 洋二, 葛谷 貞二, 本多 隆, 林 和彦, 石川 哲也, 後藤 秀実

    肝臓   Vol. 56 ( Suppl.1 ) page: A533 - A533   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  80. 超音波による放射線治療・化学療法の効果判定 当院での進行肝細胞癌に対するソラフェニブ治療における造影超音波検査の現状と役割

    葛谷 貞二, 石上 雅敏, 石津 洋二, 本多 隆, 林 和彦, 石川 哲也, 後藤 秀実

    超音波医学   Vol. 42 ( Suppl. ) page: S277 - S277   2015.4

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    researchmap

  81. 消化管ホルモンの役割を見直す 摂食行動と栄養代謝調節 高齢者食欲不振の病態における食欲関連ホルモン炎症・免疫応答の役割について

    石川 哲也, 林 由美, 松浦 俊博

    日本消化器病学会雑誌   Vol. 112 ( 臨増総会 ) page: A98 - A98   2015.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  82. B型慢性肝炎におけるcoreI97変異がその後の経過に及ぼす影響

    本多 隆, 石上 雅敏, 川口 彩, 加藤 幸一郎, 新家 卓郎, 今井 則博, 阿知波 宏一, 山田 恵一, 石津 洋二, 葛谷 貞二, 林 和彦, 石川 哲也, 中野 功, 後藤 秀実

    日本消化器病学会雑誌   Vol. 112 ( 臨増総会 ) page: A359 - A359   2015.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  83. 超低毒性量子ドットを用いた単一幹細胞ラベリングと3D in vivoイメージング

    荻原裕佑, 湯川博, 小野島大介, 亀山達矢, 林由美, 鳥本司, 石川哲也, 馬場嘉信, 馬場嘉信, 馬場嘉信

    日本化学会講演予稿集   Vol. 95th ( 2 )   2015

  84. 抗菌薬投与時に発症した薬物性肝障害の検討

    綾田穣, 石川哲也, 中野達徳, 坂井圭介, 小野幸矢, 高柳正弘, 堀田直樹, 黒川剛

    肝臓   Vol. 56 ( Supplement 1 )   2015

  85. がん化学療法及び免疫抑制療法中のB型肝炎ウイルス再活性化予防対策法の確立を目指したウイルス要因と宿主要因の包括的研究 造血幹細胞移植後におけるB型肝炎ウイルス再活性化の実態および予防に関する多施設共同臨床研究

    木村公則, 坂巻壽, 神田善伸, 石川哲也, 井上和明, 垣花和彦, 楠本茂, 香西康司, 高橋和弘, 橋野聡, 丸澤宏之, 山本正英

    がん化学療法及び免疫抑制療法中のB型肝炎ウイルス再活性化予防対策法の確立を目指したウイルス要因と宿主要因の包括的研究 平成26年度 総括・分担研究報告書     2015

  86. NIR-II近赤外蛍光ナノ粒子による幹細胞イメージング手法の構築

    嶋田泰佑, 嶋田泰佑, 湯川博, 小野島大介, 新岡宏彦, 亀山達矢, 林由美, 鳥本司, 石川哲也, 馬場嘉信, 馬場嘉信, 馬場嘉信

    日本化学会講演予稿集   Vol. 95th ( 2 )   2015

  87. 間葉系幹細胞及び肝がん細胞由来エクソソーム分離と機能比較検証

    横山亜紗実, 横山亜紗実, 湯川博, 小野島大介, 林由美, 石川哲也, 馬場嘉信, 馬場嘉信, 馬場嘉信

    日本化学会講演予稿集   Vol. 95th ( 2 )   2015

  88. 量子・磁気ナノハイブリッド粒子による幹細胞マルチモーダルイメージング

    成瀬麗奈, 成瀬麗奈, 湯川博, 小野島大介, 林由美, 石川哲也, 馬場嘉信, 馬場嘉信, 馬場嘉信

    日本化学会講演予稿集   Vol. 95th ( 2 )   2015

  89. NIR-IIイメージングシステムによる移植幹細胞in vivoイメージング

    湯川博, 大林桃子, 中川伸吾, 吉住寧真, 小野島大介, 新岡宏彦, 竹内司, 大谷敬亨, 三宅淳, 石川哲也, 馬場嘉信, 馬場嘉信, 馬場嘉信

    再生医療   Vol. 14   2015

  90. HBV cccDNAの制御と排除を目指す新規免疫治療薬の開発 HBV特異的免疫応答誘導の高効率化の試み

    石川哲也, 伊藤弘康, 石井健, 小檜山康司, 石上雅敏

    HBV cccDNAの制御と排除を目指す新規免疫治療薬の開発 平成26年度 総括・分担研究報告書     2015

  91. 進行肝細胞癌に対するソラフェニブを基軸とした集学的治療の治療成績

    葛谷 貞二, 石上 雅敏, 新家 卓郎, 今井 則博, 阿知波 宏一, 荒川 恭宏, 山田 恵一, 中野 聡, 石津 洋二, 本多 隆, 林 和彦, 石川 哲也, 後藤 秀実

    日本消化器病学会雑誌   Vol. 111 ( 臨増総会 ) page: A432 - A432   2014.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  92. 分岐鎖アミノ酸によるNASHマウスモデルにおける肝脂肪抑制効果

    本多 隆, 石上 雅敏, 新家 卓郎, 今井 則博, 阿知波 宏一, 荒川 恭宏, 山田 恵一, 中野 聡, 石津 洋二, 葛谷 貞二, 林 和彦, 石川 哲也, 中野 功, 後藤 秀実

    日本消化器病学会雑誌   Vol. 111 ( 臨増総会 ) page: A332 - A332   2014.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  93. マウス急性肝障害モデルにおける脂肪組織由来幹細胞(ASC)の炎症制御効果について

    吉住寧真, 加納由貴, 加納綾乃, 中川伸吾, 山田達也, 湯川博, 石川哲也

    再生医療   Vol. 13   2014

  94. 肝臓特異的UBXD8ノックアウトマウス表現型の検討

    今井則博, 今井則博, 鈴木倫毅, 新家卓郎, 阿知波宏一, 荒川恭宏, 山田恵一, 中野聡, 石津洋二, 葛谷貞二, 本多隆, 林和彦, 石上雅敏, 石川哲也, 藤本豊士, 後藤秀実

    肝臓   Vol. 55 ( Supplement 1 ) page: A319 - A319   2014

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  95. 肝線維化進展におけるインドールアミン酵素添加酵素の役割

    小木曽英介, 伊藤弘康, 安藤元基, 石川哲也, 森脇久隆, 清島満

    肝臓   Vol. 55 ( Supplement 2 )   2014

  96. 肝細胞癌に対するRFA治療支援としてのVirtu TRAXの有用性

    葛谷貞二, 石上雅敏, 荒川恭宏, 山田恵一, 石津洋二, 本多隆, 林和彦, 石川哲也, 後藤秀実

    超音波医学   Vol. 41 ( Suppl. ) page: S323 - S323   2014

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    J-GLOBAL

    researchmap

  97. コリン欠乏と閉経及びRaloxifeneによるNASH進展への影響

    LUO F., 加藤幸一郎, 新家卓郎, 今井則博, 阿知波宏一, 荒川恭宏, 山田恵一, 石津洋二, 葛谷貞二, 本多隆, 林和彦, 石上雅敏, 石川哲也, 後藤秀実

    肝臓   Vol. 55 ( Supplement 2 ) page: A623 - A623   2014

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  98. C型慢性肝炎に対するペグインターフェロンα2b・リバビリン療法無効例におけるcore,NS3,NS5A領域のアミノ酸変異の変化について

    林和彦, 石上雅敏, 新家卓郎, 今井則博, 阿知波宏一, 荒川恭宏, 山田恵一, 中野聡, 石津洋二, 葛谷貞二, 本多隆, 石川哲也, 片野義明, 後藤秀実

    肝臓   Vol. 55 ( Supplement 1 ) page: A448 - A448   2014

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  99. C型肝炎治療困難例への対策 C型慢性肝炎難治例におけるPeg-IFN/RBV併用療法の治療効果と発癌抑制効果

    本多隆, 石上雅敏, 新家卓郎, 今井則博, 阿知波宏一, 荒川恭宏, 山田恵一, 石津洋二, 葛谷貞二, 林和彦, 石川哲也, 中野功, 片野義明, 後藤秀実

    月刊消化器内科   Vol. 58 ( 3 ) page: 337 - 341   2014

     More details

    Language:Japanese   Publisher:(有)科学評論社  

    J-GLOBAL

    researchmap

  100. HBV cccDNAの制御と排除を目指す新規免疫治療薬の開発 HBV特異的免疫応答誘導の高効率化の試み

    石川哲也, 石上雅敏, 伊藤弘康

    HBV cccDNAの制御と排除を目指す新規免疫治療薬の開発 平成25年度 総括・分担研究報告書     2014

  101. 穿刺治療支援アプリケーションVirtuTRAXを用いた2ステップ法によるラジオ波焼灼術の試み

    葛谷 貞二, 石津 洋二, 新家 卓郎, 今井 則博, 阿知波 宏一, 荒川 恭宏, 山田 恵一, 中野 聡, 本多 隆, 林 和彦, 石上 雅敏, 石川 哲也, 中野 功, 片野 義明, 伊藤 彰浩, 廣岡 芳樹, 泉 並木, 後藤 秀実

    肝臓   Vol. 54 ( 12 ) page: 850 - 853   2013.12

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    穿刺治療支援アプリケーションVirtuTRAXを用いた2ステップ法によるラジオ波焼灼術の手技を紹介し、同手術施行の肝細胞癌患者16例23結節における実際の針先端と仮想の針先端との位置ずれについて報告した。横方向の位置ずれに関しては、外筒針が肝表面を貫く際に仮想穿刺ライナーが一時的にずれるケースがあり、肝表面がたわんだ3例、肝自体が押され変位した2例、人工腹水を用いた2例で1cm以上のずれを認めたが、外筒針が肝表面を貫いた後は認めなかった。その後の治療過程では、呼吸性変動や針先端の位置調整時において1〜5mm程度ずれるケースがみられたが、いずれもほぼ平行なずれであった。一方縦方向の位置ずれに関しては、外筒針と肝表面とのたわみがとれた後はそれぞれの穿刺ライン上での体表からの距離が一致し、問題となるケースはなかった。

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2013&ichushi_jid=J00263&link_issn=&doc_id=20140108190006&doc_link_id=10.2957%2Fkanzo.54.850&url=https%3A%2F%2Fdoi.org%2F10.2957%2Fkanzo.54.850&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  102. 放射線治療およびソラフェニブが奏効した巨大骨盤骨転移を伴うCK19陽性肝細胞癌の1症例

    葛谷 貞二, 石上 雅敏, 新家 卓郎, 今井 則博, 阿知波 宏一, 荒川 恭宏, 山田 恵一, 中野 聡, 石津 洋二, 本多 隆, 林 和彦, 片野 義明, 石川 哲也, 後藤 秀実

    Liver Cancer   Vol. 19   page: 71 - 75   2013.11

     More details

    Language:Japanese   Publisher:(株)アークメディア  

    症例は80歳男性。主訴は右下肢痛および歩行困難。既往歴はC型慢性肝炎。近医で施行したCT検査にて右骨盤部に長径140mm大の骨破壊を伴う腫瘍を認めた。同病変の腫瘍生検では低分化肝細胞癌の所見であり、精査加療目的で当院に紹介となった。原発と考えられた肝内病変は骨盤転移巣に比して小さく長径10mm大の乏血性病変1ヶ所であった。腫瘍マーカーはAFP 311,200ng/mL、PIVKA II 11,221mAU/mLといずれも高値であった。まず骨盤転移巣に対し放射線治療を施行(45Gy/15Fr)し、その後引き続いてソラフェニブを400mg/日で開始した。ソラフェニブ投与6週間後のmRECIST基準による抗腫瘍効果判定はPRで、腫瘍マーカーもAFP 8490、PIVKA II 855mAU/mLと低下した。腫瘍生検に免疫染色を追加したところCK19(Cytokeratin 19)陽性であった。(著者抄録)

    researchmap

  103. 進行肝細胞癌に対するソラフェニブ単独投与にて画像上効果不十分と判定後の治療方針とその成績-投与後初期にみられる阻血性変化にも着目して-

    葛谷貞二, 石上雅敏, 新家卓郎, 今井則博, 阿知波宏一, 荒川恭宏, 山田恵一, 中野聡, 石津洋二, 本多隆, 林和彦, 中野功, 石川哲也, 後藤秀実

    肝臓   Vol. 54 ( Supplement 3 ) page: A761 - A761   2013

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  104. 進行肝細胞癌に対するソラフェニブ投与後早期の発熱と画像上の阻血性変化との関係

    葛谷貞二, 片野義明, 今井則博, 阿知波宏一, 荒川恭宏, 山田恵一, 中野聡, 増田寛子, 石津洋二, 本多隆, 林和彦, 石上雅敏, 石川哲也, 後藤秀実

    日本消化器病学会雑誌   Vol. 110 ( 臨増総会 ) page: A261 - A261   2013

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    J-GLOBAL

    researchmap

  105. 腹満感を伴う便秘症状の原因にvildagliptinの関与が示唆された糖尿病合併末期腎不全の1例

    綾田穣, 森弘卓延, 加藤ふみ, 堀田直樹, 黒川剛, 中野達徳, 石川哲也

    腎と透析   Vol. 74 ( 3 )   2013

  106. 自己免疫性肝炎における血清IgG4値の検討

    石津洋二, 新家卓郎, 今井則博, 阿知波宏一, 荒川恭宏, 山田恵一, 中野聡, 葛谷貞二, 本多隆, 林和彦, 石上雅敏, 石川哲也, 後藤秀実

    肝臓   Vol. 54 ( Supplement 3 ) page: A779 - A779   2013

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  107. 肝細胞癌に対する肝動脈化学塞栓療法(TACE)前後の分岐鎖アミノ酸製剤投与意義の検討

    中野聡, 片野義明, 今井則博, 阿知波宏一, 山田恵一, 荒川恭宏, 石津洋二, 葛谷貞二, 本多隆, 林和彦, 石上雅敏, 中野功, 石川哲也, 後藤秀実

    肝臓   Vol. 54 ( Supplement 2 ) page: A634 - A634   2013

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  108. 炎症性腸疾患におけるB型肝炎ウイルスの再活性化とde novo B型肝炎のウイルス学検討

    林和彦, 片野義明, 今井則広, 阿知波宏一, 荒川恭宏, 山田恵一, 中野聡, 増田寛子, 石津洋二, 葛谷貞二, 本多隆, 石上雅敏, 石川哲也, 中野功, 後藤秀実

    日本消化器病学会雑誌   Vol. 110 ( 臨増総会 ) page: A389 - A389   2013

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    J-GLOBAL

    researchmap

  109. 当院における潜在性結核感染症の治療中に発症した薬物性肝障害の現状

    綾田穣, 石川哲也, 堀田直樹, 中野達徳, 黒川剛

    肝臓   Vol. 54 ( Supplement 3 )   2013

  110. 局所進行肝細胞癌(高度脈管浸潤,多発肝内転移,TACE不応および不能例)に対する第一選択としてのソラフェニブの治療成績

    葛谷貞二, 石上雅敏, 今井則博, 阿知波宏一, 荒川恭宏, 山田恵一, 中野聡, 石津洋二, 本多隆, 林和彦, 石川哲也, 後藤秀実

    肝臓   Vol. 54 ( Supplement 2 ) page: A604 - A604   2013

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  111. ベトナムのB型急性肝炎とB型慢性肝炎におけるHBV subgenotypeについての検討

    林和彦, 片野義明, 今井則博, 阿知波宏一, 荒川恭宏, 山田恵一, 中野聡, 石津洋二, 葛谷貞二, 本多隆, 石上雅敏, 石川哲也, 中野功, 後藤秀実

    肝臓   Vol. 54 ( Supplement 2 ) page: A552 - A552   2013

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  112. インドールアミン酸素添加酵素の発現抑制によるHBV特異的細胞障害性T細胞誘導効果

    伊藤弘康, 安藤量基, 石川哲也, 森脇久隆

    肝臓   Vol. 54 ( Supplement 3 )   2013

  113. インドールアミン酸素添加酵素の発現制御を用いたHBV特異的細胞障害性T細胞誘導効果の検討

    伊藤弘康, 安藤達也, 石川哲也, 清島満

    臨床病理   Vol. 61   2013

  114. C型慢性肝炎に対するペグインターフェロン・リバビリン併用療法著効後における発癌例の検討

    本多隆, 石上雅敏, 新家卓郎, 今井則博, 阿知波宏一, 山田恵一, 荒川恭宏, 中野聡, 石津洋二, 葛谷貞二, 林和彦, 中野功, 石川哲也, 片野義明, 後藤秀実

    肝臓   Vol. 54 ( Supplement 3 ) page: A767 - A767   2013

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  115. HBV cccDNAの制御と排除を目指す新規免疫治療薬の開発 B型慢性肝炎患者におけるエピトープ解析と高効率免疫法確立の試み

    石川哲也, 石上雅敏, 伊藤弘康

    HBV cccDNAの制御と排除を目指す新規免疫治療薬の開発 平成24年度 総括・分担研究報告書     2013

  116. 高齢者の食欲不振と免疫・ホルモン環境の変化との関連について

    加納綾乃, 吉住寧真, 中川伸吾, 加納由貴, 山田達也, 松浦俊博, 石川哲也

    臨床病理   Vol. 61 ( 補冊 ) page: 147 - 147   2013

     More details

    Language:Japanese   Publisher:(一社)日本臨床検査医学会  

    J-GLOBAL

    researchmap

  117. ソラフェニブ投与後,腫瘍濃染の消失・減弱(阻血性変化)が一旦認められたものの,その後の経過で腫瘍内血流が再燃した進行肝細胞癌の3例

    葛谷貞二, 片野義明, 今井則博, 阿知波宏一, 荒川恭宏, 山田恵一, 中野聡, 増田寛子, 石津洋二, 本多隆, 林和彦, 石上雅敏, 石川哲也, 後藤秀実

    Liver Cancer Journal   Vol. 4 ( 2 ) page: 140 - 141   2012

     More details

    Language:Japanese   Publisher:(株)メディカルレビュー社  

    J-GLOBAL

    researchmap

  118. プライマリーケアにおける機能性食道・胃疾患 機能性胃疾患診療における不安抑うつスコアの有用性と機能性胃疾患の発症および増悪因子としての心配性の関与について

    洪繁, 洪繁, 松浦俊博, 木村宏之, 石川哲也, 京兼和宏, 山田理

    月刊消化器内科   Vol. 55 ( 1 )   2012

  119. Late responderに対するペグインターフェロンα2b・リバビリン72週投与の治療効果とcoreとISDR変異,IL28B一塩基多型の関連ついての検討

    土居崎正雄, 片野義明, 本多隆, 林和彦, 石上雅敏, 石川哲也, 中野功, 浦野文博, 吉岡健太郎, 豊田秀徳, 熊田卓, 山口丈夫, 春田純一, 後藤秀実

    肝臓   Vol. 53 ( Supplement 1 ) page: A357 - A357   2012

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  120. 内科疾患の予防戦略 消化器疾患の予防戦略 瀉血による慢性肝炎の進展予防

    伊東和樹, 石川哲也

    Medicina   Vol. 48 ( 7 )   2011

  121. ペグインターフェロン,リバビリン併用療法における凝固因子の検討

    本多隆, 片野義明, 林寛子, 及部祐加子, 小野幸矢, 石津洋二, 清水潤一, 土居崎正雄, 舘佳彦, 林和彦, 石上雅敏, 中野功, 石川哲也, 後藤秀実

    肝臓   Vol. 52 ( Supplement 1 ) page: A380 - A380   2011

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  122. B型肝炎に対する新治療戦略 HBV-DNA陰性慢性B型肝炎患者における血清HBVコア関連抗原の意味と核酸アナログ長期投与再考の可能性

    石上雅敏, 林和彦, 舘佳彦, 石川哲也, 廣岡芳樹, 片野義明, 本多隆, 中野功, 伊藤彰浩, 後藤秀実

    月刊消化器内科   Vol. 53 ( 3 ) page: 293 - 299   2011

     More details

    Language:Japanese   Publisher:(有)科学評論社  

    B型慢性肝炎患者における血清B型肝炎コア関連抗原(HBcrAg)測定の意義について、特に人工的にではあるがHBs抗原陰性、HBs抗体陽性の、いわゆるB型肝炎の臨床的治癒状態と考えられる状態のモデルの一つとして考えられるHBV陽性の肝移植後患者と比較検討した。HBcrAgを測定した全例(311例)でHBV-DNAと有意な強い相関関係がみられた。核酸アナログ投与を行っている慢性B型肝炎患者の症例(102例)に絞って検討した。HBV-DNAが陰性化している症例は82例で、HBcrAg陽性の症例は64例であった。臨床的治癒状態のモデルと考えられる肝移植後患者19例は全例HBs抗原陰性、HBs抗体陽性、また、HBV-DNA陰性であった。HBeセロコンバージョンの診断能では圧倒的にHBcrAgが優れていた。

    J-GLOBAL

    researchmap

  123. DDW-J2004薬物性肝障害診断基準案の適応前後での当院における薬物性肝障害症例への検査施行率の変化

    綾田穣, 堀田直樹, 石川哲也

    肝臓   Vol. 52 ( Supplement 2 )   2011

  124. HIV,HBV重複感染例でHBVに対するラミブジン耐性株の出現後HBe抗体陽性が持続し肝炎が沈静化した1例

    本多隆, 片野義明, 中野聡, 増田寛子, 及部祐加子, 石津洋二, 葛谷貞二, 舘佳彦, 林和彦, 石上雅敏, 中野功, 石川哲也, 後藤秀実

    肝臓   Vol. 52 ( Supplement 3 ) page: A917 - A917   2011

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  125. 高齢者C型慢性肝炎におけるペグインターフェロン/リバビリン併用療法の発癌抑制効果

    本多隆, 片野義明, 中野聡, 増田寛子, 及部祐加子, 小野幸矢, 石津洋二, 土居崎正雄, 葛谷貞二, 舘佳彦, 林和彦, 石上雅敏, 中野功, 石川哲也, 後藤秀実

    日本消化器病学会雑誌   Vol. 108 ( 臨増大会 ) page: A931 - A931   2011

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    J-GLOBAL

    researchmap

  126. 透析患者のC型慢性肝炎に対するPEG-IFNα-2a単独投与の治療成績

    多賀 雅浩, 竹田 欽一, 宇都宮 節夫, 川田 登, 池田 誉, 水谷 佳貴, 広瀬 健, 葛谷 貞二, 石川 哲也

    肝臓   Vol. 51 ( Suppl.2 ) page: A597 - A597   2010.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  127. 【ウイルス肝炎 日常診療のポイント】B型肝炎に対する免疫療法

    石川 哲也

    Medicina   Vol. 47 ( 3 ) page: 487 - 490   2010.3

     More details

    Language:Japanese   Publisher:(株)医学書院  

    <ポイント>★免疫療法の目標は,自然経過に近いdrug-freeの臨床的治癒を達成することである.★現時点での免疫療法の効果は限定的である.★抗ウイルス療法との組み合わせの検討,新規ワクチンの開発が必要である.(著者抄録)

    researchmap

  128. MUC1標的免疫細胞療法とGemcitabineとの併用が著効した膵頭部癌多発肝転移の1例

    今井 則博, 竹田 欽一, 宇都宮 節夫, 多賀 雅浩, 川田 登, 池田 誉, 水谷 佳貴, 広瀬 健, 石川 哲也, 吉田 松年

    癌と化学療法   Vol. 37 ( 3 ) page: 527 - 529   2010.3

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    症例は52歳、女性。心窩部の違和感を主訴として当院を受診、多発肝転移を伴う膵頭部癌と診断した。胆管狭窄に対し金属ステントを留置し、その後gemcitabine(GEM)1000mg/m2週1回、3週投与1週休薬を1コースとして投与を開始した。また、MUC1をパルスした樹状細胞(DC)と活性化自己リンパ球(CAT)の投与によるMUC1標的免疫細胞療法(DC-CAT)を2週に1回を1コースとして併用した。GEM6コース、DC-CAT9コース施行後、原発巣と肝転移巣の消失を認めた。治療開始後7ヵ月後となる現在もGEMとCAT療法を継続し、complete responseを維持している。GEMと免疫細胞療法の併用治療の進行膵癌に対する有用性が示唆された。(著者抄録)

    researchmap

  129. Drugs aimed for Hepatobiliary,Pancreatic Diseaes for this 30 years. Meinyu, absorbed hepatitis B vaccine derived from cultured human cell line

    石川哲也

    肝胆膵   Vol. 61 ( 6 ) page: 1088 - 1094   2010

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  130. 当院における慢性腎疾患の有無による薬物性肝障害の現状と傾向

    綾田穣, 堀田直樹, 広瀬昭憲, 黒川剛, 黒川剛, 石川哲也, 増子美奈子, 増子和郎

    肝臓   Vol. 51 ( Supplement 2 )   2010

  131. 透析患者のC型慢性肝炎に対するPEG-IFNα-2a(90μg/回)単独投与療法の治療成績

    葛谷 貞二, 竹田 欽一, 宇都宮 節夫, 川田 登, 池田 誉, 今井 則博, 水谷 佳貴, 広瀬 健, 石川 哲也, 片野 義明, 後藤 秀実

    肝臓   Vol. 50 ( Suppl.2 ) page: A550 - A550   2009.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  132. 経皮的局所治療が困難な肝細胞癌に対して体幹部定位放射線療法を施行した5例の治療成績 プリモビスト造影MRIの経時的な画像上の変化にも注目して

    葛谷 貞二, 竹田 欽一, 宇都宮 節夫, 川田 登, 池田 誉, 今井 則博, 水谷 佳貴, 広瀬 健, 石川 哲也, 片野 義明, 後藤 秀実, 岩田 宏満, 芝本 雄太, 森 美雅

    肝臓   Vol. 50 ( Suppl.2 ) page: A572 - A572   2009.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  133. プリモビスト造影MRI検査による中分化および高分化肝細胞癌の診断能の検討

    葛谷 貞二, 竹田 欽一, 宇都宮 節夫, 川田 登, 池田 誉, 今井 則博, 水谷 佳貴, 広瀬 健, 石川 哲也, 片野 義明, 後藤 秀実

    肝臓   Vol. 50 ( Suppl.2 ) page: A590 - A590   2009.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  134. 大腸癌術前に各種画像検査によって多発肝類上皮性血管内皮腫と診断できた1例

    葛谷 貞二, 竹田 欽一, 宇都宮 節夫, 川田 登, 池田 誉, 今井 則博, 水谷 佳貴, 広瀬 健, 石川 哲也, 伊藤 将倫, 今泉 延, 小栗 健二

    肝胆膵治療研究会誌   Vol. 7 ( 1 ) page: 112 - 112   2009.8

     More details

    Language:Japanese   Publisher:肝胆膵治療研究会  

    researchmap

  135. 肝外門脈瘤からの後腹膜出血の診断に超音波内視鏡検査が有用であった一例

    葛谷 貞二, 竹田 欽一, 宇都宮 節夫, 川田 登, 池田 誉, 今井 則博, 水谷 佳貴, 広瀬 健, 石川 哲也

    Gastroenterological Endoscopy   Vol. 51 ( Suppl.1 ) page: 955 - 955   2009.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  136. 【肥満と糖尿病の薬物療法】ウコンと薬物性肝障害の関連は? ウコンと薬物性肝障害の関連について教えてください

    石川 哲也

    Q&Aでわかる肥満と糖尿病   Vol. 8 ( 2 ) page: 260 - 261   2009.3

     More details

    Language:Japanese   Publisher:(株)丹水社  

    researchmap

  137. 【肝臓領域の樹状細胞研究を究めるために】樹状細胞の基礎を網羅する 肝疾患領域での樹状細胞の臨床応用

    石川 哲也

    肝・胆・膵   Vol. 58 ( 2 ) page: 201 - 209   2009.2

     More details

    Language:Japanese   Publisher:(株)アークメディア  

    researchmap

  138. プリモビスト造影MRIによる小型肝細胞癌の検出能の検討-造影CTとの比較-

    葛谷貞二, 竹田欽一, 宇都宮節夫, 川田登, 池田誉, 今井則博, 水谷佳貴, 広瀬健, 石川哲也, 片野義明, 後藤秀実

    日本消化器病学会雑誌   Vol. 106 ( 臨増総会 ) page: A196 - A196   2009

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    J-GLOBAL

    researchmap

  139. 細胞治療 肝細胞癌に対する活性化自己リンパ球移入療法の効果について

    石川 哲也, 北野 ゆかり, 吉田 松年

    Biotherapy   Vol. 22 ( Suppl.I ) page: 77 - 77   2008.11

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    researchmap

  140. 肝細胞癌に対する活性化自己リンパ球移入療法の効果に関する検討

    石川 哲也, 北野 ゆかり, 加藤 兼房, 吉田 松年

    肝臓   Vol. 49 ( Suppl.1 ) page: A280 - A280   2008.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  141. 【C型肝炎の治療 新たな展開】肝庇護療法の適応と有効性 グリチルリチン製剤

    石川 哲也

    Modern Physician   Vol. 28 ( 1 ) page: 76 - 79   2008.1

     More details

    Language:Japanese   Publisher:(株)新興医学出版社  

    researchmap

  142. 【薬物による健康障害 肺・肝・血液・皮膚】肝臓 健康食品による薬物性肝障害

    石川 哲也, 綾田 穣

    治療   Vol. 89 ( 12 ) page: 3198 - 3203   2007.12

     More details

    Language:Japanese   Publisher:(株)南山堂  

    「いわゆる健康食品」による肝障害発症事例についての全国アンケート調査を行った。原因として多くあげられたウコンのほかにも、多様な健康食品が原因となっていた。健康食品も医薬品におけるのと同様に肝障害の原因となる可能性があることに留意する必要がある。健康被害の拡大を防ぐには、安易に健康食品に頼らぬよう、また、疾患の治療・予防に際しては、医師への相談を優先させるよう一般に啓発していくことが必要と考えられる。(著者抄録)

    researchmap

  143. 【ウイルス肝炎の免疫学的機序と治療】ワクチンによるB型肝炎の治療

    石川 哲也

    消化器科   Vol. 45 ( 4 ) page: 415 - 420   2007.10

     More details

    Language:Japanese   Publisher:(有)科学評論社  

    researchmap

  144. 【B型肝炎の新たな治療展開】B型肝炎の治療戦略 Adefovir pivoxil

    石川 哲也, 各務 伸一

    内科   Vol. 100 ( 4 ) page: 677 - 682   2007.10

     More details

    Language:Japanese   Publisher:(株)南江堂  

    adefovirは、lamivudine耐性株によるB型慢性肝疾患(breakthrough hepatitis)に対して、lamivudineとの併用で用いられる。lamivudine耐性株によるbreakthrough hepatitisに対するadefovirの治療効果は、良好である。とくにALT高値例、HBe抗原陰性例での効果は高い。adefovir耐性をもたらす主なHBV変異として、rtN236T,rtA181V/Tが報告されている。adefovir投与中の耐性株の出現率は、lamivudine耐性感感染例での使用において高くなるが、adefovirをlamivudineと併用することで、ある程度抑制することができる。adefovirの副作用として、腎障害には注意が必要である。(著者抄録)

    researchmap

  145. 肝生検とDDWJ-2004の薬物性肝障害診断基準案が診断の根拠となったウコンによる薬物性肝障害の一例

    綾田 穣, 石川 哲也, 大橋 知彦, 田村 泰弘, 佐藤 顕, 堀田 直樹, 奥村 明彦, 各務 伸一

    肝臓   Vol. 48 ( Suppl.2 ) page: A429 - A429   2007.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  146. 細経内視鏡を用いた経胃瘻的空腸瘻の有用性

    田村 泰弘, 堀田 直樹, 石原 慎, 綾田 穣, 大橋 知彦, 佐藤 顕, 奥村 明彦, 石川 哲也, 各務 伸一

    Gastroenterological Endoscopy   Vol. 49 ( Suppl.2 ) page: 2276 - 2276   2007.9

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  147. 内視鏡的にネット鉗子とオーバーチューブを用いて食道と胃に誤嚥した義歯の除去が可能であった一例

    綾田 穣, 中野 達徳, 内村 正史, 吉田 篤生, 堀田 直樹, 奥村 明彦, 石川 哲也, 各務 伸一

    Gastroenterological Endoscopy   Vol. 49 ( Suppl.2 ) page: 2321 - 2321   2007.9

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  148. 【消化器薬の使い方Update】消化器疾患の薬物治療 自己免疫性肝炎(AIH)

    石川 哲也

    Medicina   Vol. 44 ( 9 ) page: 1713 - 1715   2007.9

     More details

    Language:Japanese   Publisher:(株)医学書院  

    researchmap

  149. 肝腫瘍における3D超音波検査の有用性 ラジオ波焼灼療法(Percutaneous Radiofrequency ablation;RFA)への応用

    堀田 直樹, 田村 泰弘, 大橋 知彦, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 各務 伸一

    肝胆膵治療研究会誌   Vol. 5 ( 1 ) page: 41 - 45   2007.8

     More details

    Language:Japanese   Publisher:肝胆膵治療研究会  

    肝細胞癌9例9結節、転移性肝腫瘍1例1結節の計10例10結節を対象に、iu22を用いた心臓用プローブによる3D超音波検査の有用性について検討した。その結果、本法を用いることにより、すべての腫瘍を描出することが可能で、更にRFA治療時の針確認も可能であった。

    researchmap

  150. Sonazoidによる造影超音波検査の基礎から臨床応用 Sonazoidを用いての肝腫瘍の血流診断の有用性

    堀田 直樹, 田村 泰弘, 大橋 知彦, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 丹羽 幸佳, 井戸 誠, 各務 伸一

    Rad Fan   Vol. 5 ( 7 ) page: 66 - 68   2007.6

     More details

    Language:Japanese   Publisher:(株)メディカルアイ  

    肝腫瘍25例(男性14例、女性11例)36結節を対象として、Sonazoidを用いた造影超音波検査を施行した。目的は血流診断が14例23結節(HCC 20結節、Meta 3結節)、治療効果判定が11例13結節(TAE後11結節、RFA後2結節)で、腫瘍のサイズは1cm以内が0結節、1.1〜2cmが16結節、2.1〜3cmが11結節、3.1〜4cmが4結節、4cm以上が5結節であった。Sonazoid静脈内注入後より1分30秒までをvascular phase(早期動脈相および後期動脈相)、10分以降をKupffer phaseとし観察を行った。結果、微細な血流評価も可能で、肝表面より10cmを超える部位に位置する腫瘍1例を除き、35結節で造影可能であった。Sonazoidを用いることにより微細な血流評価も可能となり、肝細胞癌治療への応用が可能になると思われた。

    researchmap

  151. 【ウイルス肝炎 実地診療A to Z】外来で診るウイルス肝炎 効果的な病診連携のために

    八橋 弘, 伊東 和樹, 柴田 実, 石川 哲也

    Medicina   Vol. 44 ( 5 ) page: 972 - 983   2007.5

     More details

    Language:Japanese   Publisher:(株)医学書院  

    researchmap

  152. 【ウイルス肝炎 実地診療A to Z】ウイルス肝炎の的確な診断のために 肝障害患者の診断の進め方

    各務 伸一, 石川 哲也

    Medicina   Vol. 44 ( 5 ) page: 848 - 851   2007.5

     More details

    Language:Japanese   Publisher:(株)医学書院  

    researchmap

  153. Innate Immunityと肝疾患 C型肝炎ウイルス感染時のToll-like receptor発現と病態への関与について

    佐藤 顕, 石川 哲也, 奥村 明彦, 大橋 知彦, 綾田 穣, 堀田 直樹, 福沢 嘉孝, 各務 伸一

    消化器と免疫   ( 43 ) page: 19 - 22   2007.5

     More details

    Language:Japanese   Publisher:日本消化器免疫学会  

    C型肝炎ウイルス(HCV)感染時のToll-like receptor(TLR)発現パターンを、末梢血単核球(PBMC)およびHCV遺伝子導入肝癌細胞において解析した。C型慢性肝炎患者では健常者に比較し、CD14+細胞におけるTLR4,7,8の発現、およびPBMC中のTNF-α,IL-6,IL-12p35の発現が有意に増強していた。HCV全遺伝子導入肝癌細胞では、TLR3の発現が有意に抑制されていた。TLR発現がHCV感染により制御され、これによりウイルス排除機構も影響を受けていることが示唆された。(著者抄録)

    researchmap

  154. 自己免疫性肝炎(AIH)患者の樹状細胞(DC)におけるアポトーシス関連分子の発現 健常人・C型慢性肝炎患者との比較

    奥村 明彦, 石川 哲也, 各務 伸一

    肝臓   Vol. 48 ( Suppl.1 ) page: A35 - A35   2007.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  155. 自己免疫性肝炎(AIH)患者の樹状細胞(DC)におけるToll-like receptor(TLR)の発現プロフィールに関する検討 健常人・C型慢性肝炎患者との比較

    奥村 明彦, 石川 哲也, 佐藤 さやか, 山内 妙子, 土方 康孝, 大橋 知彦, 佐藤 顕, 綾田 穣, 堀田 直樹, 各務 伸一

    肝臓   Vol. 48 ( Suppl.1 ) page: A167 - A167   2007.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  156. 肝癌診断最近の動向 治療支援 Real Time 4D Ultrasound Systemを用いたRFAの有用性

    堀田 直樹, 綾田 穣, 土方 康孝, 大橋 知彦, 佐藤 顕, 奥村 明彦, 石川 哲也, 大野 長行, 各務 伸一

    超音波医学   Vol. 34 ( Suppl. ) page: S240 - S240   2007.4

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    researchmap

  157. 当院における薬物性肝障害の診断とその問題点および補助診断としての肝生検の位置づけ

    綾田 穣, 石川 哲也, 奥村 明彦, 土方 康孝, 大橋 知彦, 佐藤 顕, 堀田 直樹, 各務 伸一

    肝臓   Vol. 48 ( Suppl.1 ) page: A42 - A42   2007.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  158. 噴門部直下微小出血性病変に対する内視鏡的結紮術の有用性と安全性

    綾田 穣, 堀田 直樹, 中野 達徳, 中江 治道, 吉田 香果, 國井 伸, 佐藤 顕, 大橋 知彦, 土方 康孝, 奥村 明彦, 石川 哲也, 各務 伸一

    Gastroenterological Endoscopy   Vol. 49 ( Suppl.1 ) page: 962 - 962   2007.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  159. ウイルス肝炎の免疫学的機序と治療 B型肝炎 ワクチンによる治療

    石川 哲也, 奥村 明彦, 各務 伸一

    肝臓   Vol. 48 ( Suppl.1 ) page: A7 - A7   2007.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  160. 【肝不全 探求が続く内科的治療ブレークスルー】急性肝不全 薬物による急性肝不全

    石川 哲也

    治療学   Vol. 41 ( 4 ) page: 353 - 357   2007.4

     More details

    Language:Japanese   Publisher:ライフサイエンス出版(株)  

    researchmap

  161. 【B型肝炎の最新診療】B型肝炎の診断の進め方

    石川 哲也, 安藤 量基, 各務 伸一

    消化器の臨床   Vol. 10 ( 2 ) page: 143 - 149   2007.4

     More details

    Language:Japanese   Publisher:(株)ヴァンメディカル  

    B型肝炎ウイルス(HBV)の感染様式には、一過性感染と持続感染があり、それぞれ急性肝炎、慢性肝炎などの病態を呈する。持続感染の場合は、さらに、免疫寛容期、免疫活性期(慢性肝炎)、非複製期の各病期に分けられ、それぞれ異なった病態をとる。どの病期に属するのかを判断することが、治療の要否、治療法の選択、経過観察の方法、予後の判断などを的確に行うために重要である。これらの診断には、HBV抗原・抗体系、ウイルス増殖の状態に関しての正確な理解が必要である。(著者抄録)

    researchmap

  162. 3D超音波を用いた肝細胞癌に対するラジオ波焼灼療法の有用性

    堀田 直樹, 土方 康孝, 大橋 知彦, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 各務 伸一

    肝臓   Vol. 48 ( Suppl.1 ) page: A64 - A64   2007.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  163. 肝腫瘍における3D超音波検査の有用性 RFA治療への応用

    堀田 直樹, 土方 康孝, 大橋 知彦, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 各務 伸一

    日本消化器病学会雑誌   Vol. 104 ( 臨増総会 ) page: A151 - A151   2007.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  164. 肝生検施行し初期からフォローし得たNASHの一例

    佐藤 顕, 石川 哲也, 奥村 明彦, 土方 康孝, 大橋 知彦, 綾田 穣, 堀田 直樹, 各務 伸一

    日本消化器病学会雑誌   Vol. 104 ( 臨増総会 ) page: A227 - A227   2007.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  165. 肝生検の適応から検討した当科におけるNASHと考えられたNAFLDの現状

    綾田 穣, 石川 哲也, 奥村 明彦, 土方 康孝, 大橋 知彦, 佐藤 顕, 堀田 直樹, 各務 伸一

    日本消化器病学会雑誌   Vol. 104 ( 臨増総会 ) page: A113 - A113   2007.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  166. 栄養療法を組み入れた肝細胞癌治療のクリニカルパス

    堀田 直樹, 土方 康孝, 大橋 知彦, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 各務 伸一

    日本内科学会雑誌   Vol. 96 ( Suppl. ) page: 106 - 106   2007.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  167. 内視鏡的食道静脈瘤結紮術施行後の症状に対するProton pump inhibitor,Histamine 2-receptor antagonistの有用性についての比較検討

    綾田 穣, 堀田 直樹, 石川 哲也, 奥村 明彦, 土方 康孝, 大橋 知彦, 佐藤 顕, 各務 伸一

    日本内科学会雑誌   Vol. 96 ( Suppl. ) page: 176 - 176   2007.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  168. ペグインターフェロン・リバビリン併用療法中に皮膚サルコイド肉芽腫を発症したC型慢性肝炎の一例

    森下 宗彦, 石川 哲也, 佐藤 顕, 大橋 知彦, 綾田 穣, 堀田 直樹, 奥村 明彦, 福沢 嘉孝, 各務 伸一, 普天間 新生, 内海 恵子, 楠 正隆, 水谷 健太郎, 橋本 隆

    サルコイドーシス/肉芽腫性疾患   Vol. 26 ( Suppl. ) page: 39 - 39   2006.10

     More details

    Language:Japanese   Publisher:日本サルコイドーシス  

    researchmap

  169. Changes in intrahepatic gene expression profiles from chronic hepatitis to hepatocellular carcinoma in patients with hepatitis C virus infection

    Shinichi Kakumu, Tetsuya Ishikawa, Akihiko Okumura, Keiko Furuta, Yoshihiro Owa, Tsuyoshi Kurokawa, Minoru Ayada, Naoki Hotta, Ken Sato, Tomohiko Ohashi, Yoshitaka Fukuzawa, Toshiaki Nonami

    HEPATOLOGY   Vol. 44 ( 4 ) page: 292A - 292A   2006.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:JOHN WILEY & SONS INC  

    Web of Science

    researchmap

  170. 肝硬変症の治療抵抗性腹水症例に対するdocarpamineの有用性と安全性

    綾田 穣, 石川 哲也, 堀田 直樹, 奥村 明彦, 山内 妙子, 大橋 知彦, 松本 英司, 佐藤 顕, 天満 謙, 福沢 嘉孝, 各務 伸一

    日本消化器病学会雑誌   Vol. 103 ( 臨増大会 ) page: A945 - A945   2006.9

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  171. 経鼻的細経内視鏡による経皮内視鏡的胃瘻造設術の経験

    若林 宏和, 綾田 穣, 中野 達徳, 堀田 直樹, 中江 治道, 國井 伸, 吉田 香果, 山下 俊樹, 大橋 知彦, 松本 英司, 佐藤 顕, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 各務 伸一

    Gastroenterological Endoscopy   Vol. 48 ( Suppl.2 ) page: 2117 - 2117   2006.9

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  172. 急性肝障害における肝内Vα14NKT細胞の役割について

    伊藤 弘康, 安藤 量基, 石川 哲也, 奥村 明彦, 各務 伸一, 井廻 道夫, 森脇 久隆

    肝臓   Vol. 47 ( Suppl.2 ) page: A423 - A423   2006.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  173. マイクロコンベックスプローブ使用におけるラジオ波焼灼療法の有用性

    大橋 知彦, 堀田 直樹, 松本 英司, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 中江 治道, 村瀬 賢一, 北村 仁美, 加藤 公一, 各務 伸一

    日本消化器病学会雑誌   Vol. 103 ( 臨増大会 ) page: A968 - A968   2006.9

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  174. ストレイン法による肝線維化の測定

    堀田 直樹, 綾田 穣, 奥村 明彦, 石川 哲也, 村山 さやか, 高橋 忍, 井戸 誠, 各務 伸一

    日本消化器病学会雑誌   Vol. 103 ( 臨増大会 ) page: A942 - A942   2006.9

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  175. C型慢性肝炎から肝細胞癌の発生の過程で発現量が変化する肝内遺伝子群の検討

    大橋 知彦, 松本 英司, 石川 哲也, 奥村 明彦, 古田 恵子, 大輪 芳裕, 黒川 剛, 綾田 穣, 堀田 直樹, 佐藤 顕, 福澤 嘉孝, 野浪 敏明, 各務 伸一

    肝臓   Vol. 47 ( Suppl.2 ) page: A436 - A436   2006.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  176. RealTime 4D Ultrasound Systemを用いての肝細胞癌に対するラジオ波焼灼療法の有用性 マイクロコンベックスプローブ使用を含む

    堀田 直樹, 大橋 知彦, 松本 英司, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 大野 長行, 山下 亨, 各務 伸一

    肝臓   Vol. 47 ( Suppl.2 ) page: A455 - A455   2006.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  177. 金属沈着が示唆されたメシル酸イマチニブによる薬物性肝障害の肝組織像

    綾田 穣, 石川 哲也, 奥村 明彦, 大橋 知彦, 松本 英司, 佐藤 顕, 堀田 直樹, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 47 ( Suppl.2 ) page: A432 - A432   2006.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  178. 【治療抵抗性肝疾患へのアプローチ】治療抵抗性肝疾患の診断と治療 B型急性肝炎重症型の治療

    石川 哲也, 奥村 明彦, 各務 伸一

    Modern Physician   Vol. 26 ( 8 ) page: 1287 - 1291   2006.8

     More details

    Language:Japanese   Publisher:(株)新興医学出版社  

    researchmap

  179. 【高齢化時代を迎えた肝臓病 高齢化の実態と対策】高齢化に伴う肝疾患の病態 免疫応答の変化 肝炎の遷延,重症化

    石川 哲也, 奥村 明彦, 各務 伸一

    肝・胆・膵   Vol. 53 ( 1 ) page: 75 - 80   2006.7

     More details

    Language:Japanese   Publisher:(株)アークメディア  

    researchmap

  180. 自己免疫性肝炎患者の制御性T細胞におけるToll-like receptor(TLR)の発現プロフィールに関する検討 健常人・C型慢性肝炎患者との比較

    奥村 明彦, 石川 哲也, 伊藤 弘康, 佐藤 さやか, 山内 妙子, 大橋 知彦, 松本 英司, 佐藤 顕, 綾田 穣, 堀田 直樹, 福澤 嘉孝, 各務 伸一

    肝臓   Vol. 47 ( Suppl.1 ) page: A108 - A108   2006.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  181. 臓器相関におけるNASH,FL患者での睡眠時無呼吸症候群(SAS)の検討

    福澤 嘉孝, 木澤 仙次, 大橋 知彦, 松本 英司, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 各務 伸一

    肝臓   Vol. 47 ( Suppl.1 ) page: A267 - A267   2006.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  182. 肝疾患における非侵襲性評価 線維化のストレイン法による測定

    堀田 直樹, 大橋 知彦, 松本 英司, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 福澤 嘉孝, 村山 さやか, 井戸 誠, 各務 伸一

    肝臓   Vol. 47 ( Suppl.1 ) page: A279 - A279   2006.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  183. 潰瘍性大腸炎におけるToll-like receptor 2,4の発現と治療による変化の検討

    宮田 充樹, 佐藤 真理, 石川 哲也, 各務 伸一

    消化器と免疫   ( 42 ) page: 90 - 93   2006.4

     More details

    Language:Japanese   Publisher:日本消化器免疫学会  

    潰瘍性大腸炎(UC)におけるinnate immunityの特性と治療に対する反応を検討するため,グラム陽性菌由来のpeptidoglycanを主にリガンドとするTLR2と,グラム陰性菌細胞壁に多く存在し強い免疫刺激作用を持つlipopolysaccharideをリガンドとするTLR4の発現をRT-PCR法を用いて測定した.また,adaptive immunityとの関連を探るためTh1サイトカインであるIFNγ,Th2サイトカインであるIL-4もあわせて検討した.中等症,重症のUCで白血球除去療法を施行した8例を対象とした.TLR2は治療開始前では末梢血単核球(PBMC),粘膜固有層単核球(LPMC)とも発現が低下し,終了時は有効例のLPMCでさらなる低下傾向がみられた.TLR4の発現は治療開始前PBMCで著明に上昇したが,LPMCでは逆に低下した

    researchmap

  184. 急性肝障害におけるTNF-αの役割と由来について

    伊藤 弘康, 安藤 量基, 石川 哲也, 奥村 明彦, 各務 伸一, 森脇 久隆

    肝臓   Vol. 47 ( Suppl.1 ) page: A151 - A151   2006.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  185. 【Innate immunityと肝病態】各種肝疾患と自然免疫 肝再生と自然免疫

    石川 哲也, 奥村 明彦, 各務 伸一

    肝・胆・膵   Vol. 52 ( 4 ) page: 553 - 560   2006.4

     More details

    Language:Japanese   Publisher:(株)アークメディア  

    researchmap

  186. B型慢性肝炎の抗ウイルス療法の現状

    石川 哲也

    日本医事新報   ( 4276 ) page: 89 - 89   2006.4

     More details

    Language:Japanese   Publisher:(株)日本医事新報社  

    researchmap

  187. HCV(+)職域検診者での心血管イベントのMultiple Risk Factor Syndrome(MRFS)としての意義 肝癌・生活習慣病のSuper High Risk Groupとしての提唱

    福澤 嘉孝, 山田 晴生, 大橋 知彦, 松本 英司, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 各務 伸一

    肝臓   Vol. 47 ( Suppl.1 ) page: A165 - A165   2006.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  188. 身近に経験した小児NASHの2例

    福沢 嘉孝, 尾関 教生, 綾田 穣, 堀田 直樹, 奥村 明彦, 石川 哲也, 各務 伸一, 鶴澤 正仁, 佐賀 信介

    日本内科学会雑誌   Vol. 95 ( Suppl. ) page: 219 - 219   2006.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  189. 経鼻的細径内視鏡を用いた経皮内視鏡的胃瘻造設術の試み

    綾田 穣, 中野 達徳, 堀田 直樹, 中江 治道, 国井 伸, 吉田 香果, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 各務 伸一

    日本内科学会雑誌   Vol. 95 ( Suppl. ) page: 129 - 129   2006.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  190. 細径内視鏡を用いた経胃瘻的空腸瘻の有用性

    堀田 直樹, 綾田 穣, 松本 英司, 佐藤 顕, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 各務 伸一

    日本内科学会雑誌   Vol. 95 ( Suppl. ) page: 129 - 129   2006.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  191. 肝臓 B型肝炎 ウイルス・病態・診断

    各務 伸一, 石川 哲也, 奥村 明彦

    Annual Review消化器   Vol. 2006   page: 253 - 257   2006.1

     More details

    Language:Japanese   Publisher:(株)中外医学社  

    researchmap

  192. 重篤な皮膚症状を合併した薬物性肝障害の4例

    綾田 穣, 石川 哲也, 奥村 明彦, 大橋 知彦, 松本 英司, 佐藤 顕, 堀田 直樹, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 46 ( Suppl.3 ) page: A558 - A558   2005.11

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  193. 肝細胞癌治療後の分岐鎖アミノ酸製剤を用いたlate evening snack(LES)の有用性

    松本 英司, 堀田 直樹, 大橋 知彦, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 46 ( Suppl.3 ) page: A599 - A599   2005.11

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  194. B型慢性肝疾患患者に対するアデフォビルの使用経験-その適応,効果,副作用について

    大橋 知彦, 石川 哲也, 松本 英司, 佐藤 顕, 綾田 穣, 堀田 直樹, 奥村 明彦, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 46 ( Suppl.3 ) page: A572 - A572   2005.11

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  195. NKT細胞活性化によるHBV特異的CTL誘導の増強効果を利用したキャリアマウスにおけるtolerance breakの試み

    伊藤 弘康, 安藤 量基, 石川 哲也, 中山 俊憲, 谷口 克, 井廻 道夫, 森脇 久隆, 各務 伸一, 横地 高志

    日本免疫学会総会・学術集会記録   Vol. 35   page: 105 - 105   2005.11

     More details

    Language:Japanese   Publisher:(NPO)日本免疫学会  

    researchmap

  196. 【ウイルス肝炎からの発癌とその予防】発癌とその背景 血中SHAP-HA複合体の肝癌を含む肝疾患の病態との関連

    各務 伸一, 奥村 明彦, 石川 哲也, 木全 弘治

    犬山シンポジウム   Vol. 25回   page: 71 - 76   2005.10

     More details

    Language:Japanese   Publisher:(株)メディカルトリビューン  

    C型慢性肝疾患275例(肝炎101例,肝硬変105例,肝癌69例),B型慢性肝疾患117例(肝炎46例,肝硬変47例,肝癌24例),健常人27例について血中のSHAP(serum-derived hyaluronan associated protein)-HA(hyaluronic acid)とHAを測定し,病態との関連を詳細に検討した.C型,B型とも肝疾患群のSHAP-HA濃度,HA濃度は病変の進行とともに有意に上昇した.C型,B型ともSHAP-HA濃度とHA濃度は有意な相関を示し,C型における相関係数は肝癌群が最も高く肝炎群が最も低かった.HA/SHAP-HA濃度と血液生化学検査値との関連を調べると,C型,B型とも肝炎群と肝硬変群は血中アルブミン濃度,血小板数と有意な相関を示し,血清トランスアミナーゼ値とは相関を示さなかった.C型,B型とも肝癌群においてSHAP-HA濃度は血中αフェトプロテイン値と有意な相関を示したが,HA濃度はαフェトプロテイン値と相関を示さなかった

    researchmap

  197. Impaired regulatory T cell functions in the patients with autoimmune hepatitis

    A Okumura, T Ishikawa, H Ito, S Sato, T Yamauchi, K Sato, M Ayada, N Hotta, E Matsumoto, T Ohashi, Y Fukuzawa, S Kakumu

    HEPATOLOGY   Vol. 42 ( 4 ) page: 289A - 289A   2005.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:JOHN WILEY & SONS INC  

    Web of Science

    researchmap

  198. 肝硬変患者の難治性腹水に対するdocarpamineの有効性と安全性

    綾田 穣, 石川 哲也, 奥村 明彦, 堀田 直樹, 恒川 明久, 大橋 知彦, 松本 英司, 佐藤 顕, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 46 ( Suppl.2 ) page: A437 - A437   2005.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  199. 慢性肝疾患の線維化評価 ストレインレート法の検討

    堀田 直樹, 松本 英司, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 村山 さやか, 各務 伸一

    肝臓   Vol. 46 ( Suppl.2 ) page: A438 - A438   2005.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  200. B型急性肝炎例におけるジェノタイプと臨床像との関連について

    佐藤 顕, 奥村 明彦, 大橋 知彦, 松本 英司, 綾田 穣, 堀田 直樹, 石川 哲也, 福沢 嘉孝, 各務 伸一, 田中 靖人, 溝上 雅史

    肝臓   Vol. 46 ( Suppl.2 ) page: A439 - A439   2005.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  201. 「いわゆる健康食品」による肝障害の実態について 全国調査集計結果をもとに

    石川 哲也, 各務 伸一

    Minophagen Medical Review   Vol. 50 ( 5 ) page: 283 - 291   2005.9

     More details

    Language:Japanese   Publisher:(株)ミノファーゲン製薬  

    「いわゆる健康食品」による肝障害について行った全国アンケート調査をもとに,その実態と問題点について検討した.総回答数は235件,「いわゆる健康食品」による肝障害と考えられた事例は165例報告された.原因と疑われる健康食品がある程度明らかであった事例は131例であった.このうち36例はニトロソフェンフルラミンなどの成分が含有されることが明らかにされた中国製やせ薬などの無承認無許可医薬品によるもので,健康食品として位置付けられるものが原因とされた事例は,実際には95例であった.健康食品の品目別では,ウコンの含まれる食品が36例と最も多く,原因と考えられた健康食品は30品目以上であった.二次調査では,59例の報告が得られ,このうち,「いわゆる健康食品」が原因と考えられるものは34例で,無承認無許可医薬品が原因と考えられるものが21例,不明・その他が4例であった

    researchmap

  202. B型肝炎ウイルス特異的CTL誘導におけるNKT細胞の役割

    伊藤 弘康, 安藤 量基, 石川 哲也, 井廻 道夫, 森脇 久隆, 各務 伸一, 横地 高志

    日本臨床分子医学会学術総会プログラム・抄録集   Vol. 42回   page: 121 - 121   2005.7

     More details

    Language:Japanese   Publisher:日本臨床分子医学会  

    researchmap

  203. 血漿アミノ酸濃度を用いた新しい肝線維化ステージ診断法の開発

    奥村 明彦, 石川 哲也, 木村 毅, 野口 泰志, 大橋 知彦, 松本 英司, 前野 禎, 佐藤 顕, 綾田 穣, 堀田 直樹, 福澤 嘉孝, 各務 伸一

    肝臓   Vol. 46 ( Suppl.1 ) page: A291 - A291   2005.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  204. 自己免疫性肝炎の病態における制御性T細胞の役割

    奥村 明彦, 石川 哲也, 伊藤 弘康, 佐藤 さやか, 山内 妙子, 松本 英司, 佐藤 顕, 綾田 穣, 堀田 直樹, 福澤 嘉孝, 各務 伸一

    肝臓   Vol. 46 ( Suppl.1 ) page: A170 - A170   2005.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  205. 脂肪肝発症確率の予測モデルを用いたメタボリック症候群の危険因子出現予測

    福澤 嘉孝, 山田 晴生, 綾田 穣, 堀田 直樹, 大橋 知彦, 松本 英司, 佐藤 顕, 前野 禎, 奥村 明彦, 石川 哲也, 各務 伸一

    肝臓   Vol. 46 ( Suppl.1 ) page: A237 - A237   2005.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  206. 肝免疫の新しい展開 HBs抗原中のCTLエピトープ改変による治療用ペプタイド構築の試み

    石川 哲也, 各務 伸一, Chisari Francis V.

    消化器と免疫   ( 41 ) page: 40 - 43   2005.5

     More details

    Language:Japanese   Publisher:日本消化器免疫学会  

    HBs抗原を肝細胞で発現するトランスジェニックマウス(H-2d)には,HBs抗原の28〜39番目のアミノ酸からなるペプタイドをエピトープとしてLd拘束性に認識する細胞障害性Tリンパ球(CTL)が存在する.今回このCTLエピトープ中の様々な部位にアミノ酸置換などの改変を加え,Ld結合能や,CTLによる認識効率がどのように変化するか検討した.結果,T細胞レセプター認識部位の改変ではLd結合能を維持し,かつCTL認識効率が低下することが多かった.他部位の改変ではLd結合能,CTL認識効率とも増強されることがあった.アンタゴニストあるいはワクチンとして機能する可能性のある改変ペプタイドの存在が示唆された

    researchmap

  207. 皮膚症状からみた薬物性肝障害

    綾田 穣, 石川 哲也, 奥村 明彦, 松本 英司, 佐藤 顕, 堀田 直樹, 福沢 嘉孝, 玉田 康彦, 松本 義也, 各務 伸一

    肝臓   Vol. 46 ( Suppl.1 ) page: A244 - A244   2005.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  208. 潰瘍性大腸炎に対する白血球系細胞除去療法の有用性の検討

    宮田 充樹, 石川 哲也, 各務 伸一

    消化器と免疫   ( 41 ) page: 98 - 101   2005.5

     More details

    Language:Japanese   Publisher:日本消化器免疫学会  

    白血球系細胞除去療法の有用性を効果機序の面から検討した.中等症以上の潰瘍性大腸炎15例に対して,顆粒球吸着療法(GCAP),白血球除去療法(LCAP),遠心分離式単核球除去療法(MCAP)を各5例ずつ施行し,治療前後の患者血液および治療中脱血側と返血側で採取した血液を検体として全血球,リンパ球サブセット,各種サイトカイン,ケモカインを測定した.結果,GCAP群とLCAP群では治療終了直後に好中球数が上昇する傾向にあり,CD4+ T細胞数の選択的減少と炎症性サイトカインの上昇を伴っていた.このことから,潰瘍性大腸炎に対する白血球系細胞除去療法ではMCAPが最も有効であると考えられた

    researchmap

  209. ウイルス肝炎治療戦略の今後の展望 B型慢性肝疾患患者に対するラミブジンとHBワクチンの併用療法の効果について

    石川 哲也, 奥村 明彦, 各務 伸一

    肝臓   Vol. 46 ( Suppl.1 ) page: A28 - A28   2005.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  210. B型肝炎ウイルス特異的細胞障害性T細胞誘導におけるNKT細胞の役割

    伊藤 弘康, 安藤 量基, 石川 哲也, 井廻 道夫, 森脇 久隆, 各務 伸一

    肝臓   Vol. 46 ( Suppl.1 ) page: A84 - A84   2005.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  211. Vitamin K2投与における肝細胞癌再発抑制効果についての検討

    堀田 直樹, 松本 英司, 前野 禎, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 46 ( Suppl.1 ) page: A249 - A249   2005.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  212. C型慢性肝疾患におけるToll-like receptor(TLR)の関与

    松本 英司, 奥村 明彦, 伊藤 弘康, 大橋 知彦, 佐藤 顕, 前野 禎, 綾田 穣, 山内 妙子, 佐藤 さやか, 堀田 直樹, 福澤 嘉孝, 石川 哲也, 各務 伸一

    肝臓   Vol. 46 ( Suppl.1 ) page: A176 - A176   2005.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  213. Coded Harmonic Angio Accumulation mode用いての肝腫瘍の血流診断

    堀田 直樹, 松本 英司, 前野 禎, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 大村 一巨, 大野 長行, 各務 伸一

    肝臓   Vol. 46 ( Suppl.1 ) page: A273 - A273   2005.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  214. 噴門部胃・食道微小出血性病変に対する内視鏡的結紮術の有用性

    綾田 穣, 堀田 直樹, 石川 哲也, 奥村 明彦, 大橋 知彦, 松本 英司, 前野 禎, 佐藤 顕, 福沢 嘉孝, 各務 伸一

    Gastroenterological Endoscopy   Vol. 47 ( Suppl.1 ) page: 828 - 828   2005.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  215. 薬物性肝障害の診断における肝生検の位置づけ

    綾田 穣, 石川 哲也, 奥村 明彦, 大橋 知彦, 松本 英司, 前野 禎, 佐藤 顕, 堀田 直樹, 福沢 嘉孝, 各務 伸一

    日本消化器病学会雑誌   Vol. 102 ( 臨増総会 ) page: A348 - A348   2005.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  216. 脂肪肝およびNASH患者に対する肥満の影響(メタボリック症候群との関連)

    福沢 嘉孝, 木澤 仙次, 綾田 穣, 堀田 直樹, 大橋 知彦, 松本 英司, 佐藤 顕, 前野 禎, 奥村 明彦, 石川 哲也, 各務 伸一

    日本消化器病学会雑誌   Vol. 102 ( 臨増総会 ) page: A215 - A215   2005.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  217. 【肝臓の臨床最前線】肝疾患の病態と対策 B型肝炎の発症機序とHBV持続感染

    石川 哲也, 各務 伸一

    綜合臨床   Vol. 54 ( 3 ) page: 533 - 540   2005.3

     More details

    Language:Japanese   Publisher:(株)永井書店  

    researchmap

  218. C型慢性肝炎における柴胡桂枝湯の有用性に関する検討

    福沢 嘉孝, 綾田 穣, 堀田 直樹, 大橋 知彦, 松本 英司, 佐藤 顕, 前野 禎, 奥村 明彦, 石川 哲也, 各務 伸一

    日本消化器病学会雑誌   Vol. 102 ( 臨増総会 ) page: A195 - A195   2005.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  219. RVT-382BT使用におけるラジオ波焼灼療法の有用性

    堀田 直樹, 綾田 穣, 佐藤 顕, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 中江 治道, 一宮 洋, 村瀬 賢一, 高橋 忍, 各務 伸一

    超音波医学   Vol. 32 ( 2 ) page: 228 - 228   2005.3

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    researchmap

  220. PVT382-BTを用いてのHCCに対してのRFA経験 ApliPuretm臨床応用も含め

    堀田 直樹, 綾田 穣, 佐藤 顕, 大橋 知彦, 松本 英司, 前野 禎, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 高橋 忍, 各務 伸一

    日本消化器病学会雑誌   Vol. 102 ( 臨増総会 ) page: A291 - A291   2005.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  221. C型慢性肝炎患者におけるHelicobacter pylori感染とその意義

    佐藤 顕, 大橋 知彦, 松本 英司, 前野 禎, 綾田 穣, 等々力 勇三, 堀田 直樹, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 各務 伸一

    日本消化器病学会雑誌   Vol. 102 ( 臨増総会 ) page: A183 - A183   2005.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  222. 肝硬変患者における難治性腹水貯留に対する,ドカルパミンの有用性

    綾田 穣, 堀田 直樹, 石川 哲也, 奥村 明彦, 大橋 知彦, 松本 英司, 前野 禎, 佐藤 顕, 福沢 嘉孝, 各務 伸一

    日本内科学会雑誌   Vol. 94 ( Suppl. ) page: 172 - 172   2005.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  223. クラスターニードル使用におけるラジオ波焼灼療法の有用性

    堀田 直樹, 綾田 穣, 佐藤 顕, 大橋 和彦, 松本 英司, 前野 禎, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 各務 伸一

    日本内科学会雑誌   Vol. 94 ( Suppl. ) page: 122 - 122   2005.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  224. 【劇症肝炎の病態と治療】発症に関与する炎症メディエータと抗サイトカイン療法

    石川 哲也, 各務 伸一

    ICUとCCU   Vol. 29 ( 2 ) page: 93 - 101   2005.2

     More details

    Language:Japanese   Publisher:医学図書出版(株)  

    劇症肝炎における炎症の進展,広汎肝壊死の成立には,免疫の過剰応答が関わっていると考えられる.そして,免疫担当細胞の直接の肝細胞障害性のみではなく,それらから産生される液性因子,サイトカインなどの炎症メディエータが,劇症肝炎における炎症進展,広汎肝壊死の成立に深く関与することが示唆されている.B型肝炎ウイルストランスジェニックマウスを用いた劇症肝炎モデル,P.acnes+LPS投与による劇症肝炎モデル,どちらにおいてもTNF-α,IFN-γなどのサイトカインの過剰発現がみられており,これらが共通の機構として劇症化に関わっている可能性が示唆される.また,劇症肝炎の臨床例における検討の多くで,これらのサイトカインの肝臓での発現や血清レベルの上昇が報告されている.TNF-α,IFN-γなどを標的とした抗サイトカイン療法は有力な治療法となる可能性が期待されるが,まだ臨床応用はされておらず,今後の研究の進展が期待される(著者抄録)

    researchmap

  225. 肝臓 B型肝炎 ウイルス,病態,診断

    各務 伸一, 石川 哲也, 奥村 明彦

    Annual Review消化器   Vol. 2005   page: 263 - 266   2005.1

     More details

    Language:Japanese   Publisher:(株)中外医学社  

    researchmap

  226. 薬物性肝障害の実態と今後の課題 いわゆる健康食品による肝障害の実態について 全国調査集計結果

    石川 哲也, 各務 伸一

    肝臓   Vol. 45 ( Suppl.3 ) page: A541 - A541   2004.11

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  227. ウイルス・特殊菌に対する血液浄化法 慢性C型肝炎症例に対するウイルス減量療法併用インターフェロン治療の検討

    佐藤 顕, 宮田 充樹, 石川 哲也, 奥村 明彦, 福沢 嘉孝, 各務 伸一, 西川 和裕

    エンドトキシン血症救命治療研究会誌   Vol. 8 ( 1 ) page: 197 - 197   2004.11

     More details

    Language:Japanese   Publisher:(株)自然科学社  

    researchmap

  228. HBs transgenic/TNF-α knockout mouseを用いた急性肝障害の検討

    伊藤 弘康, 安藤 量基, 石川 哲也, 奥村 明彦, 各務 伸一, 斉藤 邦明, 森脇 久隆, 横地 高志

    日本免疫学会総会・学術集会記録   Vol. 34   page: 186 - 186   2004.11

     More details

    Language:Japanese   Publisher:(NPO)日本免疫学会  

    researchmap

  229. 【病診連携における最新ウイルス肝炎の診療】B型肝炎について知っておくべき事

    石川 哲也, 各務 伸一

    診断と治療   Vol. 92 ( 10 ) page: 1823 - 1829   2004.10

     More details

    Language:Japanese   Publisher:(株)診断と治療社  

    researchmap

  230. DFPPによるウイルス除去療法 DFPPによるC型肝炎ウイルス減量療法の効果

    西川 和裕, 宮田 充樹, 奥村 明彦, 石川 哲也, 各務 伸一

    日本アフェレシス学会雑誌   Vol. 23 ( 3 ) page: 289 - 290   2004.10

     More details

    Language:Japanese   Publisher:(一社)日本アフェレシス学会  

    researchmap

  231. 肝炎進展過程にHBV関連抗原が与える影響の関する解析

    佐藤 顕, 石川 哲也, 田邊 純一, 大橋 知彦, 松本 英司, 前野 禎, 綾田 穣, 堀田 直樹, 奥村 明彦, 福沢 義孝, 各務 伸一

    肝臓   Vol. 45 ( Suppl.2 ) page: A482 - A482   2004.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  232. 当科における大型肝細胞癌に対するラジオ波焼灼療法

    堀田 直樹, 福沢 嘉孝, 松本 英司, 前野 禎, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 各務 伸一

    日本消化器病学会雑誌   Vol. 101 ( 臨増大会 ) page: A824 - A824   2004.9

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  233. 噴門部直下出血性胃潰瘍病変に対する内視鏡的結紮術の有用性

    綾田 穣, 堀田 直樹, 福沢 嘉孝, 松本 英司, 前野 禎, 佐藤 顕, 奥村 明彦, 石川 哲也, 各務 伸一

    Gastroenterological Endoscopy   Vol. 46 ( Suppl.2 ) page: 1911 - 1911   2004.9

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  234. B型肝炎ウイルス(HBV)持続感染者の血清中に存在するHBV関連細胞障害性液性因子の検討

    奥村 明彦, 石川 哲也, 大橋 知彦, 前野 禎, 松本 英司, 佐藤 顕, 綾田 穣, 堀田 直樹, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 45 ( Suppl.2 ) page: A451 - A451   2004.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  235. 非肥満NASHに関する病態解析

    福沢 嘉孝, 木澤 仙次, 堀田 直樹, 綾田 穣, 大橋 知彦, 松本 英司, 佐藤 顕, 前野 禎, 奥村 明彦, 石川 哲也, 各務 伸一

    肝臓   Vol. 45 ( Suppl.2 ) page: A519 - A519   2004.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  236. HCCに対しての4D real-time Ultrasoundを用いてのRFAの有用性

    堀田 直樹, 福沢 嘉孝, 松本 英司, 前野 禎, 佐藤 顕, 綾田 穣, 奥村 明彦, 石川 哲也, 各務 伸一

    日本消化器集団検診学会雑誌   Vol. 42 ( 5 ) page: 136 - 136   2004.9

     More details

    Language:Japanese   Publisher:(一社)日本消化器がん検診学会  

    researchmap

  237. 【ウイルス性肝炎 基礎・臨床研究の進歩】B型肝炎ウイルス(HBV) B型慢性肝炎 治療法の最新動向 ラミブジンとHBワクチン併用療法の効果と問題点

    石川 哲也, 各務 伸一

    日本臨床   Vol. 62 ( 増刊8 ウイルス性肝炎(下) ) page: 331 - 335   2004.8

     More details

    Language:Japanese   Publisher:(株)日本臨床社  

    researchmap

  238. 【肝細胞癌治療法の新しい展開】インターフェロン療法

    奥村 明彦, 石川 哲也, 各務 伸一

    Mebio   Vol. 21 ( 7 ) page: 14 - 21   2004.7

     More details

    Language:Japanese   Publisher:(株)メジカルビュー社  

    researchmap

  239. 【肝疾患:病態,治療の最新の知見 コンセンサスに向けて】B型慢性肝炎

    石川 哲也

    現代医学   Vol. 52 ( 1 ) page: 9 - 17   2004.7

     More details

    Language:Japanese   Publisher:(公社)愛知県医師会  

    researchmap

  240. アフェレシスによるC型肝炎ウイルス減量療法

    西川 和裕, 宮田 充樹, 奥村 明彦, 石川 哲也, 北川 渡, 三浦 直人, 青木 隆成, 楊 朝隆, 山田 晴生, 佐久間 正人, 普天間 新生, 今井 裕一, 各務 伸一

    日本透析医学会雑誌   Vol. 37 ( Suppl.1 ) page: 912 - 912   2004.5

     More details

    Language:Japanese   Publisher:(一社)日本透析医学会  

    researchmap

  241. 肥満合併脂肪肝に対する防風通整散(TJ-62)の有用性に関する検討

    福沢 嘉孝, 綾田 穣, 堀田 直樹, 松本 英司, 前野 禎, 佐藤 顕, 奥村 明彦, 石川 哲也, 各務 伸一

    肝臓   Vol. 45 ( Suppl.1 ) page: A317 - A317   2004.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  242. 耐糖能異常合併脂肪肝患者の病態に関する検討

    福沢 嘉孝, 堀田 直樹, 綾田 穣, 松本 英司, 前野 禎, 佐藤 顕, 奥村 明彦, 石川 哲也, 各務 伸一

    肝臓   Vol. 45 ( Suppl.1 ) page: A312 - A312   2004.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  243. 内視鏡的結紮術が有用であった,出血性小腸angiodysplasiaの一例

    綾田 穣, 堀田 直樹, 福沢 嘉孝, 佐藤 顕, 前野 禎, 多賀谷 恒明, 奥村 明彦, 石川 哲也, 各務 伸一

    Gastroenterological Endoscopy   Vol. 46 ( Suppl.1 ) page: 715 - 715   2004.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  244. 人間ドック受健者における脂肪肝の実態

    福澤 嘉孝, 山田 晴生, 堀田 直樹, 綾田 穣, 前野 禎, 松本 英司, 佐藤 顕, 奥村 明彦, 石川 哲也, 各務 伸一

    肝臓   Vol. 45 ( Suppl.1 ) page: A314 - A314   2004.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  245. マウスモデルを用いた自己免疫性肝炎の病態の解析

    佐藤 顕, 奥村 明彦, 石川 哲也, 松本 英司, 前野 禎, 綾田 穣, 堀田 直樹, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 45 ( Suppl.1 ) page: A306 - A306   2004.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  246. C型慢性肝疾患におけるNKT細胞の意義

    前野 禎, 奥村 明彦, 石川 哲也, 佐藤 顕, 綾田 穣, 堀田 直樹, 松本 英司, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 45 ( Suppl.1 ) page: A264 - A264   2004.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  247. 肝細胞癌に対しての4D real-time Ultrasoundを用いてのラジオ波焼灼療法の経験

    堀田 直樹, 福沢 嘉孝, 佐藤 顕, 前野 禎, 綾田 穣, 奥村 明彦, 石川 哲也, 伊藤 優子, 小崎 正博, 各務 伸一

    日本消化器病学会雑誌   Vol. 101 ( 臨増総会 ) page: A212 - A212   2004.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  248. 外来の高齢C型肝硬変(LC)患者での栄養アセスメントと栄養療法 栄養は高齢者QOL向上の最も安全な活力源

    福沢 嘉孝, 綾田 穣, 堀田 直樹, 佐藤 顕, 前野 禎, 多賀谷 恒明, 奥村 明彦, 石川 哲也, 各務 伸一, 加藤 勝久

    日本消化器病学会雑誌   Vol. 101 ( 臨増総会 ) page: A206 - A206   2004.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  249. セクタ型Active Matrix Array Probe使用における肝腫瘍の血流診断の有用性

    佐藤 顕, 堀田 直樹, 福沢 嘉孝, 前野 禎, 綾田 穣, 奥村 明彦, 石川 哲也, 大野 長行, 各務 伸一

    日本消化器病学会雑誌   Vol. 101 ( 臨増総会 ) page: A211 - A211   2004.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  250. ウイルス肝炎の新しい治療戦略 B型慢性肝炎に対するラミブジンとHBワクチンの併用療法

    石川 哲也, 奥村 明彦, 各務 伸一

    日本消化器病学会雑誌   Vol. 101 ( 臨増総会 ) page: A40 - A40   2004.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  251. 高脂血症患者におけるNASHの実態 酸化ストレス(OS)の関連も含めて

    福沢 嘉孝, 尾関 教生, 堀田 直樹, 綾田 穣, 佐藤 顕, 前野 禎, 多賀谷 恒明, 奥村 明彦, 石川 哲也, 各務 伸一

    日本消化器病学会雑誌   Vol. 101 ( 臨増総会 ) page: A359 - A359   2004.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  252. 最近2年間の当院における薬物性肝障害の現状

    綾田 穣, 奥村 明彦, 石川 哲也, 前野 禎, 佐藤 顕, 堀田 直樹, 多賀谷 恒明, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 44 ( Suppl.3 ) page: A618 - A618   2003.10

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  253. 慢性C型肝炎症例に対するウィルス減量療法併用インターフェロン治療の検討

    宮田 充樹, 石川 哲也, 奥村 明彦, 前野 偵, 佐藤 顕, 綾田 穣, 堀田 直樹, 多賀谷 恒明, 福澤 嘉孝, 各務 伸一

    肝臓   Vol. 44 ( Suppl.3 ) page: A577 - A577   2003.10

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  254. Nemioにおける肝腫瘍の血流診断の有用性

    堀田 直樹, 前野 禎, 佐藤 顕, 綾田 穣, 多賀谷 恒明, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 丹羽 幸佳, 清水 亮彦, 高橋 忍, 各務 伸一

    肝臓   Vol. 44 ( Suppl.3 ) page: A596 - A596   2003.10

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  255. 肝腫瘍の血流診断におけるCoded Harmonic Angio(CHA)の有用性

    堀田 直樹, 綾田 穣, 前野 禎, 佐藤 顕, 多賀谷 恒明, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 44 ( Suppl.2 ) page: A395 - A395   2003.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  256. 潰瘍性大腸炎に対する単核球除去療法の有効性の検討 吸着系白血球除去療法との比較検討

    宮田 充樹, 高橋 邦之, 佐藤 真理, 筒井 茂, 等々力 勇三, 橋本 貴至, 春日井 邦夫, 石川 哲也, 福澤 嘉孝, 各務 伸一

    日本消化器病学会雑誌   Vol. 100 ( 臨増大会 ) page: A687 - A687   2003.9

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  257. 慢性C型肝炎患者に対するIFN・リバビリン治療中の血中アミノ酸の変化とTh1/Th2バランスの解析

    奥村 明彦, 石川 哲也, 綾田 穣, 佐藤 顕, 前野 禎, 堀田 直樹, 多賀谷 恒明, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 44 ( Suppl.2 ) page: A433 - A433   2003.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  258. 慢性肝疾患患者における血清SHAP-HA濃度 肝細胞癌のマーカーとしての有用性の検討

    申 力, 卓 麗聖, 奥村 明彦, 石川 哲也, 各務 伸一, 木全 弘治

    日本分子腫瘍マーカー研究会プログラム・講演抄録   Vol. 23回   page: 80 - 81   2003.9

     More details

    Language:Japanese   Publisher:日本分子腫瘍マーカー研究会  

    researchmap

  259. 外来診療におけるC型肝硬変患者の栄養アセスメント(NSTへの予備的検討)

    福沢 嘉孝, 綾田 穣, 佐藤 顕, 前野 禎, 堀田 直樹, 多賀谷 恒明, 奥村 明彦, 石川 哲也, 各務 伸一, 加藤 勝久

    肝臓   Vol. 44 ( Suppl.2 ) page: A418 - A418   2003.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  260. C型慢性肝炎における血清レプチン値とBMIの意義についての検討

    前野 禎, 奥村 明彦, 石川 哲也, 佐藤 顕, 綾田 穣, 堀田 直樹, 多賀谷 恒明, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 44 ( Suppl.2 ) page: A464 - A464   2003.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  261. 【ウイルス肝炎の治療はどのように変わったか】B型肝炎の治療 慢性肝炎,肝硬変の治療 ワクチン治療

    石川 哲也, 各務 伸一

    消化器病セミナー   Vol. 91   page: 57 - 69   2003.6

     More details

    Language:Japanese   Publisher:(株)へるす出版  

    researchmap

  262. B型慢性肝炎に対するラミブジンとHBワクチンの併用療法

    石川 哲也, 奥村 明彦, 前野 禎, 佐藤 顕, 綾田 穣, 堀田 直樹, 多賀谷 恒明, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 44 ( Suppl.1 ) page: A39 - A39   2003.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  263. Coded Harmonic Angio(CHA)での肝細胞癌の描出能 LOGIQ9における検討

    堀田 直樹, 佐藤 顕, 前野 禎, 綾田 穣, 多賀谷 恒明, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 44 ( Suppl.1 ) page: A252 - A252   2003.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  264. The diagnosis and therapeutic efficacy of contrast enhancement advanced dynamic flow imaging for liver tumors

    N Hotta, A Okumura, K Sato, T Tagaya, T Ishikawa, S Kakumu

    GASTROENTEROLOGY   Vol. 124 ( 4 ) page: A568 - A568   2003.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:W B SAUNDERS CO  

    Web of Science

    researchmap

  265. LOGIQ9における肝腫瘍の描出能の検討

    堀田 直樹, 綾田 穣, 佐藤 顕, 前野 禎, 多賀谷 恒明, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 伊藤 優子, 小崎 正博, 各務 伸一

    超音波医学   Vol. 30 ( Suppl. ) page: S367 - S367   2003.4

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    researchmap

  266. HBVトランスジェニックマウスにおけるP.acnes+LPS肝炎の炎症進展形式の気析

    佐藤 顕, 石川 哲也, 田邊 純一, 奥村 明彦, 前野 禎, 綾田 穣, 堀田 直樹, 多賀谷 恒明, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 44 ( Suppl.1 ) page: A182 - A182   2003.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  267. レチノイドが抗原特異的細胞傷害性T細胞(CTL)の活性化に及ぼす影響について

    奥村 明彦, 石川 哲也, 綾田 穣, 佐藤 顕, 前野 禎, 堀田 直樹, 多賀谷 恒明, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 44 ( Suppl.1 ) page: A228 - A228   2003.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  268. 【急性肝不全】サイトカインと広汎肝壊死

    石川 哲也, 各務 伸一

    BIO Clinica   Vol. 18 ( 3 ) page: 207 - 212   2003.3

     More details

    Language:Japanese   Publisher:(株)北隆館  

    researchmap

  269. C型慢性肝炎に対するグルタミン併用インターフェロン療法の試み

    奥村 明彦, 石川 哲也, 前野 禎, 佐藤 顕, 綾田 穣, 堀田 直樹, 多賀谷 恒明, 福沢 嘉孝, 各務 伸一

    日本消化器病学会雑誌   Vol. 100 ( 臨増総会 ) page: A311 - A311   2003.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  270. 肝腫瘍の血流評価におけるExtended Pure Harmonic Detectionの有用性

    綾田 穣, 堀田 直樹, 佐藤 顕, 前野 禎, 多賀谷 恒明, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 各務 伸一

    日本内科学会雑誌   Vol. 92 ( Suppl. ) page: 101 - 101   2003.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  271. 【肝臓と免疫】各種肝疾患と免疫 B型肝炎 急性肝炎

    石川 哲也

    肝・胆・膵   Vol. 45 ( 5 ) page: 787 - 795   2002.11

     More details

    Language:Japanese   Publisher:(株)アークメディア  

    researchmap

  272. 慢性肝疾患患者における血清SHAP-HA濃度の検討

    奥村 明彦, 申 力, 卓 麗聖, 石川 哲也, 各務 伸一, 木全 弘治

    生化学   Vol. 74 ( 11 ) page: 1391 - 1391   2002.11

     More details

    Language:Japanese   Publisher:(公社)日本生化学会  

    researchmap

  273. 【B型・C型肝炎治療の新たな展開】B型肝炎の治療 IFN長期投与,その他の治療(Thymosinα-1,HBワクチン,その他) B型慢性肝炎におけるラミブジンとワクチンの併用療法

    各務 伸一, 石川 哲也

    犬山シンポジウム   Vol. 23回   page: 144 - 150   2002.10

     More details

    Language:Japanese   Publisher:(株)メディカルトリビューン  

    B型慢性肝炎75例をラミブジン単独投与群37例とHBs抗原ワクチン併用群38例の2群にランダムに分け,その治療成績を比較した.ワクチン併用群の方がalanine aminotransferase値,HBe抗原量の低下幅が大きく,HBV-DNA陰性化率も高かった

    researchmap

  274. 慢性肝疾患患者における血清SHAP-HA濃度の検討

    堀田 直樹, 申 力, 奥村 明彦, 卓 麗聖, 前野 禎, 佐藤 顕, 綾田 穣, 多賀谷 恒明, 石川 哲也, 福沢 嘉孝, 各務 伸一, 木全 弘治

    肝臓   Vol. 43 ( Suppl.2 ) page: A371 - A371   2002.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  275. B型慢性肝疾患患者におけるHBc抗原領域のエピトープ解析

    石川 哲也, 田邊 純一, 奥村 明彦, 前野 禎, 佐藤 顕, 綾田 穣, 山本 賢一, 堀田 直樹, 多賀谷 恒明, 福沢 嘉孝, 各務 伸一

    Minophagen Medical Review   Vol. 47 ( 4 ) page: 196 - 200   2002.7

     More details

    Language:Japanese   Publisher:(株)ミノファーゲン製薬  

    B型慢性肝炎患者において主要な標的抗原と思われるHBc抗原領域におけるエピトーブ解析を行った.又,flow cytometryを用いて細胞内cytokineを測定し,同時に免疫応答の質的な評価が可能かどうかについても解析した.B型慢性肝炎患者24例を対象とした.P15刺激では11例中4例,P19刺激では11例中8例に何らかのcytokine/chemokine産生が誘導,増強された.P19刺激では,多くの患者で同時に複数のcytokine/chemokine産生が誘導され,同部がエピトープとなっていることが強く示唆された.flow cytometryを用いて細胞内サイトカインを検出する方法はエピトープ部位のスクリーニングに有用であることが示唆された

    researchmap

  276. 超音波造影剤を用いたラジオ波焼灼療法の治療効果判定

    堀田 直樹, 佐藤 顕, 前野 禎, 綾田 穣, 多賀谷 恒明, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 廣海 玄勝, 高橋 忍

    超音波医学   Vol. 29 ( Suppl. ) page: S511 - S511   2002.5

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    researchmap

  277. 自己免疫性肝炎のマウスモデル作製と免疫学的発症機序の解析

    佐藤 顕, 石川 哲也, 奥村 明彦, 田邊 純一, 前野 禎, 綾田 穣, 堀田 直樹, 多賀谷 恒明, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 43 ( Suppl.1 ) page: A75 - A75   2002.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  278. 超音波造影剤を用いたラジオ波焼灼療法の治療効果判定 Dynamic Flowでの検討(ハーモニックガイド下穿刺の応用も含め)

    堀田 直樹, 多賀谷 恒明, 佐藤 顕, 前野 禎, 綾田 穣, 奥村 明彦, 石川 哲也, 福沢 嘉孝, 林 起久子, 各務 伸一

    日本消化器病学会雑誌   Vol. 99 ( 臨増総会 ) page: A194 - A194   2002.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  279. 医療従事者における肝不全用経口アミノ酸・ゼリー製剤に関する調査

    今泉 佐知子, 武藤 達也, 石川 哲也, 福沢 嘉孝, 小池 三奈美, 工藤 すみ, 岡田 啓

    日本薬学会年会要旨集   Vol. 122年会 ( 4 ) page: 143 - 143   2002.3

     More details

    Language:Japanese   Publisher:(公社)日本薬学会  

    researchmap

  280. ケモカインの消化器疾患での役割 肝細胞のケモカイン産生が肝炎の病態に与える影響について

    石川 哲也, 田邊 純一, 各務 伸一

    日本消化器病学会雑誌   Vol. 99 ( 臨増総会 ) page: A74 - A74   2002.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  281. B型肝炎患者の末梢血リンパ球に対するレチノイドの影響

    綾田 穣, 奥村 明彦, 石川 哲也, 前野 禎, 佐藤 顕, 堀田 直樹, 多賀谷 恒明, 福沢 嘉孝, 各務 伸一

    日本消化器病学会雑誌   Vol. 99 ( 臨増総会 ) page: A116 - A116   2002.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  282. 生理と病態 肝と免疫

    各務 伸一, 奥村 明彦, 石川 哲也

    Annual Review消化器   Vol. 2002   page: 119 - 124   2002.1

     More details

    Language:Japanese   Publisher:(株)中外医学社  

    researchmap

  283. 【C型肝炎 現状と今後の展開】HCV感染の病態 HCV感染者の肝細胞障害機序

    各務 伸一, 奥村 明彦, 石川 哲也

    臨床医   Vol. 28 ( 1 ) page: 31 - 33   2002.1

     More details

    Language:Japanese   Publisher:(株)中外医学社  

    researchmap

  284. 【C型肝炎の全て】病態 肝細胞障害とサイトカイン(Th1/Th2)

    各務 伸一, 石川 哲也, 奥村 明彦

    肝・胆・膵   Vol. 43 ( 5 ) page: 641 - 647   2001.11

     More details

    Language:Japanese   Publisher:(株)アークメディア  

    C型肝炎においては,急性肝炎でウイルスが排除される者,及び慢性肝炎で肝炎の活動性の強い者では,Th1型サイトカインが優位にある.IL-12等によるTh1型サイトカインの誘導は,ウイルスの排除に有効であるが,肝炎悪化による肝細胞障害を招く.IL-10などTh2型優位のサイトカインは,その逆に働くことになる.Th1優位の免疫反応は病態の進展と関連しており,肝内のCD4+細胞がHCV感染者の肝障害に一定の役割を果たしている.慢性化した状態では,その病態とTh1/Th2バランスは絶えず変化しながら,密接に関連していると考えられる

    researchmap

  285. 【B型慢性肝炎の病態と治療】B型慢性肝炎に対するワクチン療法とラミブジンの併用

    石川 哲也, 各務 伸一

    消化器科   Vol. 33 ( 5 ) page: 434 - 439   2001.11

     More details

    Language:Japanese   Publisher:(有)科学評論社  

    researchmap

  286. Levovistを用いた肝細胞癌治療前後の造影超音波診断の有用性

    堀田 直樹, 福沢 嘉孝, 佐藤 顕, 前野 禎, 山本 賢一, 吉田 香果, 伊東 正道, 多賀谷 恒明, 奥村 明彦, 石川 哲也

    肝臓   Vol. 42 ( Suppl.3 ) page: A527 - A527   2001.11

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  287. B型(慢性)肝炎の今までの治療と今後 B型慢性肝炎に対するラミブジン+HBワクチン併用療法

    各務 伸一, 石川 哲也

    犬山シンポジウム   Vol. 22回   page: 105 - 107   2001.10

     More details

    Language:Japanese   Publisher:(株)メディカルトリビューン  

    HBワクチンを併用することによりラミブジンの治療効果が増強され,より短期間に治療目的を達成できるか否かを検討した.ラミブジン投与開始2ヵ月で,e抗原陽性群のALT値,HBV DNA量,e抗原価は有意に低下,HBs抗原に対するリンパ球幼若化反応も上昇傾向を示した.e抗原陰性群においてもALT値,HBV DNA量の有意な低下とHBc抗原に対するリンパ球幼若化反応の改善を認めた.ラミブジン単独10例とワクチン併用11例のリンパ球幼若化反応は投与前に比して開始2ヵ月から5ヵ月へ順次増加する傾向を示したが両群間での差はなかった.ALT値,HBV DNA量低下とそれに伴う免疫反応の改善傾向を認めた為,今後の経過が期待される

    researchmap

  288. 慢性C型肝炎患者におけるインスリン抵抗性の検討

    前野 禎, 奥村 明彦, 石川 哲也, 山本 賢一, 伊東 正道, 堀田 直樹, 多賀谷 恒明, 福沢 嘉孝, 加藤 浩一, 榊原 文彦

    肝臓   Vol. 42 ( Suppl.2 ) page: A427 - A427   2001.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  289. 慢性C型肝炎患者におけるアミノ酸バランスの変化の検討 宿主の免疫力との関連から

    奥村 明彦, 石川 哲也, 吉岡 健太郎, 各務 伸一

    肝臓   Vol. 42 ( Suppl.2 ) page: A427 - A427   2001.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  290. C型肝硬変,肝癌患者における血清中サイトカインプロフィールの比較

    伊東 正道, 石川 哲也, 奥村 明彦, 田邊 純一, 前野 禎, 山本 賢一, 堀田 直樹, 多賀谷 恒明, 福沢 嘉孝, 各務 伸一

    肝臓   Vol. 42 ( Suppl.2 ) page: A372 - A372   2001.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  291. 〔第37回日本〕肝臓学会記

    各務 伸一, 福澤 嘉孝, 石川 哲也

    日本医事新報   ( 4033 ) page: 40 - 45   2001.8

     More details

    Language:Japanese   Publisher:日本医事新報社  

    CiNii Books

    researchmap

  292. 慢性肝炎患者における血清SHAP-HA濃度の検討

    矢田 俊量, Yingsung Wannarat, 卓 麗聖, 米田 雅彦, 奥村 明彦, 石川 哲也, 各務 伸一, 木全 弘治

    生化学   Vol. 73 ( 8 ) page: 702 - 702   2001.8

     More details

    Language:Japanese   Publisher:(公社)日本生化学会  

    researchmap

  293. ヒト肝癌細胞に対するPhotodynamic therapy(PDT)の有用性の検討

    奥村 明彦, 伊達 昌孝, 石川 哲也, 各務 伸一, 高橋 弘

    肝臓   Vol. 42 ( Suppl.1 ) page: A252 - A252   2001.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  294. 【消化器疾患の分子医学】消化器疾患の臨床と分子医学の接点 肝,胆,膵 ウイルス肝炎:B型

    石川 哲也, 各務 伸一

    臨床消化器内科   Vol. 16 ( 7 ) page: 1011 - 1018   2001.5

     More details

    Language:Japanese   Publisher:(株)日本メディカルセンター  

    researchmap

  295. HBc抗原領域ペプタイド刺激によるB型慢性肝炎患者末梢血単核球のサイトカイン/ケモカイン産生パターンの検討

    石川 哲也, 田邊 純一, 前野 禎, 山本 賢一, 堀田 直樹, 吉田 篤生, 吉田 香果, 伊東 正道, 多賀谷 恒明, 奥村 明彦

    肝臓   Vol. 42 ( Suppl.1 ) page: A180 - A180   2001.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  296. B型肝炎ウイルスキャリアからの劇症化例の治療

    石川 哲也, 各務 伸一

    現代医学   Vol. 48 ( 3 ) page: 573 - 577   2001.3

     More details

    Language:Japanese   Publisher:(公社)愛知県医師会  

    B型肝炎ウイルス(HBV)キャリアからの劇症化例は亜急性の経過をとることが多く,予後不良な重篤な病態である.その治療は血漿交換等による人工肝補助に加え,HBVの増殖を抑えるための抗ウイルス療法,過剰な免疫応答を抑えるための免疫抑制療法との組み合わせにより行われる.最近,抗ウイルス療法として新規の抗ウイルス薬であるラミブジンの使用が可能になった.これにより,今後の治療成績の改善が期待されている.又,ラミブジンはB型慢性肝炎急性増悪時の,重症化,劇症化の阻止にも有用と考えられる.一方で,移植医療の普及により,内科的治療で救命困難な例では,肝移植が選択肢として加わるようになった

    researchmap

  297. HBs抗原陽性肝疾患患者と供血者におけるHBV genotype分布とその臨床的背景の検討

    折戸悦朗, 溝上雅史, 大野智義, 吉岡健太郎, 福田吉秀, 豊田英徳, 神谷忠, 石川哲也, 各務伸一

    肝臓   Vol. 42 ( Supplement 3 )   2001

  298. Th1及びTh2 cytokine刺激によるヒト肝細胞のchemokine産生に関する検討

    田邊 純一, 石川 哲也, 各務 伸一

    日本免疫学会総会・学術集会記録   Vol. 30   page: 240 - 240   2000.11

     More details

    Language:Japanese   Publisher:(NPO)日本免疫学会  

    researchmap

  299. The significance of expression of Cu, Zn-superoxide dismutase (Cu, Zn-SOD), Mn-SOD, inducible nitric oxide (INOS), nitrotyrosine mutant type p53 in hepatocellular carcinoma (HCC).

    Y Fukuzawa, N Hotta, K Furuta, T Maeno, A Yoshida, K Yoshida, M Ito, T Tagaya, T Ishikawa, S Kakumu

    HEPATOLOGY   Vol. 32 ( 4 ) page: 236A - 236A   2000.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:W B SAUNDERS CO  

    Web of Science

    researchmap

  300. II型自己免疫性肝炎のマウスモデル作製の試み

    石川 哲也, 田邊 純一, 伊東 正道, 吉田 篤生, 堀田 直樹, 奥村 明彦, 多賀谷 恒明, 福澤 嘉孝, 宮川 浩, 各務 伸一

    肝臓   Vol. 41 ( Suppl.2 ) page: A448 - A448   2000.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  301. ウイルス性肝炎の慢性化成立機構に関する検討

    石川 哲也, 各務 伸一

    肝臓   Vol. 41 ( Suppl.2 ) page: A314 - A314   2000.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  302. B型,C型肝疾患の経過と治療 現況と今後の展開 B型肝疾患の病態を規定する因子の解析と標準的治療法の確立に向けて

    各務 伸一, 石川 哲也

    日本消化器病学会雑誌   Vol. 97 ( 臨増大会 ) page: A446 - A446   2000.9

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  303. B型慢性肝炎患者におけるHBc抗原領域のエピトープ解析 Flow cytometryによる末梢血単核球(PBMC)細胞内サイトカイン検出法を用いて

    石川 哲也, 田邊 純一, 伊東 正道, 前野 禎, 吉田 香果, 奥村 明彦, 多賀谷 恒明, 福澤 嘉孝, 各務 伸一

    肝臓   Vol. 41 ( Suppl.2 ) page: A384 - A384   2000.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  304. 肝疾患におけるTh1,Th2応答 その病態生理的意義 C型肝硬変,肝癌患者における血清中サイトカインの動態の比較と発癌機序に関する考察

    伊東 正道, 石川 哲也, 田邊 純一, 堀田 直樹, 前野 禎, 多賀谷 恒明, 福澤 嘉孝, 各務 伸一

    肝臓   Vol. 41 ( Suppl.1 ) page: A23 - A23   2000.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  305. B型慢性肝炎患者におけるHBc抗原領域エピトープ決定の試み Flow cytometryによる末梢血単核球(PBMC)細胞内サイトカイン検出法を用いて

    石川 哲也, 田邊 純一, 伊東 正道, 吉田 篤生, 吉田 香果, 多賀谷 恒明, 福澤 嘉孝, 各務 伸一

    肝臓   Vol. 41 ( Suppl.1 ) page: A152 - A152   2000.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  306. HBV core抗原のヒト肝細胞における細胞増殖に対する影響

    田邊 純一, 石川 哲也, 奥村 明彦, 堀田 直樹, 多賀谷 恒明, 福澤 嘉孝, 脇田 隆字, 各務 伸一

    肝臓   Vol. 41 ( Suppl.1 ) page: A86 - A86   2000.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  307. Th1及びTh2 cytokine刺激に対するヒト肝細胞におけるchemokine産生についての検討

    田邊 純一, 石川 哲也, 伊東 正道, 多賀谷 恒明, 福澤 嘉孝, 各務 伸一

    肝臓   Vol. 41 ( Suppl.1 ) page: A187 - A187   2000.5

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  308. 慢性HCV感染と糖尿病との関連について HBV感染との比較

    福沢嘉孝, 荒尾元博, 村瀬賢一, 日下部篤彦, 吉岡健太郎, 多賀谷恒明, 石川哲也, 後藤新太郎, 各務伸一

    肝臓   Vol. 41 ( Supplement 1 ) page: A99 - A99   2000

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  309. 感染症による肝障害の分子機構とその制御法の確立

    石川哲也, 吉開泰信, 西村仁志

    愛知医科大学医学会雑誌   Vol. 28 ( 4 ) page: 279 - 279   2000

     More details

    Language:Japanese   Publisher:愛知医科大学医学会  

    J-GLOBAL

    researchmap

▼display all

Presentations 123

  1. SLC40A1遺伝子変異を伴うフェロポルチン病Aの1例

    石川哲也、林由美、玉置優貴、今井則博、伊藤隆徳、石津洋二、石上雅敏、巽康彰、二瓶渉、加藤文子、加藤宏一、林久男

    第46回日本鉄バイオサイエンス学会学術集会  2022.9.2  日本鉄バイオサイエンス学会

     More details

    Event date: 2022.9

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:東京   Country:Japan  

  2. 高脂肪食負荷による肝障害刺激感受性変化に遺伝的背景が与える影響について

    早川美咲、玉置優貴、柴田ゆりあ、待井亜美、加藤温、池田悠馬、林由美、石川哲也

    第69回日本臨床検査医学会学術集会  2022.11.18  日本臨床検査医学会

     More details

    Event date: 2022.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:宇都宮   Country:Japan  

  3. HBs抗原の肝細胞内蓄積と肝病態進展との関連について

    柴田ゆりあ、玉置優貴、早川美咲、加藤温、待井亜美、池田悠馬、林由美、石川哲也

    第69回日本臨床検査医学会学術集会  2022.11.18  日本臨床検査医学会

     More details

    Event date: 2022.11

    Language:Japanese  

    Venue:宇都宮   Country:Japan  

  4. SA-5, a novel oral agonist of Toll-like receptor (TLR) 7, induces HBs antigen specific immune reaction in chronic HBV infection model mice.

    Takayasu Ideta, Hiroyasu Ito, Tetsuya Ishikawa.

    2021.11.4 

     More details

    Event date: 2021.11

    Language:English   Presentation type:Symposium, workshop panel (public)  

    Country:Japan  

  5. 食餌性因子が肝内の免疫・ストレス応答と肝障害感受性に及ぼす影響について

    内藤沙妃、玉置優貴、堀純子、柴田ゆりあ、池田悠馬、名仁澤英里、林由美、石川哲也

    第68回日本臨床検査医学会学術集会  2021.11.12 

     More details

    Event date: 2021.11

    Language:Japanese   Presentation type:Poster presentation  

    Venue:富山   Country:Japan  

  6. HBs抗原のヒト肝細胞への取込み機序とその意義について

    堀純子、玉置優貴、内藤沙妃、柴田ゆりあ、池田悠馬、名仁澤英里、林由美、石川哲也

    第68回日本臨床検査医学会学術集会  2021.11.12 

     More details

    Event date: 2021.11

    Language:Japanese   Presentation type:Poster presentation  

    Venue:富山   Country:Japan  

  7. 肝再生不全マウスに対する肝細胞移植後の肝内環境変化と肝再生との関連について

    玉置優貴、堀純子、内藤沙妃、柴田ゆりあ、池田悠馬、名仁澤英里、林由美、石川哲也

    第68回日本臨床検査医学会学術集会  2021.11.12 

     More details

    Event date: 2021.11

    Language:Japanese   Presentation type:Poster presentation  

    Venue:富山   Country:Japan  

  8. 肝細胞移植後の肝再生過程における肝内環境変化とその役割について

    玉置優貴、林由美、石川哲也

    第42回日本炎症・再生医学会  2021.7.7 

     More details

    Event date: 2021.7

    Language:Japanese   Presentation type:Poster presentation  

    Venue:オンライン   Country:Japan  

  9. 核酸アナログ治療中止後可能予測因子とHBVコア変異との関係

    本多隆、石上雅敏、山本崇文、犬飼庸介、杉山由晃、吉岡直輝、水野和幸、武藤久哲、横山晋也、山本健太、伊藤隆徳、今井則博、石津洋二、石川哲也、藤城光弘

    第57回日本肝臓学会総会  2021.6.17 

     More details

    Event date: 2021.6

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:札幌   Country:Japan  

  10. 肝細胞キメラマウス作製系における移植肝細胞の生着、拒絶の動態と拒絶回避のための治療について

    玉置 優貴, 堀 純子, 名仁澤 英里, 林 由美, 石川 哲也

    第67回日本臨床検査医学会学術集会  2020.11.20  日本臨床検査医学会

     More details

    Event date: 2020.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:岩手(オンライン)   Country:Japan  

  11. B型肝炎症例におけるテノホビルジソプロキシルフマル酸塩への切替えによるHBV DNA,HBs抗原,ALT値の変化に関する検討

    本多隆, 石上雅敏, 山本崇文, 犬飼庸介, 吉岡直輝, 水野和幸, 武藤久哲, 横山晋也, 田中卓, 山本健太, 伊藤隆徳, 石津洋二, 葛谷貞二, 石川哲也, 藤城光弘

    第56回日本肝臓学会総会  2020.8.28  日本肝臓学会

     More details

    Event date: 2020.8

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:大阪   Country:Japan  

  12. 非肝癌症例と肝発癌症例の違いに関与する腸内細菌の検討

    本多 隆, 石上 雅敏, 山本 崇文, 犬飼 庸介, 杉山 由晃, 吉岡 直輝, 水野 和幸, 武藤 久哲, 横山 晋也, 田中 卓, 山本 健太, 伊藤 隆徳, 石津 洋二, 葛谷 貞二, 石川 哲也, 藤城 光弘

    第56回日本肝臓学会総会  2020.8.28  日本肝臓学会

     More details

    Event date: 2020.8

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:大阪   Country:Japan  

  13. 腫瘍肝占拠率50%以上の高度進行肝細胞癌に対する分子標的治療薬の治療効果の検討~ソラフェニブとレンバチニブの比較~ International conference

    武藤久哲, 葛谷貞二, 杉山由晃, 吉岡直輝, 水野和幸, 横山晋也, 田中卓, 山本健太, 伊藤隆徳, 石津洋二, 本多隆, 石川哲也, 石上雅敏, 藤城光弘

    第56回日本肝臓学会総会  2020.8.28 

     More details

    Event date: 2020.8

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  14. 肝細胞移植後の肝再生過程における肝内環境変化とその役割について

    玉置優貴, 林由美, 石川哲也

    第42回日本炎症・再生医学会  2020.7.8 

     More details

    Event date: 2020.7

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:東京(オンライン)   Country:Japan  

  15. 高脂肪食負荷マウスにおける肝障害重症化機序についての解析

    名仁澤英里、玉置優貴、宮下凛太郎、園玲華、鈴木博子、林由美、神戸歩、伊藤弘康、石川哲也

    第59回日本臨床検査医学会 東海・北陸支部総会、第340回日本臨床化学会東海・北陸支部例会  2020.2.23  日本臨床検査医学会 東海・北陸支部、日本臨床化学会東海・北陸支部

     More details

    Event date: 2020.2

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:岐阜   Country:Japan  

  16. 肝細胞キメラマウス作製系における細胞移植後の免疫拒絶応答の解析

    玉置優貴、名仁澤英里、宮下凛太郎、園玲華、鈴木博子、林由美、神戸歩、伊藤弘康、石川哲也

    第59回日本臨床検査医学会 東海・北陸支部総会、第340回日本臨床化学会東海・北陸支部例会  2020.2.23  日本臨床検査医学会 東海・北陸支部、日本臨床化学会東海・北陸支部

     More details

    Event date: 2020.2

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:岐阜   Country:Japan  

  17. B型肝炎ウイルスの生活環におけるエンドサイトーシス経路の役割

    宮下凛太郎、名仁澤英里、園玲華、玉置優貴、林由美、石川哲也

    第66回日本臨床検査医学会学術集会  2019.11.24  日本臨床検査医学会

     More details

    Event date: 2019.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:岡山   Country:Japan  

  18. 肝細胞キメラマウス作製系を用いたアロ肝細胞に対する免疫拒絶反応の解析 International conference

    玉置優貴, 名仁澤英里, 宮下凛太郎, 園玲華, 林由美, 石川哲也

    第66回日本臨床検査医学会学術集会  2019.11.22 

     More details

    Event date: 2019.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  19. 新規HBV感染マウスモデル作製と宿主免疫応答の解析

    神戸歩、伊藤弘康、石川哲也

    第55回日本肝臓学会総会  2019.5.30  日本肝臓学会

     More details

    Event date: 2019.5

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:東京   Country:Japan  

  20. HBVキャリアマウスを用いた核酸製剤による治療的ワクチン療法の開発

    伊藤弘康、石川哲也

    第105回日本消化器病学会総会  2019.5.10  日本消化器病学会

     More details

    Event date: 2019.5

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

    Venue:金沢   Country:Japan  

  21. Hepatic intracellular stress responsible for the development of HBV-related fulminant hepatitis. International conference

    Nanizawa E, Tamaki Y, Sono R, Miyashita R, Hayashi Y, Ishikawa T.

    APASL Single Topic Conference on Liver Immunology and Genetics  2019.4.19  Asian Pacific Association for the Study of the Liver

     More details

    Event date: 2019.4

    Language:English   Presentation type:Oral presentation (general)  

    Country:Japan  

  22. マウス肝障害モデルにおけるトロンボモジュリン遺伝子導入脂肪由来肝細胞の炎症軽減効果について

    山本万智、名仁澤英里、今井田藍、山崎花那子、園玲華、玉置優貴、宮下凛太郎、林由美、石川哲也

    第65回日本臨床検査医学会学術集会  2018.11.17  日本臨床検査医学会

     More details

    Event date: 2018.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:東京   Country:Japan  

  23. B型肝炎ウイルス粒子可視化技術を用いたウイルス生活環の解析

    今井田藍、山崎花那子、山本万智、名仁澤英里、玉置優貴、宮下凛太郎、園玲華、林由美、石川哲也

    第65回日本臨床検査医学会学術集会  2018.11.18  日本臨床検査医学会

     More details

    Event date: 2018.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:東京   Country:Japan  

  24. B型肝炎ウイルス粒子の蛍光ラベルによる可視化と細胞内取込み機構の解析

    山崎花那子、今井田藍、名仁澤英里、山本万智、宮下凛太郎、玉置優貴、園玲華、林由美、石川哲也

    第65回日本臨床検査医学会学術集会  2018.11.18  日本臨床検査医学会

     More details

    Event date: 2018.11

    Language:Japanese   Presentation type:Oral presentation (general)  

    Venue:東京   Country:Japan  

  25. 探針エレクトロスプレーイオン化タンデム質量分析(PESI/MS/MS)とScheduled SRM法を用いた生体組織のインタクト・メタボロミクス法の構築

    近藤健太、林由美、村田匡、土屋弥月、大原倫美、石川哲也、緒方是嗣、土橋均、石井晃、財津桂

    第43回日本医用マススペクトル学会年会  2018.9.6  日本医用マススペクトル学会